114.3 CMR 17.00: MEDICINE

Section

17.01: General Provisions17.02: General Definitions17.03: General Rate Provisions

17.04: Maximum Allowable Fees - Medical Services

17.05: Severability

17.01: General Provisions

- (1) <u>Scope, Purpose and Effective Date</u>. 114.3 CMR 17.00 governs the rates of payment used by all governmental units for medical services rendered to publicly-aided patients by eligible providers. 114.3 CMR 17.00 is effective on and after July 1, 2008. Rates for services rendered to individuals covered by the Worker's Compensation Act, M.G.L. c. 152, are set forth at 114.3 CMR 40.00.
- (2) <u>Coverage</u>. 114.3 CMR 17.00 and the rates of payment contained herein shall apply in the following situations:
 - (a) Medical services rendered to patients in a private medical office, licensed clinic, facility, hospital outpatient department, patient's residence or other appropriate setting by an eligible provider who bills for the medical services rendered and receives no other compensation for medical services rendered.
 - (b) Medical services rendered to registered bed patients in a licensed health care facility by an eligible provider who is not under contractual arrangement with such facility to provide medical services, and who bills separately and apart from such facility for medical services rendered.

The rates of payment under 114.3 CMR 17.00 are full compensation for patient care rendered to publicly aided patients as well as for any related administrative or supervisory duties in connection with patient care. The rates of payment also reimburse all overhead expenses associated with the service provided.

- (3) <u>Disclaimer of Authorization of Services</u>. 114.3 CMR 17.00 is not authorization for or approval of the procedures for which rates are determined pursuant to 114.3 CMR 17.00. Governmental units that purchase care are responsible for the definition, authorization, and approval of care and services extended to publicly aided clients.
- (4) <u>Coding Updates and Corrections</u>. The Division may publish procedure code updates and corrections in the form of an Informational Bulletin. Updates may reference coding systems including but not limited to the American Medical Association's *Current Procedural Terminology* (CPT). The publication of such updates and corrections will list:
 - (a) codes for which only the code numbers change, with the corresponding cross references between existing and new codes;
 - (b) deleted codes for which there are no corresponding new codes; and

114.3 CMR 17.00: MEDICINE

- (c) codes for entirely new services that require pricing. The Division will list these codes and apply individual consideration (I.C.) reimbursement for these codes until appropriate rates can be developed.
- (d) for entirely new codes that require new pricing and have Medicare assigned relative value units (RVUs), the Division may list these codes and price them according to the rate methodology used in setting physician rates. When RVUS are not available, the Division may apply Individual Consideration in reimbursing for these new codes until appropriate rates can be developed.
- (5) <u>Administrative Bulletins</u>. The Division may issue administrative bulletins to clarify its policy on and understanding of substantive provisions of 114.3 CMR 17.00.

17.02: General Definitions

Meaning of Terms. The descriptions and five-digit codes included in 114.3 CMR 17.00 utilize the Healthcare Common Procedure Code System (HCPCS) for Level I and Level II coding. Level I CPT-4 codes are obtained from the Physicians' *Current Procedural Terminology*, copyright 2007 by the American Medical Association (CPT) unless otherwise specified. Level II codes are obtained from 2008 HCPCS maintained jointly by the Centers for Medicare and Medicaid Services (CMS), the Blue Cross and Blue Shield Association, and the Health Insurance Association of America. HCPCS is a listing of descriptive terms and identifying codes and modifiers for reporting medical services and procedures performed by physicians and other healthcare professionals, as well as associated non-physician services. No fee schedules, basic unit value, relative value guides, conversion factors or scales are included in any part of the Physicians' *Current Procedure Terminology*.

114.3 CMR 17.00 includes only HCPCS numeric and alpha-numeric identifying codes and modifiers for reporting medical services and procedures that were selected by the Massachusetts Division of Health Care Finance and Policy. Any use of CPT outside the fee schedule should refer to the Physicians' *Current Procedural Terminology*. All rights reserved.

In addition, terms used in 114.3 CMR 17.00 shall have the meanings set forth in 114.3 CMR 17.02.

<u>Child and Adolescent Needs and Strengths (CANS).</u> A tool that provides a standardized way to organize information gathered during a psychiatric diagnostic assessment and is a treatment and service decision support tool for children and adolescents under the age of 21.

<u>Confirmatory (Additional Opinion) Consultation</u>. When the consulting physician is aware of the confirmatory nature of the opinion that is sought (e.g., when a patient requests a second/third opinion on the necessity or appropriateness of a recommended medical treatment or surgical procedure).

<u>Consultation</u>. A type of service provided by a physician whose opinion or advice regarding evaluation and/or management of a specific problem is requested by another physician or other appropriate source.

114.3 CMR 17.00: MEDICINE

A physician consultant may initiate diagnostic and/or therapeutic services.

The request for a consultation from the attending physician or other appropriate source and the need for consultation must be documented in the patient's medical record. The consultant's opinion and any services that were ordered or performed must also be documented in the patient's medical record and communicated to the requesting physician or other appropriate source.

Any specifically identifiable procedure (i.e., identified with a specific CPT code) performed on or subsequent to the date of the initial consultation should be reported separately.

If a consultant subsequently assumes responsibility for management of a portion or all of the patient's condition(s), the consultation codes should not be used.

<u>Early and Periodic Screening, Diagnosis and Treatment (EPSDT).</u> A program of health screening and other medical services for publicly-assisted individuals under the age of 21 as required by federal law. Refer to 114.3 17.03(4) for reimbursement guidelines.

<u>Eligible Provider</u>. A licensed physician or licensed osteopath, licensed podiatrist, other than an intern, resident, fellow or house officer, who also meets such conditions of participation as have been or may be adopted from time to time by a governmental unit.

A provider of diagnostic medical services, who must provide such services in accordance with generally accepted professional standards and in accordance with state licensing requirements and/or certification by national credentialing bodies, as required by law. Such medical diagnostic services may be rendered by eligible providers such as, but not limited to, independent diagnostic testing facilities (IDTFs). These eligible providers must be physically and financially independent of a hospital or a physician's office. The provider's eligibility is limited to those procedures specified by the governmental unit purchasing such services, and must meet such conditions of participation as may have been or may be adopted from time to time by a governmental unit.

A provider of radiation oncology services, who must provide such services in accordance with generally accepted professional standards and in accordance with state licensing requirements and/or certification by national credentialing bodies, as required by law. Radiation oncology services may be rendered by eligible providers such as, but not limited to, independent radiation oncology centers. These eligible providers must be physically and financially independent of a hospital or a physician's office. The provider's eligibility is limited to those procedures specified by the governmental unit purchasing such services, and must meet such conditions of participation as may have been or may be adopted from time to time by a governmental unit.

A clinic licensed by the Massachusetts Department of Public Health in accordance with regulations 105 CMR 140.000 to provide medical diagnostic services. The provider's eligibility is limited to those procedures specified by the governmental unit purchasing such services, and must meet such conditions of participation as may have been or may be adopted from time to time by a governmental unit.

Eligible Mid-Level Practitioner.

A licensed registered nurse who is authorized by the Board of Registration in Nursing to practice as a nurse practitioner, whose eligibility is limited to those procedures specified by the governmental unit purchasing such services, and who also meets such conditions of participation as may have been or may be adopted from time to time by a governmental unit.

114.3 CMR 17.00: MEDICINE

A licensed registered nurse who is authorized by the Board of Registration in Nursing to practice as a nurse midwife, whose eligibility is limited to those procedures specified by the governmental unit purchasing such services, and who also meets such conditions of participation as may have been or may be adopted from time to time by a governmental unit.

A licensed physician assistant, who is authorized by the Board of Registration for Physician Assistants to practice as a physician assistant, whose eligibility is limited to those procedures specified by the governmental unit purchasing such services, and who also meets such conditions of participation as may have been or may be adopted from time to time by a government unit.

A registered nurse providing tobacco cessation services, whose eligibility is limited to those procedures specified by the governmental unit purchasing such services, and who also meets such conditions of participation as may have been or may be adopted from time to time by a governmental unit.

A tobacco cessation counselor, who has completed appropriate training in tobacco cessation counseling according to the qualification criteria established by the purchasing governmental unit, whose eligibility is limited to those procedures specified by the governmental unit purchasing such services, and who also meets such conditions of participation as may have been or may be adopted from time to time by a governmental unit.

<u>Established Patient</u>. A patient who has received professional services from the physician within the past three years.

<u>Facility Setting</u>. Payments for services provided in a hospital, including without limitation a hospital inpatient department, outpatient department, emergency department, and hospital licensed health center, or skilled nursing facility or free standing ambulatory surgical center (ASC) will be made according to a facility fee when an applicable facility fee has been established for that procedure.

<u>Governmental Unit</u>. The Commonwealth, any department, agency, board or commission of the Commonwealth and any political subdivision of the Commonwealth.

<u>Independent (Nurse Practitioner or Nurse Midwife):</u> Qualified and eligible to bill as a MassHealth Provider. *See* Eligible Mid-Level Practitioner.

<u>Individual Consideration</u>. Medical services, which are authorized but not listed herein, medical services performed in unusual circumstances and services designated "I.C." are individually considered items. The governmental unit or purchaser shall analyze the eligible provider's report of services rendered and charges submitted under the appropriate unlisted services or procedures category. Determination of appropriate payment for procedures designated I.C. shall be in accordance with the following standards and criteria:

- (a) the amount of time required to perform the service;
- (b) the degree of skill required to perform the service;
- (c) the severity or complexity of the patient's disease, disorder or disability;
- (d) any applicable relative-value studies;

114.3 CMR 17.00: MEDICINE

- (e) any complications or other circumstances that may be deemed relevant;
- (f) the policies, procedures and practices of other third party insurers;
- the payment rate for prescribed drugs as set forth at 114.3 CMR 31.00; and
- (g) a copy of the current invoice from the supplier.

<u>Levels of E/M Services</u>. Within each category or subcategory of E/M service, there are three to five levels of E/M services available for reporting purposes. Levels of E/M services are not interchangeable among the different categories or subcategories of service.

The levels of E/M services include examinations, evaluations, treatments, conferences with or concerning patients, preventive pediatric and adult health supervision and similar medical services. The levels of E/M services encompass the wide variations in skill, effort, time, responsibility and medical knowledge required for the prevention or diagnosis and treatment of illness or injury and the promotion of optimal health. Each level of E/M services may be used by all physicians.

Coordination of care with other providers or agencies without a patient encounter on that day is reported using the case management codes.

For a full discussion of the levels of E/M services, refer to the 2008 CPT handbook.

<u>Modifiers</u>. Listed services may be modified under certain circumstances. When applicable, the modifying circumstances should be identified by the addition of the appropriate two digit number or letters.

<u>New Patient</u>. A patient who has not received any professional services from the physician within the past three years.

<u>Physical Medicine</u>. The physical medicine procedure codes apply only when:

- a) the physician prescribed the needed therapy; and
- b) the services are provided by the physician or a licensed physical or occupational therapist employed by the physician.

<u>Primary Care Clinician (PCC) Plan</u> — a managed care option administered by the MassHealth agency through which enrolled members receive primary care and certain other medical services.

<u>Publicly Aided Individual</u>. A person who receives health care and services for which a governmental unit is in whole or in part liable under a statutory program of public assistance.

<u>Referral</u>. The transfer of the total or specific care from one physician to another. For the purposes of 114.3 CMR 17.00 a referral is not a consultation.

<u>Special Report</u>. A service that is rarely provided, unusual, variable, or new may require a special report in determining medical appropriateness of the service. Pertinent information should include an adequate definition or description of the nature, extent, and need for the procedure; and the time, effort and equipment necessary to provide the service.

114.3 CMR 17.00: MEDICINE

<u>Unlisted Procedure or Service.</u> A service or procedure may be provided that is not listed in Regulation 114.3 CMR 17.04. When reporting such a service, the appropriate "Unlisted Procedure" code may be used to indicate the service, identifying it by "Special Report."

17.03: General Rate Provisions

- (1) <u>Rate Determination</u>. Rates of payment to which 114.3 CMR 17.00 applies shall be the lowest of:
- (a) The eligible provider's usual fee to patients other than publicly-aided; or
- (b) The eligible provider's actual charge submitted; or
- (c) The schedule of allowable fees set forth in 114.3 CMR 17.04(4) in accordance with 114.3 CMR 17.03.
- (2) Supplemental Payment
- (a) <u>Eligibility</u>. An eligible provider may receive a supplemental payment for services to publicly aided individuals eligible under Titles XIX and XXI of the Social Security Act if the following conditions are met:
- 1. the eligible provider is employed by a non-profit group practice that was established in accordance with St. 1997, c.163 and is affiliated with a Commonwealth-owned medical school;
- 2. such non-profit group practice shall have been established on or before January 1, 2000 in order to support the purposes of a teaching hospital affiliated with and appurtenant to a Commonwealth-owned medical school; and
- 3. the services are provided at a teaching hospital affiliated with and appurtenant to a Commonwealth-owned medical school.
- (b) Payment Method. This supplemental payment may not exceed the difference between:
- 1. payments to the eligible provider made pursuant to the rates applicable under 114.3 CMR 17.03(1), and
- 2. the Federal upper payment limit set forth in 42 CFR 447.325.
- (3) <u>Rate Variations Based on Practice Site.</u> Payments for certain services that can be routinely furnished in physicians' offices are reduced when such services are furnished in facility settings. 114.3 CMR 17.04 establishes facility setting fees applied to services rendered in a facility when a practice site differential is warranted.
- (4) Allowable Mid-Level Fee for Qualified Mid-Level Practitioners. Payment for services provided by eligible licensed nurse practitioners, eligible licensed nurse midwives, eligible licensed physician assistants, eligible registered nurses, and eligible tobacco cessation counselors as specified in 114.3 CMR 17.02 is 85% of the fees contained in 114.3 CMR 17.04(4). This rule does not apply to the EPSDT add-on code S0302 described in 114.3 CMR 17.03(5) or for tobacco cessation services, for medical nutrition therapy (97802, 97803, 97804, G0270, G0271), for diabetes self-management training (G0108, G0109), and for the administration of behavioral health screening (96110 and related modifiers)

114.3 CMR 17.00: MEDICINE

services listed in section 114.3 CMR 17.04(4). Properly adjusted rates for tobacco cessation services for mid-level practitioners are listed in section 114.3 CMR 17.04(4) according to codes G0376-SA, -SB, -HN, -TD, -U1, -U2, and -U3.

- (5) <u>Behavioral Health Screening Services</u>. Payment for the administration and scoring of standardized behavioral health screening tools is available to eligible providers (physician, independent nurse midwife, independent nurse practitioner, community health center, hospital outpatient department, or mid-level practitioner employed by a physician or community health center) and is allowed for MassHealth purchase only when accompanied by a modifier. Appropriate code and related modifiers for the standardized behavioral health screening tools are listed in a separate fee table in section 114.3 CMR 17.04 (4). For purposes of these modifiers, "Behavioral health need identified" means the provider administering the screening tool, in her or his professional judgement, identifies a child with a potential behavioral health services need.
- (6) <u>Early and Periodic Screening</u>, <u>Diagnosis and Treatment (EPSDT) Add-On Code</u>. To identify a well child office visit in accordance with the EPSDT schedule, use code S0302 in addition to the appropriate preventive medicine service in 114.3 CMR 17.04(4). S0302 is always performed in addition to the primary procedure and must never be reported as a stand-alone code.
- (7) <u>Services and Payments Covered Under Other Regulations.</u> Rules and reimbursement rates for services listed herein are contained in other Division regulations.

Regulation Title	Regulation Number	Affected Services
Chiropractic Care	114.3 CMR 28.00	Chiropractic Manipulation Codes 98940 to 98943
Rehabilitation Clinic Services, Audiology Services and Restorative Services	114.3 CMR 39.00	Audiologic Codes 92590 to 92595
Vision Care Services and Ophthalmic Materials	114.3 CMR 15.00	Spectacle Service Codes 92340-92342, 92370 and Screening Code 99173

- (8) <u>CPT Category III Codes</u>. All medicine related CPT category III codes are included as a part of this regulation and have an assigned fee of IC.
- (9) <u>PCC Plan Enhanced Fee</u>. Primary Care Clinicians (PCCs) receive an enhanced rate for certain types of primary and preventive care visits provided to PCC Plan members enrolled with the PCC on the date of service. Ten dollars is added to the rate for the procedure code

114.3 CMR 17.00: MEDICINE

billed. The MassHealth agency pays PCCs an enhanced fee for delivering primary care services in accordance with the terms of the PCC provider contract.

(10) <u>Child and Adolescent Needs and Strengths (CANS)</u>: <u>Psychiatric Diagnostic Interview Examination for Children and Adolescents Under the Age of 21</u>. Psychiatrists who complete the CANS for a MassHealth child or adolescent under the age of 21 during a Psychiatric Diagnostic Interview Examination should bill using procedure code 90801 accompanied by modifier HA.

17.04: Maximum Allowable Fees

- (1) <u>Drugs, Medications, Supplies and Laboratory Specimen Collections</u>.
 - (a) Payment rates for drugs, vaccines and immune globulins administered in a physician's office shall be the lower of the fee listed in 114.3 CMR 17.04(4) or the current Medicare fee.
 - (b) Supplies and materials used in preparation for or as part of a procedure (e.g., bandages, laboratory kits, syringes or disposable gloves) are not reimbursed separately, but included in the office visit rate. In addition, no supplemental charge shall be submitted nor payment allowed for routine specimen collection in a physician's office and preparation for clinical laboratory analysis (and activities related thereto), e.g., venipuncture, urine, fecal and sputum samples, culturing, swabbing and scraping for removal of tissues.
 - (c) Where applicable, payment for drugs, medicines, supplies, and related materials dispensed to patients shall be in accordance with rates which are the subject matter of other regulations that may be in effect and germane to the item in question (e.g., laboratory, pharmacy, medical supplies, etc.) not to exceed the cost of the item to the physician.
 - In other instances where the use of another regulation is not appropriate, certain supplies and materials (except eyeglasses), provided by the physician over and above those usually included with the office visit or other services rendered should be billed under code (99070).
 - (d) Payment for drugs and/ or biologicals may be claimed in addition to an office visit. Drugs that are considered routine and integral to the delivery of a physician's professional services in the course of diagnosis or treatment are not reimbursable. Such drugs are commonly provided without charge or are included in the physician's fee for the service.

Drugs and/or biologicals available free of charge from the Massachusetts Department of Public Health are not payable items.

When an immunization or injection is the primary purpose of an office or other outpatient visit, the provider may bill only for the injectable material and its administration. However, when the immunization or injection is not the primary purpose of the office or other outpatient visit, a provider may bill for both the visit and the immunization or injectable material, but not for its administration.

114.3 CMR 17.00: MEDICINE

(2) Unless otherwise specified, guidelines, notes and definitions provided in the 2007 CPT Coding Handbook are applicable to the use of the procedure codes and descriptions listed below

(3) Modifiers

- <u>-26</u>: <u>Professional Component.</u> The component of a service or procedure representing the physicians' work interpreting or performing the service or procedure. When the physician component is reported separately, the addition of the modifier '-26' to the appropriate procedure code will allow the professional component allowable fee (PC Fee) contained in 114.3 CMR 17.04(4) to be paid.
- <u>-50</u>: <u>Bilateral Procedures</u>. Unless otherwise identified in the procedure code listing, bilateral procedures performed at the same operative session must be identified by the appropriate service code describing the first procedure. The second bilateral procedure is identified by adding the modifier '50' to the end of the service code. The addition of the modifier '50' to the second bilateral codes allows 50% of the allowable fee contained in 114.3 CMR 17.04(4) to be paid to the eligible provider for the second bilateral procedure.
- <u>-51:</u> Multiple Procedures. This modifier must be used to report multiple procedures performed at the same session. The service code for the major procedure or service must be reported without a modifier. The secondary, additional or lesser procedure(s) must be identified by adding the modifier '51' to the end of the service code for the secondary procedure(s). The addition of the modifier '51' to the second and subsequent procedure codes allows 50% of the allowable fee contained in 114.3 CMR 17.04(4) to be paid to the eligible provider.

Note: This modifier should not be used with designated "add-on" codes or with codes in which the narrative begins with "each additional".

- <u>-52</u>: Reduced Service. Under certain circumstances a service or procedure is partially reduced or eliminated at the physician's election. Under these circumstances, the service provided can be identified by its usual procedure number and addition of the modifier '-52' signifying that the service is reduced.
- <u>-GO</u>: Services delivered personally by an occupational therapist or under an outpatient occupational therapy plan of care.
- <u>-GP</u>: Services delivered personally by a physical therapist or under an outpatient physical therapy plan of care.

114.3 CMR 17.00: MEDICINE

- -HA: Child and Adolescent Needs and Strengths (CANS): Psychiatric Diagnostic Interview Examination for Children and Adolescents Under the Age of 21: This modifier should only be applied to service code 90801 billed by psychiatrists to identify a Psychiatric Diagnostic Interview Examination for a MassHealth child or adolescent under the age of 21 using the CANS.
- <u>-HN: Bachelor's Degree Level.</u> (Use to indicate Physician Assistant) (This modifier is to be applied to service codes billed by a physician which were performed by a physician assistant employed by the physician or group practice.)
- -SA: Nurse Practitioner rendering service in collaboration with a physician. (This modifier is to be applied to service codes billed by a physician which were performed by a non-independent nurse practitioner employed by the physician or group practice.) (An independent nurse practitioner billing under his/her own individual provider number should not use this modifier.)
- <u>-SB: Nurse Midwife.</u> (This modifier is to be applied to service codes billed by a physician which were performed by a non-independent nurse midwife employed by the physician or group practice.) (An independent nurse midwife billing under his/her own individual provider number should not use this modifier.)
- <u>-SL: State Supplied Vaccine.</u> (This modifier should only be applied to codes 90465, 90467, 90471 and 90473 to identify vaccines provided at no cost by the Massachusetts Department of Public Health for individuals ages 18 years and under, including those administered under the Vaccine for Children Program (VFC).)
- <u>-TC: Technical Component.</u> The component of a service or procedure representing the cost of rent, equipment, utilities, supplies, administrative and technical salaries and benefits, and other overhead expenses of the service or procedures, excluding the physician's professional component. When the technical component is reported separately the addition of modifier '-TC' to the procedure code will allow the technical component allowable fee (TC Fee) contained in 114.3 CMR 17.04(4) to be paid.

(4) Fee Schedule

NFAC – These amounts apply when service is performed in a non-facility setting FAC – These amounts apply when service is performed in a facility setting Global Fee – These amounts apply when no site of service differential rate is specified.

114.3 CMR 17.00: MEDICINE

December	CODE	NFAC	FAC	GLOBAL FEE	PC FEE	TC FEE	DESCRIPTION
Immune globulin (IgIV), human, for intravenous use		NFAC	FAC		FEE	FEE	
Second State Seco	90201			1.C.			
Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each	90283			IC			
Subcutaneous infusions, 100 mg, each	70203			1.0.			
90287 I.C. Botulinum antitoxin, equine, any route	90284			IC			
Botulism immune globulin, human, for intravenous use							
Second	30207			1.0.			
December 2029 Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use Diphtheria antitoxin, equine, any route Hepatitis B immune globulin (HBIg), human, for intramuscular use Rabies immune globulin (Rig), human, for intramuscular use Rabies immune globulin, heat-treated (Rig-HT), human, for intramuscular and/or subcutaneous use Rabies immune globulin, heat-treated (Rig-HT), human, for intramuscular use Respiratory syncytial virus immune globulin (RSV-IgIM), for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intramuscular use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use Rho(D) immune gl	90288			I.C.			
90291 I.C. human, for intravenous use 90296 I.C. Diphtheria antitoxin, equine, any route Hepatitis B immune globulin (HBIg), human, for intramuscular use 90371 122.47 Rabies immune globulin (Rig), human, for intramuscular use 90375 68.64 Rabies immune globulin (Rig), human, for intramuscular and/or subcutaneous use Rabies immune globulin, heat-treated (Rig-HT), human, for intramuscular and/or subcutaneous use Respiratory syncytial virus immune globulin (RSV- IgIM), for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV- IgIV), human, for intravenous use Respiratory syncytial virus immune globulin (RSV- IgIV), human, for intravenous use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, for intravenous use Rho(D) immune globulin (RhIgIV), human, for intravenous use Tetanus immune globulin (RhIgIV), human, for intravenous use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 1.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single	70200			1.0.			
90296 I.C. Diphtheria antitoxin, equine, any route	90291			I.C.			
Hepatitis B immune globulin (HBIg), human, for intramuscular use							
90371 122.47 intramuscular use Rabies immune globulin (Rig), human, for intramuscular and/or subcutaneous use Rabies immune globulin, heat-treated (Rig-HT), human, for intramuscular and/or subcutaneous use Rabies immune globulin, heat-treated (Rig-HT), human, for intramuscular and/or subcutaneous use Respiratory syncytial virus immune globulin (RSV-IgIM), for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use Tetanus immune globulin (RhIgIV), human, for intravenous use Vaccinia immune globulin (Tig), human, for intravenous use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin (Rig), human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular ingetion younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single virtuamentary injection) when thephysician counsels the patient/family; first injection (single virtuamentary injection) (single virtuamentary injection) (single virtuamentary injection (single virtuamentary injection (single virtuamentary injection) (single virtuamentar							
Rabies immune globulin (Rig), human, for intramuscular and/or subcutaneous use Rabies immune globulin, heat-treated (Rig-HT), human, for intramuscular and/or subcutaneous use Respiratory syncytial virus immune globulin (RSV-IgIM), for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use Rho(D) immune globulin (Rhlg), human, full-dose, for intramuscular use Rho(D) immune globulin (Rhlg), human, for intravenous use Rho(D) immune globulin (RhlgIV), human, for intravenous use Rho(D) immune globulin (RhlgIV), human, for intravenous use Tetanus immune globulin (RhlgIV), human, for intravenous use Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin (RhlgIV), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin (RsV-IgIV), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin (RsV-IgIV), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin (RsV-IgIV), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin (RsV-IgIV), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin (RsV-IgIV), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune	90371			122.47			
90375 68.64 intramuscular and/or subcutaneous use Rabies immune globulin, heat-treated (Rig-HT), human, for intramuscular and/or subcutaneous use Respiratory syncytial virus immune globulin (RSV-IgIM), for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use Rho(D) immune globulin (RhIgIV), human, for intravenous use Tetanus immune globulin (RhIgIV), human, for intramuscular use Vaccinia immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin (Rigit vaccinia immune globulin (Rhigit vaccinia immune globulin (Rigit vaccinia immune glo							
90376 74.58 human, for intramuscular and/or subcutaneous use Respiratory syncytial virus immune globulin (RSV- IgIM), for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV- IgIV), human, for intravenous use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 1.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	90375			68.64			
90376 74.58 human, for intramuscular and/or subcutaneous use Respiratory syncytial virus immune globulin (RSV- IgIM), for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV- IgIV), human, for intravenous use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 1.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							Rabies immune globulin, heat-treated (Rig-HT),
90378 I.C. IgIM), for intramuscular use, 50 mg, each Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Intravenous use Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use I.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or or intramuscular injections) when the physician counsels the patient/family; first injection (single or or intramuscular injections) when thephysician counsels the patient/family; first injection (single or or intramuscular injections) when thephysician counsels the patient/family; first injection (single or or intramuscular injections) when thephysician counsels the patient/family; first injection (single or intramuscular injections) when thephysician counsels the patient/family; first injection (single or or intramuscular injections) when thephysician counsels the patient/family; first injection (single or intramuscular injections) when the patient/family; first injection (single or or intramuscular injections) when the patient family intradermal, subcutaneous, or intramuscular injections) when the patient family intradermal interaction (single or or intramuscular injections) when the patient family interaction interaction interaction int	90376			74.58			
Respiratory syncytial virus immune globulin (RSV- IgIV), human, for intravenous use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 1.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							Respiratory syncytial virus immune globulin (RSV-
90379 I.C. IgIV), human, for intravenous use Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intramuscular use I.C. intravenous use Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 1.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single (includes percutaneous))	90378			I.C.			IgIM), for intramuscular use, 50 mg, each
Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							Respiratory syncytial virus immune globulin (RSV-
90384 I.C. for intramuscular use Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use I.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection 17.54 Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	90379			I.C.			IgIV), human, for intravenous use
Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection 17.54 (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							Rho(D) immune globulin (RhIg), human, full-dose,
90385 23.73 for intramuscular use Rho(D) immune globulin (RhIgIV), human, for intravenous use Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin I.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	90384			I.C.			
Rho(D) immune globulin (RhIgIV), human, for intravenous use I.C. Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 1.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							
90386 I.C. intravenous use Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 1.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	90385			23.73			
Tetanus immune globulin (Tig), human, for intramuscular use Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							
90389 I.C. Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 90399 I.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	90386			I.C.			
Vaccinia immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 1.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							
90393 I.C. intramuscular use Varicella-zoster immune globulin, human, for intramuscular use 90396 I.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single or combination)	90389			I.C.			
Varicella-zoster immune globulin, human, for intramuscular use 90399 I.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	00000						
90399 I.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single)	90393			I.C.			
90399 I.C. Unlisted immune globulin Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single)	00206			1.0			
Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							
of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	90399			I.C.			
subcutaneous, or intramuscular injections) when the physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							
physician counsels the patient/family; first injection (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							
90465 17.54 (single or combination vaccine/toxoid), per day Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single							
Immunization administration under 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	90465			17.54			
(includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when thephysician counsels the patient/family; first injection (single	90403			17.54			
or intramuscular injections) when thephysician counsels the patient/family; first injection (single							1
counsels the patient/family; first injection (single							
90465-SL 15.78 or combination vaccine/toxoid), per day	90465_SI			15 78			

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Immunization administration younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections) when the
90466	8.37	7.05				physician counsels the patient/family; each additional injection (single or combination vaccine/toxoid), per day (List separately in addition to code for primary procedure)
90467	10.59	7.61				Immunization administration younger than age 8 years (includes intranasal or oral routes of administration) when the physician counsels the patient/family; first administration (single or combination vaccine/toxoid), per day
90467-SL	10.39	7.01	15.78			Immunization administration under age 8 years (includes intranasal ororal routes of administration) when the physician counsels thepatient/family; first administration (single or combinationvaccine/toxoid), per day
90407-3L			13.76			Immunization administration younger than age 8 years (includes intranasal or oral routes of administration) when the physician counsels the patient/family; each additional administration (single or combination vaccine/toxoid), per day (List separately in addition to code for primary
90468	8.04	6.06	17.54			procedure) Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single or combination vaccine/toxoid)
90471-SL			15.78			Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single orcombination vaccine/toxoid) (State Supplied Vaccine) (Only to be used for administration of Vaccine for Children (VFC) pediatric vaccines for individuals ages 18 years and under.) (Not in conjunction with an office visit or other outpatient visit)
90472	8.71	7.05				Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
90473	10.92	6.95				Immunization administration by intranasal or oral route; one vaccine (single or combination vaccine/toxoid)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	4
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
CODE	MIAC	TAC	FISE	FEE	TEE	Immunization administration by intranasal or oral
						route; one vaccine(single or combination
						vaccine/toxoid) (State Supplied Vaccine) (Only to
						be used for administration of Vaccine for Children
						(VFC) pediatric vaccines for individuals ages 18
						years and under.) (Not in conjunction with an office
90473-SL			15.78			visit or other outpatient visit)
30173 BE			13.70			Immunization administration by intranasal or oral
						route; each additional vaccine (single or
						combination vaccine/toxoid) (List separately in
90474	7.38	6.06				addition to code for primary procedure)
90476	7.50	0.00	I.C.			Adenovirus vaccine, type 4, live, for oral use
90477			I.C.			Adenovirus vaccine, type 7, live, for oral use
90581			I.C.			Anthrax vaccine, for subcutaneous use
70501			1.0.			Bacillus Calmette-Guerin vaccine (BCG) for
90585			120.45			tuberculosis, live, for percutaneous use
70202			120.13			Bacillus Calmette-Guerin vaccine (BCG) for
90586			117.34			bladder cancer, live, for intravesical use
70200			117.60			Hepatitis A vaccine, adult dosage, for intramuscular
90632			53.45			use
						Hepatitis A vaccine, pediatric/adolescent dosage-2
90633			26.69			dose schedule, for intramuscular use
						Hepatitis A vaccine, pediatric/adolescent dosage-3
90634			I.C.			dose schedule, for intramuscular use
						Hepatitis A and hepatitis B vaccine (HepA-HepB),
90636			I.C.			adult dosage, for intramuscular use
						Hemophilus influenza b vaccine (Hib), HbOC
90645			21.47			conjugate (4 dose schedule), for intramuscular use
						Hemophilus influenza b vaccine (Hib), PRP-D
90646			I.C.			conjugate, for booster use only, intramuscular use
						Hemophilus influenza b vaccine (Hib), PRP-OMP
90647			21.47			conjugate (3 dose schedule), for intramuscular use
						Hemophilus influenza b vaccine (Hib), PRP-T
90648			21.78			conjugate (4 dose schedule), for intramuscular use
						Human Papilloma virus (HPV) vaccine, types 6, 11,
00540						16, 18 (quadrivalent), 3 dose schedule, for
90649			I.C.			intramuscular use
						Influenza virus vaccine, split virus, preservative
00655			16.11			free, when administered to children 6-35 months of
90655	1		16.11	-	-	age, for intramuscular use
						Influenza virus vaccine, split virus, preservative
00656			17.27	1		free, when administered to individuals 3 years and older, for intramuscular use
90656	1		17.37	1		
				1		Influenza virus vaccine, split virus, when
90657			6.61	1		administered to children 6-35 months of age, for intramuscular use
7003/			6.61			mu amusculai use

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Influenza virus vaccine, split virus, when
						administered to individuals 3 years of age and older,
90658			13.22			for intramuscular use
90660			22.03			Influenza virus vaccine, live, for intranasal use
						Influenza virus vaccine, derived from cell cultures,
						subunit, preservative and antibiotic free, for
90661			I.C.			intramuscular use
						Influenza virus vaccine, split virus, preservative
						free, enhanced immunogenicity via increased
90662			I.C.			antigen content, for intramuscular use
90663			I.C.			Influenza virus vaccine, pandemic formulation
						Lyme disease vaccine, adult dosage, for
90665			I.C.			intramuscular use
						Pneumococcal conjugate vaccine, polyvalent, when
						administered to children younger than 5 years, for
90669			78.80			intramuscular use
90675			154.76			Rabies vaccine, for intramuscular use
90676			I.C.			Rabies vaccine, for intradermal use
						Rotavirus vaccine, pentavalent, 3 dose schedule,
90680			I.C.			live, for oral use
90690			I.C.			Typhoid vaccine, live, oral
						Typhoid vaccine, Vi capsular polysaccharide
90691			57.15			(ViCPs), for intramuscular use
						Typhoid vaccine, heat- and phenol-inactivated (H-
90692			I.C.			P), for subcutaneous or intradermal use
						Typhoid vaccine, acetone-killed, dried (AKD), for
90693			I.C.			subcutaneous use (U.S. military)
						Diphtheria, tetanus toxoids, acellular pertussis
						vaccine, haemophilus influenza Type B, and
						poliovirus vaccine, inactivated (DtaP -Hib -IPV),
90698			I.C.			for intramuscular use
						Diphtheria, tetanus toxoids, and acellular pertussis
						vaccine (DtaP), when administered to individuals
90700			31.51			younger than 7 years, for intramuscular use
						Diphtheria, tetanus toxoids, and whole cell pertussis
90701			I.C.			vaccine (DTP), for intramuscular use
						Diphtheria and tetanus toxoids (DT) adsorbed when
						administered to individuals younger than 7 years,
90702			24.96			for intramuscular use
90703			20.21			Tetanus toxoid adsorbed, for intramuscular use
90704			21.30			Mumps virus vaccine, live, for subcutaneous use
90705			16.76			Measles virus vaccine, live, for subcutaneous use
90706			17.97			Rubella virus vaccine, live, for subcutaneous use
						Measles, mumps and rubella virus vaccine (MMR),
90707			43.20			live, for subcutaneous use
						Measles and rubella virus vaccine, live, for
90708			I.C.			subcutaneous use

114.3 CMR 17.00: MEDICINE

CODE	NFAC	FAC	GLOBAL FEE	PC FEE	TC FEE	DESCRIPTION
						Measles, mumps, rubella, and varicella vaccine
90710			I.C.			(MMRV), live, for subcutaneous use
						Poliovirus vaccine, (any type[s]) (OPV), live, for
90712			I.C.			oral use
						Poliovirus vaccine, inactivated (IPV), for
90713			25.90			subcutaneous or intramuscular use
						Tetanus and diphtheria toxoids (Td) adsorbed,
						preservative free, when administered to individuals
90714			19.48			7 years or older, for intramuscular use
						Tetanus, diphtheria toxoids and acellular pertussis
00717			24.22			vaccine (Tdap), when administered to individuals 7
90715			34.32			years or older, for intramuscular use
90716			75.80			Varicella virus vaccine, live, for subcutaneous use
90717			56.07			Yellow fever vaccine, live, for subcutaneous use
						Tetanus and diphtheria toxoids (Td) adsorbed when
00710			11.55			administered to individuals 7 years or older, for
90718			11.55			intramuscular use
90719			I.C.			Diphtheria toxoid, for intramuscular use
						Diphtheria, tetanus toxoids, and whole cell pertussis
90720			I.C.			vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use
90720			1.C.			Diphtheria, tetanus toxoids, and acellular pertussis
						vaccine and Hemophilus influenza B vaccine (DtaP-
90721			42.89			Hib), for intramuscular use
70721			72.07			Diphtheria, tetanus toxoids, acellular pertussis
						vaccine, Hepatitis B, and poliovirus vaccine,
90723			I.C.			inactivated (DtaP-HepB-IPV), for intramuscular use
90725			I.C.			Cholera vaccine for injectable use
90727			I.C.			Plague vaccine, for intramuscular use
, , , , ,			1.0.			Pneumococcal polysaccharide vaccine, 23-valent,
						adult or immunosuppressed patient dosage, when
						administered to individuals 2 years or older, for
90732			29.73			subcutaneous or intramuscular use
						Meningococcal polysaccharide vaccine (any
90733			86.10			group(s)), for subcutaneous use
						Meningococcal conjugate vaccine, serogroups A, C,
90734			I.C.			Y and W-135 (tetravalent), for intramuscular use
						Japanese encephalitis virus vaccine, for
90735			99.11			subcutaneous use
						Zoster (shingles) vaccine, live, for subcutaneous
90736			I.C.			injection
						Hepatitis B vaccine, dialysis or immunosuppressed
						patient dosage (3 dose schedule), for intramuscular
90740			114.51			use
						Hepatitis B vaccine, adolescent (2 dose schedule),
90743			24.36			for intramuscular use
						Hepatitis B vaccine, pediatric/adolescent dosage (3
90744			24.36			dose schedule), for intramuscular use

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Hepatitis B vaccine, adult dosage, for intramuscular
90746			57.26			use
						Hepatitis B vaccine, dialysis or immunosuppressed
						patient dosage (4 dose schedule), for intramuscular
90747			114.51			use
00=40						Hepatitis B and Hemophilus influenza b vaccine
90748			I.C.			(HepB-Hib), for intramuscular use
90749			I.C.			Unlisted vaccine/toxoid
00760			71.61			Intravenous infusion, hydration; initial, 31 minutes
90760			51.61			to 1 hour
						Intravenous infusion, hydration; each additional
90761			15.29			hour (List separately in addition to code for primary procedure)
90/01			13.29			Intravenous infusion, for therapy, prophylaxis, or
						diagnosis (specify substance or drug); initial, up to 1
90765			63.32			hour
70703			03.32			Intravenous infusion, for therapy, prophylaxis, or
						diagnosis (specify substance or drug); each
						additional hour (List separately in addition to code
90766			19.79			for primary procedure)
70,00			23113			Intravenous infusion, for therapy, prophylaxis, or
						diagnosis (specify substance or drug); additional
						sequential infusion, up to 1 hour (List separately in
90767			32.32			addition to code for primary procedure)
						Intravenous infusion, for therapy, prophylaxis, or
						diagnosis (specify substance or drug); concurrent
						infusion (List separately in addition to code for
90768			18.52			primary procedure)
						Subcutaneous infusion for therapy or prophylaxis
						(specify substance or drug); initial, up to one hour,
						including pump set-up and establishment of
90769			137.26			subcutaneous infusion site(s)
						Subcutaneous infusion for therapy or prophylaxis
						(specify substance or drug); each additional hour
90770			12.17			(List separately in addition to code for primary
<i>3</i> 0 / /U			13.17		1	procedure) Subcutaneous infusion for therapy or prophylaxis
						(specify substance or drug); additional pump set-up
						with establishment of new subcutaneous infusion
						site(s) (List separately in addition to code for
90771			61.80			primary procedure)
			51.00			Therapeutic, prophylactic or diagnostic injection
						(specify substance or drug); subcutaneous or
90772			17.54			intramuscular
						Therapeutic, prophylactic or diagnostic injection
90773			15.44			(specify substance or drug); intra-arterial

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Therapeutic, prophylactic or diagnostic injection
						(specify substance or drug); intravenous push, single
90774			49.59			or initial substance/drug
						Therapeutic, prophylactic or diagnostic injection
						(specify substance or drug); each additional sequential intravenous push of a new substance/drug
						(List separately in addition to code for primary
90775			21.53			procedure)
30773			21.33			Therapeutic, prophylactic or diagnostic injection
						(specify substance or drug); each additional
						sequential intravenous push of the same
						substance/drug provided in a facility (List separately
90776			I.C.			in addition to code for primary procedure)
						Unlisted therapeutic, prophylactic or diagnostic
90779			I.C.			intravenous or intra-arterial injection or infusion
90801	123.48	104.60				Psychiatric diagnostic interview examination
						Psychiatric diagnostic interview examination (by a
90801-HA	143.02					psychiatrist for MassHealth children and
90801-HA	143.02					adolescents under the age of 21 using the CANS) Interactive psychiatric diagnostic interview
						examination using play equipment, physical
						devices, language interpreter, or other mechanisms
90802	130.88	113.00				of communication
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an office or
						outpatient facility, approximately 20 to 30 minutes
90804	51.63	44.35				face-to-face with the patient;
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an office or
						outpatient facility, approximately 20 to 30 minutes
90805	57.09	49.81				face-to-face with the patient; with medical evaluation and management services
90803	37.09	49.01				Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an office or
						outpatient facility, approximately 45 to 50 minutes
90806	72.97	68.00				face-to-face with the patient;
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an office or
						outpatient facility, approximately 45 to 50 minutes
						face-to-face with the patient; with medical
90807	80.63	73.68				evaluation and management services
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an office or
00808	107.64	102.24				outpatient facility, approximately 75 to 80 minutes
90808	107.64	102.34				face-to-face with the patient;

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an office or
						outpatient facility, approximately 75 to 80 minutes
						face-to-face with the patient; with medical
90809	114.63	107.68				evaluation and management services
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an office or outpatient facility, approximately 20
90810	54.92	48.63				to 30 minutes face-to-face with the patient;
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an office or outpatient facility, approximately 20
						to 30 minutes face-to-face with the patient; with
90811	63.36	54.09				medical evaluation and management services
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an office or outpatient facility, approximately 45
90812	79.68	72.07				to 50 minutes face-to-face with the patient;
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an office or outpatient facility, approximately 45
						to 50 minutes face-to-face with the patient; with
90813	87.01	77.74				medical evaluation and management services
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an office or outpatient facility, approximately 75
90814	113.69	107.06				to 80 minutes face-to-face with the patient;
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an office or outpatient facility, approximately 75
						to 80 minutes face-to-face with the patient; with
90815	120.68	111.41				medical evaluation and management services
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an inpatient
						hospital, partial hospital or residential care setting,
						approximately 20 to 30 minutes face-to-face with
90816			48.45			the patient;

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	T
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
CODE	INFAC	TAC	TEE	TEE	Tible	Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an inpatient
						hospital, partial hospital or residential care setting,
						approximately 20 to 30 minutes face-to-face with
						the patient; with medical evaluation and
90817			53.24			management services
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an inpatient
						hospital, partial hospital or residential care setting,
						approximately 45 to 50 minutes face-to-face with
90818			72.15			the patient;
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an inpatient
						hospital, partial hospital or residential care setting,
						approximately 45 to 50 minutes face-to-face with
						the patient; with medical evaluation and
90819			76.83			management services
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an inpatient
						hospital, partial hospital or residential care setting,
						approximately 75 to 80 minutes face-to-face with
90821			106.77			the patient;
						Individual psychotherapy, insight oriented, behavior
						modifying and/or supportive, in an inpatient
						hospital, partial hospital or residential care setting,
						approximately 75 to 80 minutes face-to-face with
						the patient; with medical evaluation and
90822			111.33			management services
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an inpatient hospital, partial hospital or
						residential care setting, approximately 20 to 30
90823			52.18			minutes face-to-face with the patient;
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an inpatient hospital, partial hospital or
						residential care setting, approximately 20 to 30
00024			57.50			minutes face-to-face with the patient; with medical
90824			57.52			evaluation and management services
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an inpatient hospital, partial hospital or
00026			76.71			residential care setting, approximately 45 to 50
90826			76.71	İ	Ì	minutes face-to-face with the patient;

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an inpatient hospital, partial hospital or
						residential care setting, approximately 45 to 50
						minutes face-to-face with the patient; with medical
90827			80.57			evaluation and management services
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an inpatient hospital, partial hospital or
						residential care setting, approximately 75 to 80
90828			111.16			minutes face-to-face with the patient;
						Individual psychotherapy, interactive, using play
						equipment, physical devices, language interpreter,
						or other mechanisms of non-verbal communication,
						in an inpatient hospital, partial hospital or
						residential care setting, approximately 75 to 80
						minutes face-to-face with the patient; with medical
90829			114.85			evaluation and management services
90845	66.71	65.06				Psychoanalysis
90846	71.14	69.82				Family psychotherapy (without the patient present)
						Family psychotherapy (conjoint psychotherapy)
90847	88.58	83.62				(with patient present)
90849	26.83	24.18				Multiple-family group psychotherapy
						Group psychotherapy (other than of a multiple-
90853	25.29	23.64				family group)
90857	28.72	25.41				Interactive group psychotherapy
						Pharmacologic management, including prescription,
						use, and review of medication with no more than
90862	43.83	36.55				minimal medical psychotherapy
						Narcosynthesis for psychiatric diagnostic and
						therapeutic purposes (eg, sodium amobarbital
90865	123.56	107.34				(Amytal) interview)
						Electroconvulsive therapy (includes necessary
90870	117.23	69.56				monitoring)
						Individual psychophysiological therapy
						incorporating biofeedback training by any modality
						(face-to-face with the patient), with psychotherapy
						(eg, insight oriented, behavior modifying or
						supportive psychotherapy); approximately 20-30
90875	57.86	46.60				minutes
						Individual psychophysiological therapy
						incorporating biofeedback training by any modality
						(face-to-face with the patient), with psychotherapy
						(eg, insight oriented, behavior modifying or
						supportive psychotherapy); approximately 45-50
90876	84.57	73.31				minutes

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
90880	89.02	80.08				Hypnotherapy
00002			20.05			Environmental intervention for medical management purposes on a psychiatric patient's
90882			39.95			behalf with agencies, employers, or institutions Psychiatric evaluation of hospital records, other
90885			37.44			psychiatric reports, psychometric and/or projective tests, and other accumulated data for medical diagnostic purposes
90887	65.68	57.07				Interpretation or explanation of results of psychiatric, other medical examinations and procedures, or other accumulated data to family or other responsible persons, or advising them how to assist patient
						Preparation of report of patient's psychiatric status, history, treatment, or progress (other than for legal or consultative purposes) for other physicians,
90889			I.C.			agencies, or insurance carriers
90899			I.C.			Unlisted psychiatric service or procedure
90901	30.41	15.85				Biofeedback training by any modality
90911	74.80	36.06				Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry
90918	498.34	482.45				End-stage renal disease (ESRD) related services per full month; for patients younger than two years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents
90919	360.86	352.91				End-stage renal disease (ESRD) related services per full month; for patients between two and eleven years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents
90920	314.85	307.23				End-stage renal disease (ESRD) related services per full month; for patients between twelve and nineteen years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents
90921	196.36	194.70				End-stage renal disease (ESRD) related services per full month; for patients twenty years of age and older
90922	16.50	16.17				End-stage renal disease (ESRD) related services (less than full month), per day; for patients younger than two years of age
90923			11.67			End-stage renal disease (ESRD) related services (less than full month), per day; for patients between two and eleven years of age

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						End-stage renal disease (ESRD) related services
						(less than full month), per day; for patients between
90924			10.22			twelve and nineteen years of age
						End-stage renal disease (ESRD) related services
						(less than full month), per day; for patients twenty
90925			6.72			years of age and older
						Hemodialysis procedure with single physician
90935			54.78			evaluation
						Hemodialysis procedure requiring repeated
						evaluation(s) with or without substantial revision of
90937			89.20			dialysis prescription
						Hemodialysis access flow study to determine blood
						flow in grafts and arteriovenous fistulae by an
90940			I.C.			indicator method
						Dialysis procedure other than hemodialysis (eg,
						peritoneal dialysis, hemofiltration, or other
						continuous renal replacement therapies), with single
90945			57.11			physician evaluation
						Dialysis procedure other than hemodialysis (eg,
						peritoneal dialysis, hemofiltration, or other
						continuous renal replacement therapies) requiring
						repeated physician evaluations, with or without
90947			91.26			substantial revision of dialysis prescription
						Dialysis training, patient, including helper where
90989			I.C.			applicable, any mode, completed course
						Dialysis training, patient, including helper where
						applicable, any mode, course not completed, per
90993			I.C.			training session
						Hemoperfusion (eg, with activated charcoal or
90997			71.85			resin)
90999			I.C.			Unlisted dialysis procedure, inpatient or outpatient
						Esophageal intubation and collection of washings
						for cytology, including preparation of specimens
91000			61.96	28.97	32.99	(separate procedure)
						Esophageal motility (manometric study of the
91010			171.22	52.40	118.82	esophagus and/or gastroesophageal junction) study;
						Esophageal motility (manometric study of the
						esophagus and/or gastroesophageal junction) study;
91011			220.13	63.90	156.23	with mecholyl or similar stimulant
			1			Esophageal motility (manometric study of the
						esophagus and/or gastroesophageal junction) study;
91012	1		228.95	61.90	167.04	with acid perfusion studies
91020	1		197.60	59.91	137.69	Gastric motility (manometric) studies
91022	1		167.47	60.24	107.23	Duodenal motility (manometric) study
						Esophagus, acid perfusion (Bernstein) test for
91030			115.09	38.51	76.58	esophagitis

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Esophagus, gastroesophageal reflux test; with nasal
						catheter pH electrode(s) placement, recording,
91034			184.93	40.94	143.98	analysis and interpretation
						Esophagus, gastroesophageal reflux test; with
						mucosal attached telemetry pH electrode placement,
91035			414.45	66.53	347.93	recording, analysis and interpretation
						Esophageal function test, gastroesophageal reflux
						test with nasal catheter intraluminal impedance
						electrode(s) placement, recording, analysis and
91037			135.60	41.27	94.32	interpretation;
						Esophageal function test, gastroesophageal reflux
						test with nasal catheter intraluminal impedance
I						electrode(s) placement, recording, analysis and
						interpretation; prolonged (greater than 1 hour, up to
91038			116.71	46.89	69.82	24 hours)
91040			341.86	38.63	303.23	Esophageal balloon distension provocation study
						Gastric analysis test with injection of stimulant of
						gastric secretion (eg, histamine, insulin,
91052			111.85	33.29	78.56	pentagastrin, calcium and secretin)
						Gastric intubation, washings, and preparing slides
91055			119.12	36.58	82.54	for cytology (separate procedure)
						Breath hydrogen test (eg, for detection of lactase
						deficiency, fructose intolerance, bacterial
91065			52.58	8.11	44.46	overgrowth, or oro-cecal gastrointestinal transit)
						Intestinal bleeding tube, passage, positioning and
91100	113.42	41.58				monitoring
						Gastric intubation, and aspiration or lavage for
91105	73.55	13.62				treatment (eg, for ingested poisons)
						Gastrointestinal tract imaging, intraluminal (eg,
						capsule endoscopy), esophagus through ileum, with
91110			814.21	152.20	662.01	physician interpretation and report
						Gastrointestinal tract imaging, intraluminal (eg,
						capsule endoscopy), esophagus with physician
91111			652.74	43.45	609.28	interpretation and report
						Rectal sensation, tone, and compliance test (ie,
91120			358.53	38.84	319.69	response to graded balloon distention)
91122			209.52	72.39	137.13	Anorectal manometry
91123			I.C.			Pulsed irrigation of fecal impaction
91132			ļ	22.23		Electrogastrography, diagnostic, transcutaneous;
				1		Electrogastrography, diagnostic, transcutaneous;
91133				28.34		with provocative testing
91299			I.C.	I.C.	I.C.	Unlisted diagnostic gastroenterology procedure
				1		Ophthalmological services: medical examination
				1		and evaluation with initiation of diagnostic and
92002	56.44	34.92				treatment program; intermediate, new patient

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Ophthalmological services: medical examination
						and evaluation with initiation of diagnostic and
						treatment program; comprehensive, new patient, one
92004	105.62	72.19				or more visits
						Ophthalmological services: medical examination
						and evaluation, with initiation or continuation of
00010	50.55	26.04				diagnostic and treatment program; intermediate,
92012	59.55	36.04				established patient
						Ophthalmological services: medical examination
						and evaluation, with initiation or continuation of
92014	86.30	55.51				diagnostic and treatment program; comprehensive, established patient, one or more visits
92014	36.98	14.79				Determination of refractive state
72013	30.70	17.77				Ophthalmological examination and evaluation,
						under general anesthesia, with or without
						manipulation of globe for passive range of motion
						or other manipulation to facilitate diagnostic
92018			103.07			examination; complete
						Ophthalmological examination and evaluation,
						under general anesthesia, with or without
						manipulation of globe for passive range of motion
						or other manipulation to facilitate diagnostic
92019		1.7.10	52.44			examination; limited
92020	20.14	15.18				Gonioscopy (separate procedure)
02025			26.42	12.06	10.46	Computerized corneal topography, unilateral or
92025			26.42	13.96	12.46	bilateral, with interpretation and report
						Sensorimotor examination with multiple measurements of ocular deviation (eg, restrictive or
						paretic muscle with diplopia) with interpretation and
92060			44.73	28.30	16.44	report (separate procedure)
32000			11175	20.50	10.11	Orthoptic and/or pleoptic training, with continuing
92065			33.60	14.52	19.09	medical direction and evaluation
						Fitting of contact lens for treatment of disease,
92070	52.74	28.91				including supply of lens
						Visual field examination, unilateral or bilateral, with
						interpretation and report; limited examination (eg,
						tangent screen, Autoplot, arc perimeter, or single
						stimulus level automated test, such as Octopus 3 or
92081			41.93	14.57	27.36	7 equivalent)
						Visual field examination, unilateral or bilateral, with
						interpretation and report; intermediate examination
						(eg, at least 2 isopters on Goldmann perimeter, or semiquantitative, automated suprathreshold
						screening program, Humphrey suprathreshold
92082			54.76	17.79	36.96	automatic diagnostic test, Octopus program 33)
92002			34.70	17.79	30.90	automatic diagnostic test, Octopus program 53)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Visual field examination, unilateral or bilateral, with
						interpretation and report; extended examination (eg,
						Goldmann visual fields with at least 3 isopters
						plotted and static determination within the central
						30°, or quantitative, automated threshold perimetry,
						Octopus program G-1, 32 or 42, Humphrey visual
						field analyzer full threshold programs 30-2, 24-2, or
92083			63.05	20.46	42.59	30/60-2)
						Serial tonometry (separate procedure) with multiple
						measurements of intraocular pressure over an
						extended time period with interpretation and report,
						same day (eg, diurnal curve or medical treatment of
92100	68.82	36.70				acute elevation of intraocular pressure)
						Tonography with interpretation and report,
						recording indentation tonometer method or
92120	56.81	32.31				perilimbal suction method
92130	63.76	33.63				Tonography with water provocation
						Scanning computerized ophthalmic diagnostic
						imaging, posterior segment, (eg, scanning laser)
92135			36.35	14.29	22.07	with interpretation and report, unilateral
						Ophthalmic biometry by partial coherence
						interferometry with intraocular lens power
92136			67.78	22.57	45.21	calculation
						Provocative tests for glaucoma, with interpretation
92140	45.29	20.13				and report, without tonography
						Ophthalmoscopy, extended, with retinal drawing
00005	10.44	15.46				(eg, for retinal detachment, melanoma), with
92225	18.44	15.46				interpretation and report; initial
						Ophthalmoscopy, extended, with retinal drawing
02226	16.71	12.72				(eg, for retinal detachment, melanoma), with
92226	16.71	13.73				interpretation and report; subsequent
02220	52.60	22.47				Fluorescein angioscopy with interpretation and
92230	53.60	23.47				report
92235			105.11	33.96	71 15	Fluorescein angiography (includes multiframe
92233			103.11	33.90	71.15	imaging) with interpretation and report
92240			206.45	46.25	160.21	Indocyanine-green angiography (includes multiframe imaging) with interpretation and report
92240			59.39	17.79	41.60	Fundus photography with interpretation and report
	12.74	0 15	39.39	17.79	41.00	
92260	13.74	8.45		1		Ophthalmodynamometry Needle couled attempts greatly one or more
						Needle oculoelectromyography, one or more extraocular muscles, one or both eyes, with
92265			64.95	32.08	32.88	interpretation and report
92203			70.70	32.52	38.17	Electro-oculography with interpretation and report
92270			101.44	41.75	59.69	Electro-oculography with interpretation and report
34413			101.44	41.73	27.07	Color vision examination, extended, eg,
92283			35.30	6.95	28.36	anomaloscope or equivalent
72203			33.30	0.93	20.30	Dark adaptation examination with interpretation and
92284			56.79	9.23	47.56	*
72204	1		30.79	9.23	47.30	report

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						External ocular photography with interpretation and
						report for documentation of medical progress (eg,
						close-up photography, slit lamp photography,
92285			35.48	8.45	27.03	goniophotography, stereo-photography)
						Special anterior segment photography with
						interpretation and report; with specular endothelial
92286			104.04	27.13	76.91	microscopy and cell count
						Special anterior segment photography with
						interpretation and report; with fluorescein
92287	93.89	32.64				angiography
						Prescription of optical and physical characteristics
						of and fitting of contact lens, with medical
						supervision of adaptation; corneal lens, both eyes,
92310	69.60	45.43				except for aphakia
						Prescription of optical and physical characteristics
						of and fitting of contact lens, with medical
						supervision of adaptation; corneal lens for aphakia,
92311	69.86	41.71				one eye
						Prescription of optical and physical characteristics
						of and fitting of contact lens, with medical
						supervision of adaptation; corneal lens for aphakia,
92312	77.86	49.72				both eyes
						Prescription of optical and physical characteristics
						of and fitting of contact lens, with medical
92313	67.16	36.04				supervision of adaptation; corneoscleral lens
						Prescription of optical and physical characteristics
						of contact lens, with medical supervision of
						adaptation and direction of fitting by independent
						technician; corneal lens, both eyes except for
92314	53.91	26.43				aphakia
						Prescription of optical and physical characteristics
						of contact lens, with medical supervision of
00015	40.52	17.41				adaptation and direction of fitting by independent
92315	48.53	17.41				technician; corneal lens for aphakia, one eye
						Prescription of optical and physical characteristics
						of contact lens, with medical supervision of
02216	61 46	20.02				adaptation and direction of fitting by independent
92316	61.46	28.02				technician; corneal lens for aphakia, both eyes
						Prescription of optical and physical characteristics
						of contact lens, with medical supervision of
92317	49.86	17.08				adaptation and direction of fitting by independent technician; corneoscleral lens
94311	49.00	17.08				
92325			20.74			Modification of contact lens (separate procedure),
			40.36			with medical supervision of adaptation
92326			40.30			Replacement of contact lens Eiting of appetrals prostheris for appelies
02252	21.07	1/10				Fitting of spectacle prosthesis for aphakia;
92352	31.07	14.18			l	monofocal

114.3 CMR 17.00: MEDICINE

CODE	NFAC	FAC	GLOBAL FEE	PC FEE	TC FEE	DESCRIPTION
						Fitting of spectacle prosthesis for aphakia;
92353	36.24	19.35				multifocal
						Fitting of spectacle mounted low vision aid; single
92354			153.78			element system
						Fitting of spectacle mounted low vision aid;
92355			79.34			telescopic or other compound lens system
						Prosthesis service for aphakia, temporary
92358			20.94			(disposable or loan, including materials)
						Repair and refitting spectacles; spectacle prosthesis
92371			14.67			for aphakia
92499			I.C.	I.C.	I.C.	Unlisted ophthalmological service or procedure
						Otolaryngologic examination under general
92502			76.66			anesthesia
						Binocular microscopy (separate diagnostic
92504	23.45	7.56				procedure)
						Evaluation of speech, language, voice,
92506	125.63	35.91				communication, and/or auditory processing
						Treatment of speech, language, voice,
						communication, and/or auditory processing
92507	53.68	21.23				disorder; individual
						Treatment of speech, language, voice,
						communication, and/or auditory processing
92508	25.02	11.11				disorder; group, 2 or more individuals
						Nasopharyngoscopy with endoscope (separate
92511	130.70	47.93				procedure)
92512	51.21	21.74				Nasal function studies (eg, rhinomanometry)
						Facial nerve function studies (eg,
92516	52.28	18.18				electroneuronography)
						Laryngeal function studies (ie, aerodynamic testing
92520	45.42	31.84				and acoustic testing)
						Treatment of swallowing dysfunction and/or oral
92526	71.07	21.74				function for feeding
92531			I.C.			Spontaneous nystagmus, including gaze
92532			I.C.			Positional nystagmus test
						Caloric vestibular test, each irrigation (binaural,
92533			I.C.			bithermal stimulation constitutes four tests)
92534			I.C.			Optokinetic nystagmus test
						Spontaneous nystagmus test, including gaze and
92541			48.11	16.56	31.55	fixation nystagmus, with recording
						Positional nystagmus test, minimum of 4 positions,
92542			50.25	13.73	36.52	with recording
						Caloric vestibular test, each irrigation (binaural,
						bithermal stimulation constitutes four tests), with
92543			23.42	4.33	19.09	recording
						Optokinetic nystagmus test, bidirectional, foveal or
92544			40.02	10.78	29.23	peripheral stimulation, with recording
92545			36.86	9.61	27.25	Oscillating tracking test, with recording
92546			71.64	11.62	60.02	Sinusoidal vertical axis rotational testing

114.3 CMR 17.00: MEDICINE

	1		GLOBAL	PC	TC	T
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
CODE	INFAC	TAC	TEE	FEE	TEE	Use of vertical electrodes (List separately in
92547			4.27			addition to code for primary procedure)
92548			82.73	21.01	61.72	Computerized dynamic posturography
92551			8.49	21.01	01.72	Screening test, pure tone, air only
92552			18.07			Pure tone audiometry (threshold); air only
92553			24.79			Pure tone audiometry (threshold); air and bone
92555			14.10			Speech audiometry threshold;
92333			14.10			Speech audiometry threshold; with speech
92556			19.17			recognition
92557	43.82	42.17				Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)
92559			I.C.			Audiometric testing of groups
92560			I.C.			Bekesy audiometry; screening
92561			24.79			Bekesy audiometry; diagnostic
92562			17.74			Loudness balance test, alternate binaural or monaural
92563			16.09			Tone decay test
92564			16.63			Short increment sensitivity index (SISI)
92565			11.78			Stenger test, pure tone
92567	17.80	16.47				Tympanometry (impedance testing)
92568			16.90			Acoustic reflex testing; threshold
92569			14.39			Acoustic reflex testing; decay
92571			14.43			Filtered speech test
92572			11.47			Staggered spondaic word test
92575			24.60			Sensorineural acuity level test
92576			17.96			Synthetic sentence identification test
92577			17.73			Stenger test, speech
92579	38.70	36.72				Visual reinforcement audiometry (VRA)
92582			32.74			Conditioning play audiometry
92583			28.53			Select picture audiometry
92584			68.08			Electrocochleography
						Auditory evoked potentials for evoked response
						audiometry and/or testing of the central nervous
92585			86.47	20.56	65.91	system; comprehensive
						Auditory evoked potentials for evoked response
00505			 2-	1		audiometry and/or testing of the central nervous
92586			57.30	ļ		system; limited
						Evoked otoacoustic emissions; limited (single
92587			39.64	5.50	2/15	stimulus level, either transient or distortion products)
74301	1		39.04	5.50	34.15	1
						Evoked otoacoustic emissions; comprehensive or diagnostic evaluation (comparison of transient
				1		and/or distortion product otoacoustic emissions at
92588			58.74	14.90	43.84	multiple levels and frequencies)
				14.90	45.04	
92596			27.77	1		Ear protector attenuation measurements

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
02507	05.57	26.00				Evaluation for use and/or fitting of voice prosthetic
92597	85.57	36.90				device to supplement oral speech
02601	141.50	124.02				Diagnostic analysis of cochlear implant, patient
92601	141.52	134.23				younger than 7 years of age; with programming
						Diagnostic analysis of cochlear implant, patient
92602	91.09	02 01				younger than 7 years of age; subsequent
92002	91.09	83.81				reprogramming
02602	110.60	111 00				Diagnostic analysis of cochlear implant, age 7 years
92603	119.60	111.98				or older; with programming
02604	71.40	65.50				Diagnostic analysis of cochlear implant, age 7 years
92604	71.49	65.53				or older; subsequent reprogramming
						Evaluation for prescription of non-speech- generating augmentative and alternative
92605			I.C.			communication device
92003			1.C.			
						Therapeutic service(s) for the use of non-speech- generating device, including programming and
92606			I.C.			modification
92000			i.c.			Evaluation for prescription for speech-generating
						augmentative and alternative communication
92607			128.87			device, face-to-face with the patient; first hour
92007			120.07			Evaluation for prescription for speech-generating
						augmentative and alternative communication
						device, face-to-face with the patient; each additional
						30 minutes (List separately in addition to code for
92608			24.91			primary procedure)
72000			21.71			Therapeutic services for the use of speech-
						generating device, including programming and
92609			67.74			modification
						Evaluation of oral and pharyngeal swallowing
92610			86.80			function
						Motion fluoroscopic evaluation of swallowing
92611			90.78			function by cine or video recording
						Flexible fiberoptic endoscopic evaluation of
92612	131.00	54.19				swallowing by cine or video recording;
						Flexible fiberoptic endoscopic evaluation of
						swallowing by cine or video recording; physician
92613	31.49	31.15				interpretation and report only
						Flexible fiberoptic endoscopic evaluation, laryngeal
92614	117.75	54.19				sensory testing by cine or video recording;
						Flexible fiberoptic endoscopic evaluation, laryngeal
						sensory testing by cine or video recording;
92615			27.93			physician interpretation and report only
						Flexible fiberoptic endoscopic evaluation of
						swallowing and laryngeal sensory testing by cine or
92616	162.36	80.25				video recording;

114.3 CMR 17.00: MEDICINE

CODE	NFAC	FAC	GLOBAL FEE	PC FEE	TC FEE	DESCRIPTION
						Flexible fiberoptic endoscopic evaluation of
						swallowing and laryngeal sensory testing by cine or
						video recording; physician interpretation and report
92617			34.71			only
						Evaluation of central auditory function, with report;
92620			52.27			initial 60 minutes
						Evaluation of central auditory function, with report;
92621			12.54			each additional 15 minutes
						Assessment of tinnitus (includes pitch, loudness
92625			51.94			matching, and masking)
						Evaluation of auditory rehabilitation status; first
92626			70.81			hour
						Evaluation of auditory rehabilitation status; each
			4 6 0 0			additional 15 minutes (List separately in addition to
92627			16.98			code for primary procedure)
92630			I.C.			Auditory rehabilitation; prelingual hearing loss
92633			I.C.			Auditory rehabilitation; postlingual hearing loss
0.5.4.0						Diagnostic analysis with programming of auditory
92640			44.58			brainstem implant, per hour
02700			1.0			Unlisted otorhinolaryngological service or
92700			I.C.			procedure
02050	224.06	1.40.60				Cardiopulmonary resuscitation (eg, in cardiac
92950	234.96	140.60	0.17			arrest)
92953			9.17			Temporary transcutaneous pacing
92960	241.10	107.60				Cardioversion, elective, electrical conversion of
92900	241.10	107.68				arrhythmia; external Cardioversion, elective, electrical conversion of
92961			209.17			arrhythmia; internal (separate procedure)
92970			143.12			Cardioassist-method of circulatory assist; internal
92970			82.81			Cardioassist-method of circulatory assist, internal
92911			62.61			Percutaneous transluminal coronary thrombectomy
						(List separately in addition to code for primary
92973			146.81			procedure)
72713			110.01			Transcatheter placement of radiation delivery device
						for subsequent coronary intravascular brachytherapy
						(List separately in addition to code for primary
92974			134.60			procedure)
						Thrombolysis, coronary; by intracoronary infusion,
92975			323.07			including selective coronary angiography
92977			171.77			Thrombolysis, coronary; by intravenous infusion
						Intravascular ultrasound (coronary vessel or graft)
						during diagnostic evaluation and/or therapeutic
						intervention including imaging supervision,
						interpretation and report; initial vessel (List
						separately in addition to code for primary
92978	1		251.56	79.34	170.30	procedure)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Intravascular ultrasound (coronary vessel or graft)
						during diagnostic evaluation and/or therapeutic
						intervention including imaging supervision,
						interpretation and report; each additional vessel
						(List separately in addition to code for primary
92979			151.05	63.66	85.99	procedure)
						Transcatheter placement of an intracoronary
						stent(s), percutaneous, with or without other
92980			670.51			therapeutic intervention, any method; single vessel
						Transcatheter placement of an intracoronary
						stent(s), percutaneous, with or without other
						therapeutic intervention, any method; each
						additional vessel (List separately in addition to code
92981			186.24			for primary procedure)
						Percutaneous transluminal coronary balloon
92982			497.37			angioplasty; single vessel
						Percutaneous transluminal coronary balloon
						angioplasty; each additional vessel (List separately
92984			132.77			in addition to code for primary procedure)
92986			1115.96			Percutaneous balloon valvuloplasty; aortic valve
92987			1156.00			Percutaneous balloon valvuloplasty; mitral valve
						Percutaneous balloon valvuloplasty; pulmonary
92990			881.48			valve
						Atrial septectomy or septostomy; transvenous
						method, balloon (eg, Rashkind type) (includes
92992			I.C.			cardiac catheterization)
						Atrial septectomy or septostomy; blade method
92993			I.C.			(Park septostomy) (includes cardiac catheterization)
						Percutaneous transluminal coronary atherectomy, by
02007			5.46.06			mechanical or other method, with or without
92995			546.96			balloon angioplasty; single vessel
						Percutaneous transluminal coronary atherectomy, by
						mechanical or other method, with or without
						balloon angioplasty; each additional vessel (List
92996			142.12			separately in addition to code for primary
92996			143.13			procedure)
92997			515 90			Percutaneous transluminal pulmonary artery balloon
92991			515.80			angioplasty; single vessel Percutaneous transluminal pulmonary artery balloon
				1		angioplasty; each additional vessel (List separately
92998			259.29	1		in addition to code for primary procedure)
14330			439.43			Electrocardiogram, routine ECG with at least 12
93000			19.29	1		leads; with interpretation and report
9300U			17.47	1		Electrocardiogram, routine ECG with at least 12
93005			12.35	1		leads; tracing only, without interpretation and report
22002			14.33	1		Electrocardiogram, routine ECG with at least 12
93010			6.95	1		leads; interpretation and report only
93U1U	1]	0.93	L		icaus, interpretation and report only

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Telephonic transmission of post-symptom
						electrocardiogram rhythm strip(s), 24-hour attended
93012			172.38			monitoring, per 30 day period of time; tracing only
						Telephonic transmission of post-symptom
						electrocardiogram rhythm strip(s), 24-hour attended
						monitoring, per 30 day period of time; physician
93014			21.90			review with interpretation and report only
						Cardiovascular stress test using maximal or
						submaximal treadmill or bicycle exercise,
						continuous electrocardiographic monitoring, and/or
						pharmacological stress; with physician supervision,
93015			88.17			with interpretation and report
						Cardiovascular stress test using maximal or
						submaximal treadmill or bicycle exercise,
						continuous electrocardiographic monitoring, and/or
						pharmacological stress; physician supervision only,
93016			19.61			without interpretation and report
						Cardiovascular stress test using maximal or
						submaximal treadmill or bicycle exercise,
						continuous electrocardiographic monitoring, and/or
						pharmacological stress; tracing only, without
93017			55.67			interpretation and report
						Cardiovascular stress test using maximal or
						submaximal treadmill or bicycle exercise,
						continuous electrocardiographic monitoring, and/or
						pharmacological stress; interpretation and report
93018			12.89			only
93024			100.79	50.40	50.39	Ergonovine provocation test
						Microvolt T-wave alternans for assessment of
93025			214.97	32.83	182.14	ventricular arrhythmias
						Rhythm ECG, one to three leads; with interpretation
93040			11.52			and report
						Rhythm ECG, one to three leads; tracing only
93041			5.18			without interpretation and report
						Rhythm ECG, one to three leads; interpretation and
93042			6.34			report only
						Electrocardiographic monitoring for 24 hours by
			1			continuous original ECG waveform recording and
						storage, with visual superimposition scanning;
						includes recording, scanning analysis with report,
93224			118.00			physician review and interpretation
						Electrocardiographic monitoring for 24 hours by
						continuous original ECG waveform recording and
						storage, with visual superimposition scanning;
						recording (includes hook-up, recording, and
93225			36.48			disconnection)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Electrocardiographic monitoring for 24 hours by
						continuous original ECG waveform recording and
						storage, with visual superimposition scanning;
93226			58.96			scanning analysis with report
						Electrocardiographic monitoring for 24 hours by
						continuous original ECG waveform recording and
						storage, with visual superimposition scanning;
93227			22.56			physician review and interpretation
						Electrocardiographic monitoring for 24 hours by
						continuous original ECG waveform recording and
						storage without superimposition scanning utilizing a
						device capable of producing a full miniaturized
						printout; includes recording, microprocessor-based
0.0.0.0						analysis with report, physician review and
93230			122.73			interpretation
						Electrocardiographic monitoring for 24 hours by
						continuous original ECG waveform recording and
						storage without superimposition scanning utilizing a
						device capable of producing a full miniaturized
02221			20.44			printout; recording (includes hook-up, recording,
93231			39.44			and disconnection)
						Electrocardiographic monitoring for 24 hours by
						continuous original ECG waveform recording and storage without superimposition scanning utilizing a
						device capable of producing a full miniaturized
93232			61.39			printout; microprocessor-based analysis with report
93232			01.39			Electrocardiographic monitoring for 24 hours by
						continuous original ECG waveform recording and
						storage without superimposition scanning utilizing a
						device capable of producing a full miniaturized
93233			21.90			printout; physician review and interpretation
70 2 00			21.50			Electrocardiographic monitoring for 24 hours by
						continuous computerized monitoring and non-
						continuous recording, and real-time data analysis
						utilizing a device capable of producing intermittent
						full-sized waveform tracings, possibly patient
						activated; includes monitoring and real-time data
						analysis with report, physician review and
93235			117.75			interpretation
						Electrocardiographic monitoring for 24 hours by
						continuous computerized monitoring and non-
						continuous recording, and real-time data analysis
						utilizing a device capable of producing intermittent
						full-sized waveform tracings, possibly patient
						activated; monitoring and real-time data analysis
93236			97.95			with report

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Electrocardiographic monitoring for 24 hours by
						continuous computerized monitoring and non-
						continuous recording, and real-time data analysis
						utilizing a device capable of producing intermittent
						full-sized waveform tracings, possibly patient
93237			19.28			activated; physician review and interpretation
						Patient demand single or multiple event recording
						with presymptom memory loop, 24-hour attended
						monitoring, per 30 day period of time; includes
93268			239.37			transmission, physician review and interpretation
						Patient demand single or multiple event recording
						with presymptom memory loop, 24-hour attended
						monitoring, per 30 day period of time; recording
93270			26.88			(includes hook-up, recording, and disconnection)
						Patient demand single or multiple event recording
						with presymptom memory loop, 24-hour attended
						monitoring, per 30 day period of time; monitoring,
93271			190.92			receipt of transmissions, and analysis
						Patient demand single or multiple event recording
						with presymptom memory loop, 24-hour attended
						monitoring, per 30 day period of time; physician
93272			21.57			review and interpretation only
						Signal-averaged electrocardiography (SAECG),
93278			40.34	10.50	29.84	with or without ECG
						Transthoracic echocardiography for congenital
93303			188.09	53.70	134.39	cardiac anomalies; complete
						Transthoracic echocardiography for congenital
93304			112.55	30.96	81.59	cardiac anomalies; follow-up or limited study
						Echocardiography, transthoracic, real-time with
						image documentation (2D) with or without M-mode
93307			162.70	39.57	123.13	recording; complete
						Echocardiography, transthoracic, real-time with
						image documentation (2D) with or without M-mode
93308			96.81	22.84	73.97	recording; follow-up or limited study
						Echocardiography, transesophageal, real time with
						image documentation (2D) (with or without M-
						mode recording); including probe placement, image
93312			267.34	92.26	175.08	acquisition, interpretation and report
						Echocardiography, transesophageal, real time with
						image documentation (2D) (with or without M-
			1			mode recording); placement of transesophageal
93313			33.43			probe only
						Echocardiography, transesophageal, real time with
						image documentation (2D) (with or without M-
						mode recording); image acquisition, interpretation
93314			231.68	52.63	179.05	and report only

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Transesophageal echocardiography for congenital
						cardiac anomalies; including probe placement,
93315			258.12	117.93	131.97	image acquisition, interpretation and report
						Transesophageal echocardiography for congenital
						cardiac anomalies; placement of transesophageal
93316			35.87			probe only
						Transesophageal echocardiography for congenital
						cardiac anomalies; image acquisition, interpretation
93317			215.92	72.99	132.84	and report only
						Echocardiography, transesophageal (TEE) for
						monitoring purposes, including probe placement,
						real time 2-dimensional image acquisition and
						interpretation leading to ongoing (continuous)
						assessment of (dynamically changing) cardiac
						pumping function and to therapeutic measures on an
93318				86.59		immediate time basis
						Doppler echocardiography, pulsed wave and/or
						continuous wave with spectral display (List
02220			72.00	16.45	55.55	separately in addition to codes for
93320			72.00	16.45	55.55	echocardiographic imaging); complete
						Doppler echocardiography, pulsed wave and/or
						continuous wave with spectral display (List
						separately in addition to codes for
						echocardiographic imaging); follow-up or limited
93321			35.59	6.72	28.87	study (List separately in addition to codes for echocardiographic imaging)
93321			33.39	0.72	20.07	Doppler echocardiography color flow velocity
						mapping (List separately in addition to codes for
93325			66.27	3.16	63.11	echocardiography)
75525			00.27	3.10	03.11	Echocardiography, transthoracic, real-time with
						image documentation (2D), with or without M-
						mode recording, during rest and cardiovascular
						stress test using treadmill, bicycle exercise and/or
						pharmacologically induced stress, with
93350			168.01	64.23	103.77	interpretation and report
93501			720.41	133.83	586.58	Right heart catheterization
						Insertion and placement of flow directed catheter
93503			105.29			(eg, Swan-Ganz) for monitoring purposes
93505			538.75	193.97	344.78	Endomyocardial biopsy
						Catheter placement in coronary artery(s), arterial
						coronary conduit(s), and/or venous coronary bypass
						graft(s) for coronary angiography without
93508			855.22	190.69	664.53	concomitant left heart catheterization
						Left heart catheterization, retrograde, from the
						brachial artery, axillary artery or femoral artery;
93510			1290.69	200.85	1089.84	percutaneous

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Left heart catheterization, retrograde, from the
						brachial artery, axillary artery or femoral artery; by
93511			1597.48	232.06	1349.96	cutdown
						Left heart catheterization by left ventricular
93514			1671.52	307.67	1334.94	puncture
						Combined transseptal and retrograde left heart
93524			2100.55	318.90	1042.19	catheterization
						Combined right heart catheterization and retrograde
93526			1666.16	274.92	1391.24	left heart catheterization
						Combined right heart catheterization and transseptal
					.=	left heart catheterization through intact septum (with
93527			2116.99	332.73	1766.34	or without retrograde left heart catheterization)
						Combined right heart catheterization with left
02520			2100.40	40.4.20	1760.07	ventricular puncture (with or without retrograde left
93528			2199.49	404.29	1768.07	heart catheterization)
						Combined right heart catheterization and left heart
02520			1000.26	221.24	1764 22	catheterization through existing septal opening (with
93529			1998.26	221.24	1764.32	or without retrograde left heart catheterization)
02520			940.27	106.50	(2)(12)	Right heart catheterization, for congenital cardiac
93530			840.37	186.59	636.12	anomalies
						Combined right heart catheterization and retrograde
02521			2218.19	262 77	1822.31	left heart catheterization, for congenital cardiac anomalies
93531			2210.19	363.77	1022.31	Combined right heart catheterization and transseptal
						left heart catheterization through intact septum with
						or without retrograde left heart catheterization, for
93532			2220.85	424.43	1748.62	congenital cardiac anomalies
75552			2220.03	727.73	1740.02	Combined right heart catheterization and transseptal
						left heart catheterization through existing septal
						opening, with or without retrograde left heart
93533			2056.78	295.48	1743.50	catheterization, for congenital cardiac anomalies
						Injection procedure during cardiac catheterization;
						for selective opacification of arterial conduits (eg,
						internal mammary), whether native or used for
93539	54.75	17.67				bypass
						Injection procedure during cardiac catheterization;
						for selective opacification of aortocoronary venous
93540	157.56	18.84				bypass grafts, one or more coronary arteries
						Injection procedure during cardiac catheterization;
93541			12.61			for pulmonary angiography
						Injection procedure during cardiac catheterization;
				1		for selective right ventricular or right atrial
93542	96.05	12.61				angiography
				1		Injection procedure during cardiac catheterization;
						for selective left ventricular or left atrial
93543	53.67	12.61				angiography
						Injection procedure during cardiac catheterization;
93544	39.31	11.17				for aortography

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Injection procedure during cardiac catheterization;
						for selective coronary angiography (injection of
93545	111.03	17.67				radiopaque material may be by hand)
						Imaging supervision, interpretation and report for
						injection procedure(s) during cardiac
						catheterization; ventricular and/or atrial
93555			149.41	35.50	113.91	angiography
						Imaging supervision, interpretation and report for
						injection procedure(s) during cardiac
						catheterization; pulmonary angiography,
						aortography, and/or selective coronary angiography
						including venous bypass grafts and arterial conduits
93556			218.51	36.39	182.12	(whether native or used in bypass)
						Indicator dilution studies such as dye or thermal
						dilution, including arterial and/or venous
						catheterization; with cardiac output measurement
93561			42.07	19.35	20.46	(separate procedure)
						Indicator dilution studies such as dye or thermal
						dilution, including arterial and/or venous
						catheterization; subsequent measurement of cardiac
93562			19.77	6.00	12.76	output
						Intravascular Doppler velocity and/or pressure
						derived coronary flow reserve measurement
						(coronary vessel or graft) during coronary
						angiography including pharmacologically induced
			• • • • • •	- 0.60	.=0.45	stress; initial vessel (List separately in addition to
93571			250.66	78.68	170.42	code for primary procedure)
						Intravascular Doppler velocity and/or pressure
						derived coronary flow reserve measurement
						(coronary vessel or graft) during coronary
						angiography including pharmacologically induced
02572			147.54	(1.50	04.70	stress; each additional vessel (List separately in
93572			147.54	61.58	84.78	addition to code for primary procedure)
						Percutaneous transcatheter closure of congenital
02500			906.53			interatrial communication (ie, Fontan fenestration,
93580			806.52			atrial septal defect) with implant
02501			1064.67			Percutaneous transcatheter closure of a congenital
93581			1064.67	04.20	72.60	ventricular septal defect with implant
93600			171.35	94.39	73.69	Bundle of His recording
93602			139.29	93.61	41.67	Intra-atrial recording
93603	1		160.68	93.50	63.18	Right ventricular recording
						Intraventricular and/or intra-atrial mapping of
						tachycardia site(s) with catheter manipulation to
						record from multiple sites to identify origin of
02600			222.20	222.61	102.52	tachycardia (List separately in addition to code for
93609	 		332.30	222.61	102.52	primary procedure)
93610	1		189.98	132.82	51.11	Intra-atrial pacing
93612			196.00	132.37	60.74	Intraventricular pacing

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Intracardiac electrophysiologic 3-dimensional
						mapping (List separately in addition to code for
93613			312.56			primary procedure)
						Esophageal recording of atrial electrogram with or
93615			52.67	41.52	12.09	without ventricular electrogram(s);
						Esophageal recording of atrial electrogram with or
93616			75.82	55.11	12.08	without ventricular electrogram(s); with pacing
93618			344.53	190.29	148.85	Induction of arrhythmia by electrical pacing
						Comprehensive electrophysiologic evaluation with
						right atrial pacing and recording, right ventricular
						pacing and recording, His bundle recording,
						including insertion and repositioning of multiple
						electrode catheters, without induction or attempted
93619			636.27	331.86	289.01	induction of arrhythmia
						Comprehensive electrophysiologic evaluation
						including insertion and repositioning of multiple
						electrode catheters with induction or attempted
						induction of arrhythmia; with right atrial pacing and
00.00						recording, right ventricular pacing and recording,
93620			842.93	520.89	308.39	His bundle recording
						Comprehensive electrophysiologic evaluation
						including insertion and repositioning of multiple
						electrode catheters with induction or attempted
						induction of arrhythmia; with left atrial pacing and
						recording from coronary sinus or left atrium (List
93621				93.62		separately in addition to code for primary procedure)
93021				93.02		Comprehensive electrophysiologic evaluation
						including insertion and repositioning of multiple
						electrode catheters with induction or attempted
						induction of arrhythmia; with left ventricular pacing
						and recording (List separately in addition to code
93622				137.27		for primary procedure)
-				· · ·		Programmed stimulation and pacing after
						intravenous drug infusion (List separately in
93623				126.88		addition to code for primary procedure)
						Electrophysiologic follow-up study with pacing and
						recording to test effectiveness of therapy, including
93624			306.06	220.52	74.63	induction or attempted induction of arrhythmia
						Intra-operative epicardial and endocardial pacing
						and mapping to localize the site of tachycardia or
93631			585.46	324.06	234.59	zone of slow conduction for surgical correction
						Electrophysiologic evaluation of single or dual
						chamber pacing cardioverter-defibrillator leads
						including defibrillation threshold evaluation
						(induction of arrhythmia, evaluation of sensing and
						pacing for arrhythmia termination) at time of initial
93640			430.16	155.77	269.35	implantation or replacement;

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Electrophysiologic evaluation of single or dual
						chamber pacing cardioverter-defibrillator leads
						including defibrillation threshold evaluation
						(induction of arrhythmia, evaluation of sensing and
						pacing for arrhythmia termination) at time of initial
						implantation or replacement; with testing of single
						or dual chamber pacing cardioverter-defibrillator
93641			541.57	263.76	269.32	pulse generator
						Electrophysiologic evaluation of single or dual
						chamber pacing cardioverter-defibrillator (includes
						defibrillation threshold evaluation, induction of
						arrhythmia, evaluation of sensing and pacing for
						arrhythmia termination, and programming or
						reprogramming of sensing or therapeutic
93642			425.89	219.22	206.67	parameters)
						Intracardiac catheter ablation of atrioventricular
						node function, atrioventricular conduction for
						creation of complete heart block, with or without
93650			477.98			temporary pacemaker placement
						Intracardiac catheter ablation of arrhythmogenic
						focus; for treatment of supraventricular tachycardia
						by ablation of fast or slow atrioventricular
						pathways, accessory atrioventricular connections or
93651			723.27			other atrial foci, singly or in combination
						Intracardiac catheter ablation of arrhythmogenic
93652			787.89			focus; for treatment of ventricular tachycardia
						Evaluation of cardiovascular function with tilt table
						evaluation, with continuous ECG monitoring and
						intermittent blood pressure monitoring, with or
93660			144.19	82.18	62.01	without pharmacological intervention
						Intracardiac echocardiography during
						therapeutic/diagnostic intervention, including
						imaging supervision and interpretation (List
						separately in addition to code for primary
93662				122.80		procedure)
						Peripheral arterial disease (PAD) rehabilitation, per
93668			13.79			session
93701			32.99	7.28	25.71	Bioimpedance, thoracic, electrical
						Plethysmography, total body; with interpretation
93720			38.36			and report
						Plethysmography, total body; tracing only, without
93721			31.75			interpretation and report
						Plethysmography, total body; interpretation and
93722			6.62			report only

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Electronic analysis of antitachycardia pacemaker
						system (includes electrocardiographic recording,
						programming of device, induction and termination
						of tachycardia via implanted pacemaker, and
93724			295.23	209.95	85.27	interpretation of recordings)
						Electronic analysis of implantable loop recorder
						(ILR) system (includes retrieval of recorded and
						stored ECG data, physician review and
						interpretation of retrieved ECG data and
93727			28.85			reprogramming)
						Electronic analysis of dual-chamber pacemaker
						system (includes evaluation of programmable
						parameters at rest and during activity where
						applicable, using electrocardiographic recording and
						interpretation of recordings at rest and during
						exercise, analysis of event markers and device
93731			37.47	19.40	18.07	response); without reprogramming
						Electronic analysis of dual-chamber pacemaker
						system (includes evaluation of programmable
						parameters at rest and during activity where
						applicable, using electrocardiographic recording and
						interpretation of recordings at rest and during
						exercise, analysis of event markers and device
93732			60.62	40.23	20.39	response); with reprogramming
						Electronic analysis of dual chamber internal
						pacemaker system (may include rate, pulse
						amplitude and duration, configuration of wave form,
						and/or testing of sensory function of pacemaker),
93733			34.72	7.28	27.44	telephonic analysis
						Electronic analysis of single chamber pacemaker
						system (includes evaluation of programmable
						parameters at rest and during activity where
						applicable, using electrocardiographic recording and
						interpretation of recordings at rest and during
						exercise, analysis of event markers and device
93734			31.12	16.45	14.67	response); without reprogramming
						Electronic analysis of single chamber pacemaker
						system (includes evaluation of programmable
						parameters at rest and during activity where
						applicable, using electrocardiographic recording and
						interpretation of recordings at rest and during
						exercise, analysis of event markers and device
93735			49.75	32.01	17.74	response); with reprogramming
						Electronic analysis of single chamber internal
						pacemaker system (may include rate, pulse
						amplitude and duration, configuration of wave form,
						and/or testing of sensory function of pacemaker),
93736			31.84	6.39	25.46	telephonic analysis

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
93740			8.54	6.00	2.53	Temperature gradient studies
						Electronic analysis of pacing cardioverter-
						defibrillator (includes interrogation, evaluation of
						pulse generator status, evaluation of programmable
						parameters at rest and during activity where
						applicable, using electrocardiographic recording and
						interpretation of recordings at rest and during
						exercise, analysis of event markers and device
						response); single chamber or wearable cardioverter-
93741			56.61	34.89	21.72	defibrillator system, without reprogramming
						Electronic analysis of pacing cardioverter-
						defibrillator (includes interrogation, evaluation of
						pulse generator status, evaluation of programmable
						parameters at rest and during activity where
						applicable, using electrocardiographic recording and
						interpretation of recordings at rest and during
						exercise, analysis of event markers and device
						response); single chamber or wearable cardioverter-
93742			62.99	39.95	23.04	defibrillator system, with reprogramming
						Electronic analysis of pacing cardioverter-
						defibrillator (includes interrogation, evaluation of
						pulse generator status, evaluation of programmable
						parameters at rest and during activity where
						applicable, using electrocardiographic recording and
						interpretation of recordings at rest and during
						exercise, analysis of event markers and device
93743			68.66	44.95	23.70	response); dual chamber, without reprogramming
						Electronic analysis of pacing cardioverter-
						defibrillator (includes interrogation, evaluation of
						pulse generator status, evaluation of programmable
						parameters at rest and during activity where
						applicable, using electrocardiographic recording and
						interpretation of recordings at rest and during
02744			75.20	51.67	22.70	exercise, analysis of event markers and device
93744			75.38	51.67	23.70	response); dual chamber, with reprogramming
						Initial set-up and programming by a physician of
			1			wearable cardioverter-defibrillator includes initial programming of system, establishing baseline
				1		electronic ECG, transmission of data to data
				1		repository, patient instruction in wearing system and
93745			I.C.	I.C.	I.C.	patient reporting of problems or events
93743			I.C.	1.0.	1.0.	Thermogram; cephalic
93760			I.C.			Thermogram; cepnanc Thermogram; peripheral
93762			6.55	6.00	0.55	Determination of venous pressure
73110			0.33	0.00	0.33	Ambulatory blood pressure monitoring, utilizing a
				1		system such as magnetic tape and/or computer disk,
				1		for 24 hours or longer; including recording,
93784			59.92	1		scanning analysis, interpretation and report
7J / 04	<u> </u>		J7.7 <i>L</i>	l	<u> </u>	scanning analysis, interpretation and report

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Ambulatory blood pressure monitoring, utilizing a
						system such as magnetic tape and/or computer disk,
93786			28.69			for 24 hours or longer; recording only
						Ambulatory blood pressure monitoring, utilizing a
						system such as magnetic tape and/or computer disk,
93788			16.11			for 24 hours or longer; scanning analysis with report
						Ambulatory blood pressure monitoring, utilizing a
						system such as magnetic tape and/or computer disk,
						for 24 hours or longer; physician review with
93790			15.13			interpretation and report
						Physician services for outpatient cardiac
						rehabilitation; without continuous ECG monitoring
93797	15.50	7.89				(per session)
						Physician services for outpatient cardiac
						rehabilitation; with continuous ECG monitoring (per
93798	22.93	12.00				session)
93799			I.C.	I.C.	I.C.	Unlisted cardiovascular service or procedure
						Noninvasive physiologic studies of extracranial
						arteries, complete bilateral study (eg, periorbital
						flow direction with arterial compression, ocular
						pneumoplethysmography, Doppler ultrasound
93875			89.50	8.67	80.83	spectral analysis)
						Duplex scan of extracranial arteries; complete
93880			218.80	24.23	194.57	bilateral study
						Duplex scan of extracranial arteries; unilateral or
93882			143.22	16.33	126.89	limited study
						Transcranial Doppler study of the intracranial
93886			263.68	38.12	225.56	arteries; complete study
						Transcranial Doppler study of the intracranial
93888			175.48	25.33	150.15	arteries; limited study
						Transcranial Doppler study of the intracranial
93890			225.63	41.12	184.51	arteries; vasoreactivity study
						Transcranial Doppler study of the intracranial
						arteries; emboli detection without intravenous
93892			240.41	46.30	194.11	microbubble injection
						Transcranial Doppler study of the intracranial
						arteries; emboli detection with intravenous
93893			240.74	46.30	194.44	microbubble injection
						Noninvasive physiologic studies of upper or lower
						extremity arteries, single level, bilateral (eg,
						ankle/brachial indices, Doppler waveform analysis,
						volume plethysmography, transcutaneous oxygen
93922			106.21	10.06	96.16	tension measurement)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	<u> </u>
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
CODE	MIAC	TAC	FEE	FEE	TEE	Noninvasive physiologic studies of upper or lower
						extremity arteries, multiple levels or with
						provocative functional maneuvers, complete
						bilateral study (eg, segmental blood pressure
						measurements, segmental Doppler waveform
						analysis, segmental volume plethysmography,
						segmental transcutaneous oxygen tension
						measurements, measurements with postural
						provocative tests, measurements with reactive
93923			162.16	18.05	144.11	hyperemia)
						Noninvasive physiologic studies of lower extremity
						arteries, at rest and following treadmill stress
93924			197.86	20.66	177.20	testing, complete bilateral study
						Duplex scan of lower extremity arteries or arterial
93925			269.56	23.34	246.22	bypass grafts; complete bilateral study
						Duplex scan of lower extremity arteries or arterial
93926			168.98	15.72	153.26	bypass grafts; unilateral or limited study
						Duplex scan of upper extremity arteries or arterial
93930			213.67	18.66	195.00	bypass grafts; complete bilateral study
						Duplex scan of upper extremity arteries or arterial
93931			141.25	12.61	128.64	bypass grafts; unilateral or limited study
						Noninvasive physiologic studies of extremity veins,
						complete bilateral study (eg, Doppler waveform
						analysis with responses to compression and other
						maneuvers, phleborheography, impedance
93965			108.79	13.84	94.95	plethysmography)
						Duplex scan of extremity veins including responses
						to compression and other maneuvers; complete
93970			218.56	27.55	191.01	bilateral study
						Duplex scan of extremity veins including responses
00074			1.15.00	40.45	125.62	to compression and other maneuvers; unilateral or
93971			145.80	18.17	127.63	limited study
						Duplex scan of arterial inflow and venous outflow
93975			328.45	73.23	255.22	of abdominal, pelvic, scrotal contents and/or
93973			328.43	13.23	233.22	retroperitoneal organs; complete study
						Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or
93976			188.62	48.42	140.20	retroperitoneal organs; limited study
737/0			100.02	40.42	140.20	Duplex scan of aorta, inferior vena cava, iliac
93978			202.18	26.71	175.47	vasculature, or bypass grafts; complete study
73710			202.10	20.71	113.41	Duplex scan of aorta, inferior vena cava, iliac
				1		vasculature, or bypass grafts; unilateral or limited
93979			140.25	17.89	122.35	study
75717			170.23	17.09	144.33	Duplex scan of arterial inflow and venous outflow
93980			148.53	50.84	97.68	of penile vessels; complete study
72700			110.55	20.07	27.00	Duplex scan of arterial inflow and venous outflow
93981			114.06	17.68	96.38	of penile vessels; follow-up or limited study
73701	1	l	117.00	17.00	70.50	or perme vessers, ronow-up or minicu study

114.3 CMR 17.00: MEDICINE

	<u> </u>		GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
0022	112120				122	Noninvasive physiologic study of implanted
						wireless pressure sensor in aneurysmal sac
						following endovascular repair, complete study
						including recording, analysis of pressure and
93982			35.07			waveform tracings, interpretation and report
						Duplex scan of hemodialysis access (including
93990			165.19	10.27	154.92	arterial inflow, body of access and venous outflow)
						Ventilation assist and management, initiation of
						pressure or volume preset ventilators for assisted or
						controlled breathing; hospital inpatient/observation,
94002			68.73			initial day
						Ventilation assist and management, initiation of
						pressure or volume preset ventilators for assisted or
						controlled breathing; hospital inpatient/observation,
94003			50.12			each subsequent day
						Ventilation assist and management, initiation of
						pressure or volume preset ventilators for assisted or
94004			36.39			controlled breathing; nursing facility, per day
						Home ventilator management care plan oversight of
						a patient (patient not present) in home, domiciliary
						or rest home (eg, assisted living) requiring review of
						status, review of laboratories and other studies and
						revision of orders and respiratory care plan (as
						appropriate), within a calendar month, 30 minutes or
94005			66.33			more
						Spirometry, including graphic record, total and
						timed vital capacity, expiratory flow rate
04010			20.00	((2	22.20	measurement(s), with or without maximal voluntary
94010			28.90	6.62	22.28	ventilation
						Patient-initiated spirometric recording per 30-day
						period of time; includes reinforced education,
						transmission of spirometric tracing, data capture,
94014			40.98			analysis of transmitted data, periodic recalibration and physician review and interpretation
94014			40.96			Patient-initiated spirometric recording per 30-day
						period of time; recording (includes hook-up,
						reinforced education, data transmission, data
94015			21.07			capture, trend analysis, and periodic recalibration)
94013			21.07			Patient-initiated spirometric recording per 30-day
						period of time; physician review and interpretation
94016			19.91			only
77010	+		17.71			Bronchodilation responsiveness, spirometry as in
94060			49.55	11.52	38.04	94010, pre- and post-bronchodilator administration
77000	+		77.33	11.J4	20.04	Bronchospasm provocation evaluation, multiple
						spirometric determinations as in 94010, with
						administered agents (eg, antigen[s], cold air,
94070			49.34	22.69	26.65	methacholine)
94150			17.94	2.83	15.11	Vital capacity, total (separate procedure)
74120			11.77	2.03	12.11	, mai capacity, total (separate procedure)

114.3 CMR 17.00: MEDICINE

CODE	NEAC	EAC	GLOBAL	PC	TC	DESCRIPTION
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
0.4200			10.20	4.20	15.00	Maximum breathing capacity, maximal voluntary
94200			19.28	4.28	15.00	ventilation
						Functional residual capacity or residual volume:
94240			22.05	0.70	22.26	helium method, nitrogen open circuit method, or other method
94240			33.05	9.79	23.26	
0.4250			22.70	4.20	10.42	Expired gas collection, quantitative, single
94250 94260			22.70	4.28	18.42	procedure (separate procedure)
94200			26.55	4.84	21.72	Thoracic gas volume
						Determination of maldistribution of inspired gas: multiple breath nitrogen washout curve including
94350			31.18	9.79	21.39	alveolar nitrogen or helium equilibration time
94330			31.10	9.19	21.39	Determination of resistance to airflow, oscillatory or
94360			35.91	9.79	26.12	plethysmographic methods
94300			33.91	9.19	20.12	
94370			29.75	9.79	19.96	Determination of airway closing volume, single breath tests
94375			31.15	11.52		
					19.63	Respiratory flow volume loop Breathing response to CO2 (CO2 response curve)
94400			44.22	15.45	28.77	
04450			12.19	14.01	27.50	Breathing response to hypoxia (hypoxia response
94450			42.48	14.91	27.58	curve) High altitude simulation test (HAST), with
94452			47.25	11.72	35.52	
94432			47.23	11.73	33.32	physician interpretation and report;
						High altitude simulation test (HAST), with
94453			65.00	15 24	40.76	physician interpretation and report; with
94433			03.00	15.24	49.76	supplemental oxygen titration
94610			49.22			Intrapulmonary surfactant administration by a physician through endotracheal tube
94010			49.22			Pulmonary stress testing; simple (eg, 6-minute walk
						test, prolonged exercise test for bronchospasm with
94620			74.95	24.47	50.48	pre- and post-spirometry and oximetry)
94020			74.93	24.47	30.40	Pulmonary stress testing; complex (including
						measurements of CO2 production, O2 uptake, and
94621			132.13	55.49	76.64	electrocardiographic recordings)
74021			132.13	33.43	70.04	Pressurized or nonpressurized inhalation treatment
						for acute airway obstruction or for sputum induction
						for diagnostic purposes (eg, with an aerosol
						generator, nebulizer, metered dose inhaler or
						intermittent positive pressure breathing [IPPB]
94640			11.69			device)
71010			11.05			Aerosol inhalation of pentamidine for pneumocystis
94642			31.15			carinii pneumonia treatment or prophylaxis
2.101 <u>2</u>			51.15			Continuous inhalation treatment with aerosol
94644			32.21			medication for acute airway obstruction; first hour
			52.21			Continuous inhalation treatment with aerosol
						medication for acute airway obstruction; each
			1			additional hour (List separately in addition to code
94645			12.02			for primary procedure)
× 10 13			12.02			Continuous positive airway pressure ventilation
94660	46.24	29.02				(CPAP), initiation and management

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Continuous negative pressure ventilation (CNP),
94662			28.81			initiation and management
						Demonstration and/or evaluation of patient
						utilization of an aerosol generator, nebulizer,
94664			12.78			metered dose inhaler or IPPB device
						Manipulation chest wall, such as cupping,
						percussing, and vibration to facilitate lung function;
94667			18.62			initial demonstration and/or evaluation
						Manipulation chest wall, such as cupping,
						percussing, and vibration to facilitate lung function;
94668			16.32			subsequent
						Oxygen uptake, expired gas analysis; rest and
94680			57.10	9.79	47.31	exercise, direct, simple
						Oxygen uptake, expired gas analysis; including CO2
94681			67.64	7.45	60.18	output, percentage oxygen extracted
						Oxygen uptake, expired gas analysis; rest, indirect
94690			53.35	2.83	50.52	(separate procedure)
						Carbon monoxide diffusing capacity (eg, single
94720			44.52	9.79	34.73	breath, steady state)
94725			74.28	9.79	64.49	Membrane diffusion capacity
31723			7 1.20	7.17	01.12	Pulmonary compliance study (eg, plethysmography,
94750			58.81	8.62	50.19	volume and pressure measurements)
74750			30.01	0.02	30.17	Noninvasive ear or pulse oximetry for oxygen
94760			2.08			saturation; single determination
74700			2.00			Noninvasive ear or pulse oximetry for oxygen
						saturation; multiple determinations (eg, during
94761			4.27			exercise)
94701			4.27			Noninvasive ear or pulse oximetry for oxygen
						saturation; by continuous overnight monitoring
94762			24.00			(separate procedure)
94702			24.00			Carbon dioxide, expired gas determination by
94770			31.73	5.73	26.00	infrared analyzer
94770			31.73	3.13	20.00	Circadian respiratory pattern recording (pediatric
						pneumogram), 12-24 hour continuous recording,
94772			I.C.	I.C.	I.C.	infant
74112			I.C.	i.C.	I.C.	Pediatric home apnea monitoring event recording
						including respiratory rate, pattern and heart rate per
						30-day period of time; includes monitor attachment,
94774			I.C.			download of data, physician review, interpretation,
74114			I.C.			and preparation of a report
						Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per
						30-day period of time; monitor attachment only
04775			I.C			(includes hook-up, initiation of recording and
94775			I.C.			disconnection)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Pediatric home apnea monitoring event recording
						including respiratory rate, pattern and heart rate per
						30-day period of time; monitoring, download of
						information, receipt of transmission(s) and analyses
94776			I.C.			by computer only
						Pediatric home apnea monitoring event recording
						including respiratory rate, pattern and heart rate per
						30-day period of time; physician review,
94777			I.C.			interpretation and preparation of report only
94799			I.C.	I.C.	I.C.	Unlisted pulmonary service or procedure
						Percutaneous tests (scratch, puncture, prick) with
						allergenic extracts, immediate type reaction,
						including test interpretation and report by a
95004			4.80			physician, specify number of tests
						Percutaneous tests (scratch, puncture, prick)
						sequential and incremental, with drugs, biologicals
						or venoms, immediate type reaction, specify number
95010			15.00			of tests
95012			16.44			Nitric oxide expired gas determination
						Intracutaneous (intradermal) tests, sequential and
						incremental, with drugs, biologicals, or venoms,
95015			10.36			immediate type reaction, specify number of tests
						Intracutaneous (intradermal) tests with allergenic
						extracts, immediate type reaction, including test
						interpretation and report by a physician, specify
95024			5.79			number of tests
						Intracutaneous (intradermal) tests, sequential and
						incremental, with allergenic extracts for airborne
						allergens, immediate type reaction, including test
						interpretation and report by a physician, specify
95027			4.47			number of tests
						Intracutaneous (intradermal) tests with allergenic
						extracts, delayed type reaction, including reading,
95028			9.15			specify number of tests
95044			6.17			Patch or application test(s) (specify number of tests)
95052			6.84			Photo patch test(s) (specify number of tests)
95056			23.72			Photo tests
95060			18.31			Ophthalmic mucous membrane tests
95065			15.11			Direct nasal mucous membrane test
						Inhalation bronchial challenge testing (not including
						necessary pulmonary function tests); with
95070			51.75			histamine, methacholine, or similar compounds
						Inhalation bronchial challenge testing (not including
						necessary pulmonary function tests); with antigens
95071			64.99			or gases, specify
						Ingestion challenge test (sequential and incremental
						ingestion of test items, eg, food, drug or other
95075	51.99	37.76				substance such as metabisulfite)

114.3 CMR 17.00: MEDICINE

CODE	NFAC	FAC	GLOBAL FEE	PC FEE	TC FEE	DESCRIPTION
						Professional services for allergen immunotherapy
						not including provision of allergenic extracts; single
95115			10.69			injection
						Professional services for allergen immunotherapy
						not including provision of allergenic extracts; two or
95117			13.34			more injections
						Professional services for allergen immunotherapy in
						prescribing physicians office or institution,
						including provision of allergenic extract; single
95120			I.C.			injection
						Professional services for allergen immunotherapy in
						prescribing physicians office or institution,
						including provision of allergenic extract; two or
95125			I.C.			more injections
	<u> </u>					Professional services for allergen immunotherapy in
						prescribing physicians office or institution,
						including provision of allergenic extract; single
95130			I.C.			stinging insect venom
70100			1.01			Professional services for allergen immunotherapy in
						prescribing physicians office or institution,
						including provision of allergenic extract; two
95131			I.C.			stinging insect venoms
70101			1.01			Professional services for allergen immunotherapy in
						prescribing physicians office or institution,
						including provision of allergenic extract; three
95132			I.C.			stinging insect venoms
30102			1.01			Professional services for allergen immunotherapy in
						prescribing physicians office or institution,
						including provision of allergenic extract; four
95133			I.C.			stinging insect venoms
						Professional services for allergen immunotherapy in
						prescribing physicians office or institution,
						including provision of allergenic extract; five
95134			I.C.			stinging insect venoms
						Professional services for the supervision of
						preparation and provision of antigens for allergen
						immunotherapy, single dose vial(s) (specify number
95144	9.50	2.55				of vials)
	1					Professional services for the supervision of
						preparation and provision of antigens for allergen
						immunotherapy (specify number of doses); single
95145	13.15	2.55				stinging insect venom
						Professional services for the supervision of
						preparation and provision of antigens for allergen
						immunotherapy (specify number of doses); two
95146	20.43	2.55				single stinging insect venoms

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Professional services for the supervision of
						preparation and provision of antigens for allergen
						immunotherapy (specify number of doses); three
95147	19.77	2.55				single stinging insect venoms
						Professional services for the supervision of
						preparation and provision of antigens for allergen
						immunotherapy (specify number of doses); four
95148	27.71	2.55				single stinging insect venoms
						Professional services for the supervision of
						preparation and provision of antigens for allergen
						immunotherapy (specify number of doses); five
95149	36.65	2.55				single stinging insect venoms
						Professional services for the supervision of
						preparation and provision of antigens for allergen
						immunotherapy; single or multiple antigens (specify
95165	9.50	2.55				number of doses)
						Professional services for the supervision of
						preparation and provision of antigens for allergen
						immunotherapy; whole body extract of biting insect
95170	7.52	2.55				or other arthropod (specify number of doses)
						Rapid desensitization procedure, each hour (eg,
95180	118.21	85.10				insulin, penicillin, equine serum)
						Unlisted allergy/clinical immunologic service or
95199			I.C.			procedure
						Ambulatory continuous glucose monitoring of
						interstitial tissue fluid via a subcutaneous sensor for
						up to 72 hours; sensor placement, hook-up,
						calibration of monitor, patient training, removal of
95250			126.03			sensor, and printout of recording
30200			120,00			Ambulatory continuous glucose monitoring of
						interstitial tissue fluid via a subcutaneous sensor for
95251			31.44			up to 72 hours; physician interpretation and report
75231			31.11			Multiple sleep latency or maintenance of
						wakefulness testing, recording, analysis and
						interpretation of physiological measurements of
95805			463.64	73.61	390.03	sleep during multiple trials to assess sleepiness
75005	+		703.07	75.01	370.03	Sleep study, simultaneous recording of ventilation,
						respiratory effort, ECG or heart rate, and oxygen
95806			175.22	64.94	110.28	saturation, unattended by a technologist
75000	1		113.44	04.74	110.20	Sleep study, simultaneous recording of ventilation,
						respiratory effort, ECG or heart rate, and oxygen
95807			457.01	63 61	302.40	
93007	+		457.01	63.61	393.40	saturation, attended by a technologist
05000			565 10	102.50	161.60	Polysomnography; sleep staging with 1-3 additional
95808	1		565.18	103.58	461.60	parameters of sleep, attended by a technologist
						Polysomnography; sleep staging with 4 or more
05010			602.62	126.22	557.20	additional parameters of sleep, attended by a
95810			693.62	136.33	557.28	technologist

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Polysomnography; sleep staging with 4 or more
						additional parameters of sleep, with initiation of
						continuous positive airway pressure therapy or
95811			762.83	146.40	616.43	bilevel ventilation, attended by a technologist
						Electroencephalogram (EEG) extended monitoring;
95812			198.34	44.01	154.33	41-60 minutes
						Electroencephalogram (EEG) extended monitoring;
95813			243.61	69.75	173.86	greater than one hour
						Electroencephalogram (EEG); including recording
95816			182.24	44.01	138.22	awake and drowsy
						Electroencephalogram (EEG); including recording
95819			184.55	44.01	140.54	awake and asleep
						Electroencephalogram (EEG); recording in coma or
95822			201.75	44.01	157.74	sleep only
						Electroencephalogram (EEG); cerebral death
95824				30.12		evaluation only
95827			269.95	42.81	227.15	Electroencephalogram (EEG); all night recording
95829			1107.50	250.90	856.60	Electrocorticogram at surgery (separate procedure)
						Insertion by physician of sphenoidal electrodes for
95830	153.44	68.68				electroencephalographic (EEG) recording
						Muscle testing, manual (separate procedure) with
95831	22.27	11.67				report; extremity (excluding hand) or trunk
						Muscle testing, manual (separate procedure) with
						report; hand, with or without comparison with
95832	20.11	12.17				normal side
						Muscle testing, manual (separate procedure) with
95833	31.43	19.51				report; total evaluation of body, excluding hands
						Muscle testing, manual (separate procedure) with
95834	36.59	25.01				report; total evaluation of body, including hands
						Range of motion measurements and report (separate
						procedure); each extremity (excluding hand) or each
95851	14.94	6.67				trunk section (spine)
						Range of motion measurements and report (separate
0.50.50	11.50	4.64				procedure); hand, with or without comparison with
95852	11.56	4.61				normal side
95857	34.76	21.51				Tensilon test for myasthenia gravis
05060			71.01	40.12	20.00	Needle electromyography; one extremity with or
95860	+		71.01	40.12	30.89	without related paraspinal areas
05061			06.42	64.02	20.41	Needle electromyography; two extremities with or
95861	1		96.43	64.02	32.41	without related paraspinal areas
05063			115.65	76.64	20.02	Needle electromyography; three extremities with or
95863	1		115.67	76.64	39.03	without related paraspinal areas
05064			120.51	01.00	57.54	Needle electromyography; four extremities with or
95864	1		139.51	81.98	57.54	without related paraspinal areas
95865	1		93.20	66.40	26.80	Needle electromyography; larynx
95866	1		71.14	51.95	19.18	Needle electromyography; hemidiaphragm
05065			55.00	22.22	27.60	Needle electromyography; cranial nerve supplied
95867			57.99	32.30	25.69	muscle(s), unilateral

114.3 CMR 17.00: MEDICINE

		=~	GLOBAL	PC	TC	200
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
05060			70.79	10 50	21.20	Needle electromyography; cranial nerve supplied
95868			79.78	48.58	31.20	muscles, bilateral Needle electromyography; thoracic paraspinal
95869			34.36	15.39	18.97	muscles (excluding T1 or T12)
93609			34.30	13.39	10.97	Needle electromyography; limited study of muscles
						in one extremity or non-limb (axial) muscles
						(unilateral or bilateral), other than thoracic
						paraspinal, cranial nerve supplied muscles, or
95870			33.70	15.39	18.31	sphincters
75010			33.70	13.37	10.51	Needle electromyography using single fiber
						electrode, with quantitative measurement of jitter,
						blocking and/or fiber density, any/all sites of each
95872			130.52	106.94	23.59	muscle studied
			155.52	100.71	20.07	Electrical stimulation for guidance in conjunction
						with chemodenervation (List separately in addition
95873			34.03	15.72	18.31	to code for primary procedure)
						Needle electromyography for guidance in
						conjunction with chemodenervation (List separately
95874			33.37	15.72	17.65	in addition to code for primary procedure)
						Ischemic limb exercise test with serial specimen(s)
95875			81.40	46.01	35.39	acquisition for muscle(s) metabolite(s)
						Nerve conduction, amplitude and latency/velocity
95900			48.67	17.45	31.22	study, each nerve; motor, without F-wave study
						Nerve conduction, amplitude and latency/velocity
95903			54.24	24.68	29.56	study, each nerve; motor, with F-wave study
						Nerve conduction, amplitude and latency/velocity
95904			42.46	14.22	28.24	study, each nerve; sensory
						Intraoperative neurophysiology testing, per hour
						(List separately in addition to code for primary
95920			129.72	88.15	41.56	procedure)
						Testing of autonomic nervous system function;
						cardiovagal innervation (parasympathetic function),
						including two or more of the following: heart rate
						response to deep breathing with recorded R-R
95921			57.53	35.58	21.95	interval, Valsalva ratio, and 30:15 ratio
						Testing of autonomic nervous system function;
						vasomotor adrenergic innervation (sympathetic
						adrenergic function), including beat-to-beat blood
0.5022			67.70	20.70	20.00	pressure and R-R interval changes during Valsalva
95922			67.70	38.79	28.90	maneuver and at least five minutes of passive tilt
						Testing of autonomic nervous system function;
						sudomotor, including one or more of the following:
						quantitative sudomotor axon reflex test (QSART),
05022			07.47	26.70	60.60	silastic sweat imprint, thermoregulatory sweat test,
95923			97.47	36.79	60.69	and changes in sympathetic skin potential

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Short-latency somatosensory evoked potential
						study, stimulation of any/all peripheral nerves or
						skin sites, recording from the central nervous
95925			86.75	22.22	64.52	system; in upper limbs
						Short-latency somatosensory evoked potential
						study, stimulation of any/all peripheral nerves or
05026			05.54	22.01	(2.52	skin sites, recording from the central nervous
95926			85.54	22.01	63.53	system; in lower limbs
						Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or
						skin sites, recording from the central nervous
95927			88.40	22.88	65.52	system; in the trunk or head
)3)2T			00.10	22.00	03.32	Central motor evoked potential study (transcranial
95928			159.02	61.03	97.98	motor stimulation); upper limbs
						Central motor evoked potential study (transcranial
95929			167.62	61.37	106.26	motor stimulation); lower limbs
						Visual evoked potential (VEP) testing central
95930			91.53	14.50	77.03	nervous system, checkerboard or flash
						Orbicularis oculi (blink) reflex, by electrodiagnostic
95933			54.04	24.28	29.76	testing
						H-reflex, amplitude and latency study; record
95934			36.28	20.96	15.33	gastrocnemius/soleus muscle
05026			22.64	22.62	11.00	H-reflex, amplitude and latency study; record
95936			33.64	22.62	11.02	muscle other than gastrocnemius/soleus muscle
						Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any one
95937			45.45	27.48	17.98	method
73731			75.75	27.40	17.50	Monitoring for identification and lateralization of
						cerebral seizure focus, electroencephalographic (eg,
						8 channel EEG) recording and interpretation, each
95950			199.76	61.41	138.35	24 hours
						Monitoring for localization of cerebral seizure focus
						by cable or radio, 16 or more channel telemetry,
						combined electroencephalographic (EEG) and video
0.50.51			1 601 70	24425	1217 10	recording and interpretation (eg, for presurgical
95951			1601.79	244.25	1317.18	localization), each 24 hours
						Monitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG,
						electroencephalographic (EEG) recording and
95953			350.98	132.51	218.47	interpretation, each 24 hours
73733			550.70	152.51	210.77	Pharmacological or physical activation requiring
						physician attendance during EEG recording of
95954			214.83	95.34	119.48	activation phase (eg, thiopental activation test)
						Electroencephalogram (EEG) during nonintracranial
95955			117.01	39.86	77.15	surgery (eg, carotid surgery)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Monitoring for localization of cerebral seizure focus
						by cable or radio, 16 or more channel telemetry,
05056			602.72	105.16	400 57	electroencephalographic (EEG) recording and
95956			623.73	125.16	498.57	interpretation, each 24 hours
05057			100.26	90.90	110 15	Digital analysis of electroencephalogram (EEG) (eg,
95957			199.26	80.80	118.45	for epileptic spike analysis)
						Wada activation test for hemispheric function,
95958			204.50	172 10	122 21	including electroencephalographic (EEG)
93938			294.50	172.19	122.31	monitoring
						Functional cortical and subcortical mapping by
						stimulation and/or recording of electrodes on brain
						surface, or of depth electrodes, to provoke seizures
05061			100 72	129.62	50.11	or identify vital brain structures; initial hour of
95961			188.73	129.62	59.11	physician attendance
						Functional cortical and subcortical mapping by
						stimulation and/or recording of electrodes on brain
						surface, or of depth electrodes, to provoke seizures
						or identify vital brain structures; each additional
0.50.62			170.00	12454	44.54	hour of physician attendance (List separately in
95962			179.09	134.54	44.54	addition to code for primary procedure)
						Magnetoencephalography (MEG), recording and
05065				220.24		analysis; for spontaneous brain magnetic activity
95965				329.24		(eg, epileptic cerebral cortex localization)
						Magnetoencephalography (MEG), recording and
						analysis; for evoked magnetic fields, single
95966				162.45		modality (eg, sensory, motor, language, or visual
93900				163.45		cortex localization)
						Magnetoencephalography (MEG), recording and
						analysis; for evoked magnetic fields, each additional
						modality (eg, sensory, motor, language, or visual
05067				126.04		cortex localization) (List separately in addition to
95967				136.94		code for primary procedure)
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient compliance
						measurements); simple or complex brain, spinal
						cord, or peripheral (ie, cranial nerve, peripheral
						nerve, autonomic nerve, neuromuscular)
05070	42.01	1751				neurostimulator pulse generator/transmitter, without
95970	42.01	17.51				reprogramming

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient compliance
						measurements); simple spinal cord, or peripheral
						(ie, peripheral nerve, autonomic nerve,
						neuromuscular) neurostimulator pulse
						generator/transmitter, with intraoperative or
95971	44.13	29.90				subsequent programming
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient compliance
						measurements); complex spinal cord, or peripheral
						(except cranial nerve) neurostimulator pulse
						generator/transmitter, with intraoperative or
95972	83.94	60.10				subsequent programming, first hour
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient compliance
						measurements); complex spinal cord, or peripheral
						(except cranial nerve) neurostimulator pulse
						generator/transmitter, with intraoperative or
						subsequent programming, each additional 30
						minutes after first hour (List separately in addition
95973	45.39	36.45				to code for primary procedure)
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient compliance
						measurements); complex cranial nerve
						neurostimulator pulse generator/transmitter, with
						intraoperative or subsequent programming, with or
95974	139.15	121.60				without nerve interface testing, first hour

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient compliance
						measurements); complex cranial nerve
						neurostimulator pulse generator/transmitter, with
						intraoperative or subsequent programming, each
						additional 30 minutes after first hour (List
						separately in addition to code for primary
95975	76.84	69.89				procedure)
						Electronic analysis of implanted neurostimulator
1						pulse generator system (eg, rate, pulse amplitude
						and duration, battery status, electrode selectability
						and polarity, impedance and patient compliance
						measurements), complex deep brain neurostimulator
						pulse generator/transmitter, with initial or
95978	164.46	139.96				subsequent programming; first hour
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, battery status, electrode selectability
						and polarity, impedance and patient compliance
						measurements), complex deep brain neurostimulator
						pulse generator/transmitter, with initial or
						subsequent programming; each additional 30
						minutes after first hour (List separately in addition
95979	73.98	66.70				to code for primary procedure)
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient measurements)
						gastric neurostimulator pulse generator/transmitter;
95980			32.11			intraoperative, with programming
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient measurements)
						gastric neurostimulator pulse generator/transmitter;
95981	23.37	12.78				subsequent, without reprogramming
						Electronic analysis of implanted neurostimulator
						pulse generator system (eg, rate, pulse amplitude
						and duration, configuration of wave form, battery
						status, electrode selectability, output modulation,
						cycling, impedance and patient measurements)
						gastric neurostimulator pulse generator/transmitter;
95982	34.78	25.18				subsequent, with reprogramming

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Refilling and maintenance of implantable pump or
						reservoir for drug delivery, spinal (intrathecal,
95990			52.94			epidural) or brain (intraventricular);
						Refilling and maintenance of implantable pump or
						reservoir for drug delivery, spinal (intrathecal,
05001	74.10	20.41				epidural) or brain (intraventricular); administered by
95991	74.10	28.41				physician The Control of the Control
95999			I.C.			Unlisted neurological or neuromuscular diagnostic procedure
93999			I.C.			Comprehensive computer-based motion analysis by
96000			68.50			video-taping and 3-D kinematics;
90000			08.50			Comprehensive computer-based motion analysis by
						video-taping and 3-D kinematics; with dynamic
96001			82.35			plantar pressure measurements during walking
						Dynamic surface electromyography, during walking
96002			16.18			or other functional activities, 1-12 muscles
						Dynamic fine wire electromyography, during
96003			14.07			walking or other functional activities, 1 muscle
						Physician review and interpretation of
						comprehensive computer-based motion analysis,
						dynamic plantar pressure measurements, dynamic
						surface electromyography during walking or other
						functional activities, and dynamic fine wire
96004			88.25			electromyography, with written report
						Neurofunctional testing selection and administration
						during noninvasive imaging functional brain
						mapping, with test administered entirely by a
96020				134.81		physician or psychologist, with review of test results and report
90020				154.01		Medical genetics and genetic counseling services,
96040			32.66			each 30 minutes face-to-face with patient/family
70010			52.00			Psychological testing (includes psychodiagnostic
						assessment of emotionality, intellectual abilities,
						personality and psychopathology, eg, MMPI,
						Rorschach, WAIS), per hour of the psychologist's or
						physician's time, both face-to-face time
						administering tests to the patient and time
						interpreting these test results and preparing the
96101	69.54	68.88				report
						Psychological testing (includes psychodiagnostic
						assessment of emotionality, intellectual abilities,
						personality and psychopathology, eg, MMPI and
						WAIS), with qualified health care professional
06102	12 21	10 47				interpretation and report, administered by
96102	43.31	18.47]			technician, per hour of technician time, face-to-face

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Psychological testing (includes psychodiagnostic
						assessment of emotionality, intellectual abilities,
						personality and psychopathology, eg, MMPI),
06102	22.20	10.20				administered by a computer, with qualified health
96103	33.20	19.30				care professional interpretation and report
						Assessment of aphasia (includes assessment of expressive and receptive speech and language
						function, language comprehension, speech
						production ability, reading, spelling, writing, eg, by
						Boston Diagnostic Aphasia Examination) with
96105			60.48			interpretation and report, per hour
70100			551.15			Developmental testing; limited (eg, Developmental
						Screening Test II, Early Language Milestone
96110			9.82			Screen), with interpretation and report
						Developmental testing; extended (includes
						assessment of motor, language, social, adaptive
						and/or cognitive functioning by standardized
						developmental instruments) with interpretation and
96111	105.24	103.25				report
						Neurobehavioral status exam (clinical assessment of
						thinking, reasoning and judgment, eg, acquired
						knowledge, attention, language, memory, planning
						and problem solving, and visual spatial abilities),
						per hour of the psychologist's or physician's time,
96116	78.29	73.00				both face-to-face time with the patient and time interpreting test results and preparing the report
90110	10.29	13.00				Neuropsychological testing (eg, Halstead-Reitan
						Neuropsychological Battery, Wechsler Memory
						Scales and Wisconsin Card Sorting Test), per hour
						of the psychologist's or physician's time, both face-
						to-face time administering tests to the patient and
						time interpreting these test results and preparing the
96118	92.53	71.67				report
						Neuropsychological testing (eg, Halstead-Reitan
						Neuropsychological Battery, Wechsler Memory
						Scales and Wisconsin Card Sorting Test), with
						qualified health care professional interpretation and
0.544-						report, administered by technician, per hour of
96119	61.26	23.85				technician time, face-to-face
						Neuropsychological testing (eg, Wisconsin Card
						Sorting Test), administered by a computer, with
06120	54.72	10.07				qualified health care professional interpretation and
96120	54.73	18.97				report

114.3 CMR 17.00: MEDICINE

CODE	NFAC	FAC	GLOBAL FEE	PC FEE	TC FEE	DESCRIPTION
CODE	NFAC	FAC	FEE	FEE	FEE	Standardized cognitive performance testing (eg,
						Ross Information Processing Assessment) per hour
						of a qualified health care professional's time, both
						face-to-face time administering tests to the patient
						and time interpreting these test results and preparing
96125	76.05	63.14				the report
30120	7 0100	5577				Health and behavior assessment (eg, health-focused
						clinical interview, behavioral observations,
						psychophysiological monitoring, health-oriented
						questionnaires), each 15 minutes face-to-face with
96150	18.81	18.47				the patient; initial assessment
						Health and behavior assessment (eg, health-focused
						clinical interview, behavioral observations,
						psychophysiological monitoring, health-oriented
						questionnaires), each 15 minutes face-to-face with
96151	18.25	17.92				the patient; re-assessment
						Health and behavior intervention, each 15 minutes,
96152	17.36	17.03				face-to-face; individual
						Health and behavior intervention, each 15 minutes,
96153	4.00	3.67				face-to-face; group (2 or more patients)
						Health and behavior intervention, each 15 minutes,
96154	17.08	16.75				face-to-face; family (with the patient present)
						Health and behavior intervention, each 15 minutes,
96155			17.35			face-to-face; family (without the patient present)
						Chemotherapy administration, subcutaneous or
96401			56.07			intramuscular; non-hormonal anti-neoplastic
						Chemotherapy administration, subcutaneous or
96402			34.98			intramuscular; hormonal anti-neoplastic
						Chemotherapy administration; intralesional, up to
96405	116.47	23.10				and including 7 lesions
						Chemotherapy administration; intralesional, more
96406	132.56	33.24				than 7 lesions
						Chemotherapy administration; intravenous, push
96409			102.68			technique, single or initial substance/drug
						Chemotherapy administration; intravenous, push
						technique, each additional substance/drug (List
						separately in addition to code for primary
96411			58.19			procedure)
						Chemotherapy administration, intravenous infusion
						technique; up to 1 hour, single or initial
96413			138.99			substance/drug
						Chemotherapy administration, intravenous infusion
						technique; each additional hour (List separately in
96415			30.31			addition to code for primary procedure)
						Chemotherapy administration, intravenous infusion
						technique; initiation of prolonged chemotherapy
						infusion (more than 8 hours), requiring use of a
96416			151.27			portable or implantable pump

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Chemotherapy administration, intravenous infusion
						technique; each additional sequential infusion
						(different substance/drug), up to 1 hour (List separately in addition to code for primary
96417			68.28			procedure)
90417			06.26			Chemotherapy administration, intra-arterial; push
96420			96.52			technique
90420	+		90.32			*
96422			160.75			Chemotherapy administration, intra-arterial;
90422			100.73			infusion technique, up to one hour Chemotherapy administration, intra-arterial;
						infusion technique, each additional hour (List
						separately in addition to code for primary
96423			69.40			procedure)
90423			09.40			Chemotherapy administration, intra-arterial;
						infusion technique, initiation of prolonged infusion
						(more than 8 hours), requiring the use of a portable
96425			157.77			or implantable pump
70423			137.77			Chemotherapy administration into pleural cavity,
96440	296.26	106.22				requiring and including thoracentesis
70440	270.20	100.22				Chemotherapy administration into peritoneal cavity,
96445	287.23	99.84				requiring and including peritoneocentesis
70443	201.23	77.0 1				Chemotherapy administration, into CNS (eg,
96450	242.29	79.73				intrathecal), requiring and including spinal puncture
96521	242.29	19.13	121.70			Refilling and maintenance of portable pump
90321			121.70			Refilling and maintenance of implantable pump or
						reservoir for drug delivery, systemic (eg,
96522			96.87			intravenous, intra-arterial)
70322			30.07			Irrigation of implanted venous access device for
96523			23.51			drug delivery systems
3 00 20			20.01			Chemotherapy injection, subarachnoid or
						intraventricular via subcutaneous reservoir, single or
96542	151.56	38.66				multiple agents
96549	101100	20100	I.C.			Unlisted chemotherapy procedure
			2.01			Photodynamic therapy by external application of
						light to destroy premalignant and/or malignant
						lesions of the skin and adjacent mucosa (eg, lip) by
						activation of photosensitive drug(s), each
96567			95.22			phototherapy exposure session
						Photodynamic therapy by endoscopic application of
						light to ablate abnormal tissue via activation of
						photosensitive drug(s); first 30 minutes (List
						separately in addition to code for endoscopy or
96570			45.65			bronchoscopy procedures of lung and esophagus)
						Photodynamic therapy by endoscopic application of
						light to ablate abnormal tissue via activation of
						photosensitive drug(s); each additional 15 minutes
						(List separately in addition to code for endoscopy or
96571			22.29			bronchoscopy procedures of lung and esophagus)

114.3 CMR 17.00: MEDICINE

	T		GLOBAL	PC	TC	T
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
96900	INFAC	TAC	16.98	Tible	FEE	Actinotherapy (ultraviolet light)
70700			10.50			Microscopic examination of hairs plucked or
						clipped by the examiner (excluding hair collected by
						the patient) to determine telogen and anagen counts,
96902	16.62	15.96				or structural hair shaft abnormality
7 0 7 0 2	10.02	1000				Whole body integumentary photography, for
						monitoring of high risk patients with dysplastic
						nevus syndrome or a history of dysplastic nevi, or
						patients with a personal or familial history of
96904			63.12			melanoma
						Photochemotherapy; tar and ultraviolet B
						(Goeckerman treatment) or petrolatum and
96910			50.52			ultraviolet B
						Photochemotherapy; psoralens and ultraviolet A
96912			64.64			(PUVA)
						Photochemotherapy (Goeckerman and/or PUVA)
						for severe photoresponsive dermatoses requiring at
						least four to eight hours of care under direct
						supervision of the physician (includes application of
96913			87.23			medication and dressings)
						Laser treatment for inflammatory skin disease
96920	133.84	51.07				(psoriasis); total area less than 250 sq cm
						Laser treatment for inflammatory skin disease
96921	131.63	51.18				(psoriasis); 250 sq cm to 500 sq cm
						Laser treatment for inflammatory skin disease
96922	193.89	86.95				(psoriasis); over 500 sq cm
96999			I.C.			Unlisted special dermatological service or procedure
97001			57.74			Physical therapy evaluation
97002			31.08			Physical therapy re-evaluation
97003			61.93			Occupational therapy evaluation
97004			37.37			Occupational therapy re-evaluation
97005			I.C.			Athletic training evaluation
97006			I.C.			Athletic training re-evaluation
07010			2.00			Application of a modality to one or more areas; hot
97010			3.88			or cold packs
07012			11.02			Application of a modality to one or more areas;
97012			11.83			traction, mechanical
07014			11.20			Application of a modality to one or more areas;
97014			11.20			electrical stimulation (unattended)
97016			12.19			Application of a modality to one or more areas; vasopneumatic devices
9/010	1		12.19		-	Application of a modality to one or more areas;
97018			6.19			paraffin bath
21010			0.19			Application of a modality to one or more areas;
97022			13.90			whirlpool
71022	+		13.90			Application of a modality to one or more areas;
97024			4.21			diathermy (eg, microwave)
J1U ∠ Ħ			7.∠1			diamenting (eg, iniciowave)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Application of a modality to one or more areas;
97026			3.88			infrared
						Application of a modality to one or more areas;
97028			5.10			ultraviolet
						Application of a modality to one or more areas;
97032			13.15			electrical stimulation (manual), each 15 minutes
07022			10.20			Application of a modality to one or more areas;
97033			19.39			iontophoresis, each 15 minutes
07024			11.70			Application of a modality to one or more areas;
97034			11.70			contrast baths, each 15 minutes
07025			9.39			Application of a modality to one or more areas; ultrasound, each 15 minutes
97035			9.39			Application of a modality to one or more areas;
97036			20.61			Hubbard tank, each 15 minutes
97030			20.01			Unlisted modality (specify type and time if constant
97039			I.C.			attendance)
91039			1.C.			Therapeutic procedure, one or more areas, each 15
						minutes; therapeutic exercises to develop strength
97110			22.59			and endurance, range of motion and flexibility
37110			22.57			Therapeutic procedure, one or more areas, each 15
						minutes; neuromuscular reeducation of movement,
						balance, coordination, kinesthetic sense, posture,
						and/or proprioception for sitting and/or standing
97112			23.70			activities
						Therapeutic procedure, one or more areas, each 15
97113			27.73			minutes; aquatic therapy with therapeutic exercises
						Therapeutic procedure, one or more areas, each 15
97116			19.99			minutes; gait training (includes stair climbing)
						Therapeutic procedure, one or more areas, each 15
						minutes; massage, including effleurage, petrissage
						and/or tapotement (stroking, compression,
97124			18.26			percussion)
97139			I.C.			Unlisted therapeutic procedure (specify)
						Manual therapy techniques (eg, mobilization/
07140			21.16			manipulation, manual lymphatic drainage, manual
97140			21.16			traction), one or more regions, each 15 minutes
07150			14.27			Therapeutic procedure(s), group (2 or more individuals)
97150			14.37			Therapeutic activities, direct (one-on-one) patient
						contact by the provider (use of dynamic activities to
97530			24.08			improve functional performance), each 15 minutes
71330			27.00			Development of cognitive skills to improve
						attention, memory, problem solving (includes
						compensatory training), direct (one-on-one) patient
97532			19.45			contact by the provider, each 15 minutes

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	T
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Sensory integrative techniques to enhance sensory
						processing and promote adaptive responses to
						environmental demands, direct (one-on-one) patient
97533			20.77			contact by the provider, each 15 minutes
						Self-care/home management training (eg, activities
						of daily living (ADL) and compensatory training,
						meal preparation, safety procedures, and
						instructions in use of assistive technology
			24.26			devices/adaptive equipment) direct one-on-one
97535			24.36			contact by provider, each 15 minutes
İ						Community/work reintegration training (eg,
İ						shopping, transportation, money management,
I						avocational activities and/or work
İ						environment/modification analysis, work task
I						analysis, use of assistive technology device/adaptive
07527			21.71			equipment), direct one-on-one contact by provider, each 15 minutes
97537			21.71			
97542			22.05			Wheelchair management (eg, assessment, fitting, training), each 15 minutes
97545			I.C.			Work hardening/conditioning; initial 2 hours
97343			I.C.			Work hardening/conditioning; midal 2 hours Work hardening/conditioning; each additional hour
						(List separately in addition to code for primary
97546			I.C.			procedure)
71340			1.0.			Removal of devitalized tissue from wound(s),
						selective debridement, without anesthesia (eg, high
						pressure waterjet with/without suction, sharp
						selective debridement with scissors, scalpel and
						forceps), with or without topical application(s),
						wound assessment, and instruction(s) for ongoing
						care, may include use of a whirlpool, per session;
						total wound(s) surface area less than or equal to 20
97597	46.40	30.17				square centimeters
						Removal of devitalized tissue from wound(s),
						selective debridement, without anesthesia (eg, high
						pressure waterjet with/without suction, sharp
						selective debridement with scissors, scalpel and
						forceps), with or without topical application(s),
						wound assessment, and instruction(s) for ongoing
						care, may include use of a whirlpool, per session;
						total wound(s) surface area greater than 20 square
97598	57.50	39.29				centimeters
						Removal of devitalized tissue from wound(s), non-
						selective debridement, without anesthesia (eg, wet-
						to-moist dressings, enzymatic, abrasion), including
07605			. ~			topical application(s), wound assessment, and
97602			I.C.			instruction(s) for ongoing care, per session

114.3 CMR 17.00: MEDICINE

CODE NFAC FAC FEE FEE FEE FEE DESCRIPTION				GLOBAL	PC	TC	
assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters. Negative pressure wound therapy (e.g. wacum assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters. Physical performance test or measurement (e.g. musculoskeletal, functional capacity), with written report, each 15 minutes. Assistive technology assessment (e.g. to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes. Prostect of the provider, with written report, each 15 minutes. Prostect of the patient, each 15 minutes. Prostect training, upper and/or lower extremity(s), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes. Prostect training, upper and/or lower extremity(s), each 15 minutes. Prostect or or or or or or or or or or or or or	CODE	NFAC	FAC				DESCRIPTION
97605 28.03 21.41							Negative pressure wound therapy (eg, vacuum
97605 28.03 21.41 for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters area less than or equal to 50 square centimeters area less than or equal to 50 square centimeters application(s), wound assessment, and instruction(s) surface area greater than 50 square centimeters 97606 29.97 23.35 physical performance test or measurement (eg. musculoskeletal, functional capacity), with written report, each 15 minutes 97750 23.58 Physical performance test or measurement (eg. musculoskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg. to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes 97760 25.79 Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s) and/or trunk, each 15 minutes 97761 22.92 Prosthetic training, upper and/or lower extremity(s), each 15 minutes 97762 26.61 Prosthetic training, upper and/or lower extremity(s), each 15 minutes 97799 I.C. Unlisted physical medicine/rehabilitation service or procedure 97800 22.71 22.38 Physical medicine/rehabilitation service or procedure 97801 11.50 11.17 Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes 97803 20.14 19.81 Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes 97804 11.50 11.17 Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes 97804 11.50 11.17 Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes 97805 27.99 23.35 Prosthetic and stimulation, initial 15 minutes of personal one-on-one contact with the patient, wit							
97605 28.03 21.41 Regative pressure wound therapy (eg, vacuum assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total mount (eg, musculoskeletal, functional capacity), with written report, each 15 minutes Physical performance test or measurement (eg, musculoskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg, to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-none contact by provider, with written report, each 15 minutes 97755 27.01 September Prostheic training, upper and/or lower extremity(s), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes 97760 25.79 Prostheic training, upper and/or lower extremity(s), each 15 minutes 97761 22.92 Prostheic training, upper and/or lower extremity(s), each 15 minutes 97762 26.61 Prostheic training, upper and/or lower extremity(s), each 15 minutes 97780 20.14 19.81 Prostheic training, upper and/or lower extremity on procedure 97800 22.71 22.38 Prostheic training, upper and/or lower extremity on procedure 97801 11.50 11.17 Medical nutrition therapy; entitial assessment and intervention, individual, face-to-face with the patient, each 15 minutes 97801 11.50 11.17 Medical nutrition therapy; encodes with the patient, each 15 minutes 97802 22.71 22.38 Prostheic training, upper and/or lower extremity on procedure 97803 20.14 19.81 Prostheic upper and/or lower extremity on procedure 97804 11.50 11.17 Prostheic upper and/or lower extremity on procedure 97805 Prostheic training, upper and/or lower extremity on procedure 97806 Prostheic training, upper and/or lower extremity on procedure 97807 Prostheic training, upper and/or lower extremity on procedure 97808 Prostheic training, upper and/or lower extremity on procedure 97809							
Negative pressure wound therapy (eg. vacuum assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters. Physical performance test or measurement (eg. musculoskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg. to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes 27.01 Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, each additional 15 minutes of personal one-on-one contact with the patient, with the patient, each additional 15 minutes of personal one-on-one contact with the patient, with the patient expenses of personal one-on-one contact with the patient, with the patient one-on-one contact with the patient, with the patient as timulation, initial 15 minutes of personal one-on-one contact with the patient, with the patient one-on-one contact with the patient, with the eartier of personal one-on-one contact with the patient, with the eartier of personal one-on-one contact with the patient, with the eartier of personal one-on-one contact with the patient, with the eartier of personal one-on-one contact with the patient,							
assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters Physical performance test or measurement (eg, musculoskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg, to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Orceckout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Patient, each 15 minutes Medical nutrition therapy; group (2 or more individuals)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, each 15 minutes of personal one-on-one contact with the patient, each 15 minutes of personal one-on-one contact with the patient, each 15 minutes of personal one-on-one contact with the patient, each 15 minutes of personal one-on-one contact with the patient, with 12 minutes of personal one-on-one contact with the patient, with 12 minutes of personal one-on-one contact with the patient, with 12 minutes of personal one-on-one contact with the patient, with 12 minutes of personal one-on-one contact with the patient, with 12 minutes of personal one-on-one contact with the patient, with 12 minutes of personal one	97605	28.03	21.41				
application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters Physical performance test or measurement (eg. musculoskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg. to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s), each 15 minutes Orthotic(s) management and training or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Orthotic(s) management and reported to the patient, each 15 minutes Orthotic(s) management and training (including assessment and intervention, individual, face-to-face with the patient, each 15 minutes Orthotic(s) management and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with the patient one-one-one contact with the patient, in addition to code for primary procedure) Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with re-insertion of needles) (List separately in addition to code for primary procedure)							1, 0
97606 29.97 23.35 For ongoing care, per session; total wound(s) surface area greater than 50 square centimeters Physical performance test or measurement (eg. musculoskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg. to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one-one-one-one-one-one-one-one-o							
97606 29.97 23.35 area greater than 50 square centimeters Physical performance test or measurement (eg, musucloskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg, to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes 97755 27.01 Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes 97760 25.79 Prosthetic training, upper and/or lower extremity(s), each 15 minutes 97761 22.92 Prosthetic training, upper and/or lower extremity(s), each 15 minutes 97762 26.61 Prosthetic training, upper and/or lower extremity(s), each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual), each 30 minutes Medical nutrition therapy; group (2 or more individual), each 30 minutes Medical nutrition therapy; group (2 or more individual), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient.							11 17
Physical performance test or measurement (eg, musculoskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg, to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)	07.00	20.05	22.25				
musculoskeletal, functional capacity), with written report, each 15 minutes Assistive technology assessment (eg., to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes 27.01 Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, each patient additional 15 minutes of personal one-on-one contact with the patient, each patient additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one-on-one-on-one-on-one-on-one-on-one-on-one-on-one-on-one-on-one-on-one-on-one-on-one-on-one-on-on-one-on-on-one-on-on-on-on-on-on-on-on-on-on-on-on-on-	97606	29.97	23.35				
97750 23.58 report, each 15 minutes Assistive technology assessment (eg., to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes 97755 27.01 Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s) and/or trunk, each 15 minutes 97760 25.79 Prosthetic training, upper and/or lower extremity(s), each 15 minutes 97761 22.92 each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient. Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, each is minutes of personal one-on-one-contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one-contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)							
Assistive technology assessment (eg. to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 30 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, nintial 15 minutes of personal one-on-one-one-one-one-one-one-one-one-o	07750			22.50			
augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)	97750			23.58			
optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)							
environmental accessibility), direct one-on-one contact by provider, with written report, each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, each additional 15 minutes of personal one-on-one contact with the patient, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, ence additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, ence additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)							
27.01							
97755 27.01 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes 97760 25.79 each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s), each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Orthotic(s) management and training (including assessment and) reach 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(ss)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)							
Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one or or primary procedure)	97755			27.01			* *
assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)	71133			27.01			
97760 25.79 upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)							
97760 25.79 each 15 minutes Prosthetic training, upper and/or lower extremity(s), each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)							
97761 22.92 each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individuals), each 30 minutes Medical nutrition therapy; group (2 or more individuals), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one-contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)	97760			25.79			* * * * * * * * * * * * * * * * * * * *
97761 22.92 each 15 minutes Checkout for orthotic/prosthetic use, established patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individuals), each 30 minutes Medical nutrition therapy; group (2 or more individuals), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one-contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)							Prosthetic training, upper and/or lower extremity(s),
97762 26.61 patient, each 15 minutes Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)	97761			22.92			
Unlisted physical medicine/rehabilitation service or procedure Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one-one-one-one-one-one-one-one-o							Checkout for orthotic/prosthetic use, established
97802 22.71 22.38 Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)	97762			26.61			patient, each 15 minutes
Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)							Unlisted physical medicine/rehabilitation service or
intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes 20.14 19.81 Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one more needles; with electrical stimulation, initial 15 minutes of personal one-on-one-one-one-one-one-one-one-one-o	97799			I.C.			*
97802 22.71 22.38 patient, each 15 minutes Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one stimulation, initial 15 minutes of personal one-on-one stimulation, initial 15 minutes of personal one-on-one-one-one-one-one-one-one-one-o							
Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)							
intervention, individual, face-to-face with the patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-	97802	22.71	22.38				
97803 20.14 19.81 patient, each 15 minutes Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one initial 15 minutes of personal one-on-one contact with electrical stimulation, initial 15 minutes of personal one-on-one initial 15 minutes of personal one-on-one-one-one-one-one-one-one-one-o							
Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with electrical stimulation, initial 15 minutes of personal one-on-one contact with electrical stimulation, initial 15 minutes of personal one-on-one-one-one-one-one-one-one-one-o	0.7000	20.14	10.01				
97804 11.50 11.17 individual(s)), each 30 minutes Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one initial 15 minutes of personal one-on-one one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure)	97803	20.14	19.81				
Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one one-one-one-one-one-one-one-one-one-one-	07004	11.50	11 17				
stimulation, initial 15 minutes of personal one-on- one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re- insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-	9/804	11.50	11.1/				
97810 27.99 23.35 one contact with the patient Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-							
Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-	07810	27.00	22.25				-
stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with reinsertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-	9/010	21.99	23.33			-	
one-on-one contact with the patient, with re- insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-							
97811 21.22 19.57 insertion of needle(s) (List separately in addition to code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-							
97811 21.22 19.57 code for primary procedure) Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-							
Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-	97811	21 22	19 57				, , ,
stimulation, initial 15 minutes of personal one-on-	7/011	21.22	17.31			1	
							*
	97813	29.71	25.41				one contact with the patient

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Acupuncture, 1 or more needles; with electrical
						stimulation, each additional 15 minutes of personal
						one-on-one contact with the patient, with re-
						insertion of needle(s) (List separately in addition to
97814	23.94	21.62				code for primary procedure)
						Osteopathic manipulative treatment (OMT); one to
98925	22.92	17.29				two body regions involved
0000	24.70	25.74				Osteopathic manipulative treatment (OMT); three to
98926	31.70	25.74				four body regions involved
00027	40.02	22.54				Osteopathic manipulative treatment (OMT); five to
98927	40.82	33.54				six body regions involved
00020	47.92	20.54				Osteopathic manipulative treatment (OMT); seven
98928	47.82	39.54				to eight body regions involved
98929	54.82	45.21				Osteopathic manipulative treatment (OMT); nine to ten body regions involved
96929	34.02	43.21				Education and training for patient self-management
						by a qualified, nonphysician health care professional
						using a standardized curriculum, face-to-face with
						the patient (could include caregiver/family) each 30
98960			19.42			minutes; individual patient
70700			15.12			Education and training for patient self-management
						by a qualified, nonphysician health care professional
						using a standardized curriculum, face-to-face with
						the patient (could include caregiver/family) each 30
98961			9.48			minutes; 2-4 patients
						Education and training for patient self-management
						by a qualified, nonphysician health care professional
						using a standardized curriculum, face-to-face with
						the patient (could include caregiver/family) each 30
98962			6.84			minutes; 5-8 patients
						Telephone assessment and management service
						provided by a qualified nonphysician health care
						professional to an established patient, parent, or
						guardian not originating from a related assessment
						and management service provided within the
						previous seven days nor leading to an assessment and management service or procedure within the
						next 24 hours or soonest available appointment; 5-
98966	10.17	9.18				10 minutes of medical discussion
, , , , ,	10.17	2.10				Telephone assessment and management service
						provided by a qualified nonphysician health care
						professional to an established patient, parent, or
						guardian not originating from a related assessment
						and management service provided within the
						previous seven days nor leading to an assessment
						and management service or procedure within the
						next 24 hours or soonest available appointment; 11-
98967	19.02	18.03				20 minutes of medical discussion

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	1
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
CODE	MFAC	TAC	FEE	FEE	FEE	Telephone assessment and management service
						provided by a qualified nonphysician health care
						professional to an established patient, parent, or
						guardian not originating from a related assessment
						and management service provided within the
						previous seven days nor leading to an assessment
						and management service or procedure within the
						next 24 hours or soonest available appointment; 21-
98968	28.20	27.21				30 minutes of medical discussion
98908	26.20	27.21				
						Online assessment and management service
						provided by a qualified nonphysician health care
						professional to an established patient, guardian, or
						health care provider not originating from a related
						assessment and management service provided
00060			1.0			within the previous 7 days, using the Internet or
98969			I.C.			similar electronic communications network
00000			1.00			Handling and/or conveyance of specimen for
99000			1.00			transfer from the physician's office to a laboratory
						Handling and/or conveyance of specimen for
						transfer from the patient in other than a physician's
99001			I.C.			office to a laboratory (distance may be indicated)
						Handling, conveyance, and/or any other service in
						connection with the implementation of an order
						involving devices (eg, designing, fitting, packaging,
						handling, delivery or mailing) when devices such as
						orthotics, protectives, prosthetics are fabricated by
						an outside laboratory or shop but which items have
						been designed, and are to be fitted and adjusted by
99002			I.C.			the attending physician
						Postoperative follow-up visit, normally included in
						the surgical package, to indicate that an evaluation
						and management service was performed during a
						postoperative period for a reason(s) related to the
99024			I.C.			original procedure
						Hospital mandated on call service; in-hospital, each
99026			I.C.			hour
						Hospital mandated on call service; out-of-hospital,
99027			I.C.			each hour
			1			Services provided in the office at times other than
						regularly scheduled office hours, or days when the
			1			office is normally closed (eg, holidays, Saturday or
99050			17.05			Sunday), in addition to basic service
						Service(s) provided in the office during regularly
						scheduled evening, weekend, or holiday office
99051			17.05			hours, in addition to basic service
						Service(s) provided between 10:00 PM and 8:00
99053			I.C.			AM at 24-hour facility, in addition to basic service

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Service(s) typically provided in the office, provided
						out of the office at request of patient, in addition to
99056			I.C.			basic service
						Service(s) provided on an emergency basis in the
						office, which disrupts other scheduled office
99058			I.C.			services, in addition to basic service
						Service(s) provided on an emergency basis, out of
						the office, which disrupts other scheduled office
99060			I.C.			services, in addition to basic service
						Supplies and materials (except spectacles), provided
						by the physician over and above those usually
						included with the office visit or other services
1						rendered (list drugs, trays, supplies, or materials
99070			I.C.			provided)
						Educational supplies, such as books, tapes, and
						pamphlets, provided by the physician for the
99071			I.C.			patient's education at cost to physician
99075			I.C.			Medical testimony
						Physician educational services rendered to patients
						in a group setting (eg, prenatal, obesity, or diabetic
99078			I.C.			instructions)
						Special reports such as insurance forms, more than
						the information conveyed in the usual medical
99080			I.C.			communications or standard reporting form
						Unusual travel (eg, transportation and escort of
99082			I.C.			patient)
						Analysis of clinical data stored in computers (eg,
99090			I.C.			ECGs, blood pressures, hematologic data)
						Collection and interpretation of physiologic data
						(eg, ECG, blood pressure, glucose monitoring)
						digitally stored and/or transmitted by the patient
						and/or caregiver to the physician or other qualified
						health care professional, requiring a minimum of 30
99091			39.84			minutes of time
						Anesthesia for patient of extreme age, younger than
						1 year and older than 70 (List separately in addition
99100			I.C.			to code for primary anesthesia procedure)
						Anesthesia complicated by utilization of total body
						hypothermia (List separately in addition to code for
99116			I.C.			primary anesthesia procedure)
						Anesthesia complicated by utilization of controlled
0010-						hypotension (List separately in addition to code for
99135			I.C.			primary anesthesia procedure)
						Anesthesia complicated by emergency conditions
						(specify) (List separately in addition to code for
99140	1		I.C.			primary anesthesia procedure)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Moderate sedation services (other than those
						services described by codes 00100-01999) provided
						by the same physician performing the diagnostic or
						therapeutic service that the sedation supports,
						requiring the presence of an independent trained
						observer to assist in the monitoring of the patient's
						level of consciousness and physiological status;
						younger than 5 years of age, first 30 minutes intra-
99143			I.C.			service time
						Moderate sedation services (other than those
						services described by codes 00100-01999) provided
						by the same physician performing the diagnostic or
						therapeutic service that the sedation supports,
						requiring the presence of an independent trained
						observer to assist in the monitoring of the patient's
						level of consciousness and physiological status; age
99144			I.C.			5 years or older, first 30 minutes intra-service time
						Moderate sedation services (other than those
						services described by codes 00100-01999) provided
						by the same physician performing the diagnostic or
						therapeutic service that the sedation supports,
						requiring the presence of an independent trained
						observer to assist in the monitoring of the patient's
						level of consciousness and physiological status;
						each additional 15 minutes intra-service time (List
99145			I.C.			separately in addition to code for primary service)
						Moderate sedation services (other than those
						services described by codes 00100-01999), provided
						by a physician other than the health care
						professional performing the diagnostic or
						therapeutic service that the sedation supports;
004.40			T G			younger than 5 years of age, first 30 minutes intra-
99148			I.C.			service time
						Moderate sedation services (other than those
						services described by codes 00100-01999), provided
						by a physician other than the health care
						professional performing the diagnostic or
00140			IC			therapeutic service that the sedation supports; age 5
99149			I.C.			years or older, first 30 minutes intra-service time
						Moderate sedation services (other than those
						services described by codes 00100-01999), provided
						by a physician other than the health care
						professional performing the diagnostic or
						therapeutic service that the sedation supports; each
00150			I.C.			additional 15 minutes intra-service time (List
99150			I.C.			separately in addition to code for primary service)
00170	110.16	60.77				Anogenital examination with colposcopic
99170	110.16	69.77				magnification in childhood for suspected trauma

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Visual function screening, automated or semi-
						automated bilateral quantitative determination of
						visual acuity, ocular alignment, color vision by
						pseudoisochromatic plates, and field of vision (may
						include all or some screening of the
						determination[s] for contrast sensitivity, vision
99172			I.C.			under glare)
						Ocular photoscreening with interpretation and
99174			I.C.			report, bilateral
						Ipecac or similar administration for individual
						emesis and continued observation until stomach
99175			30.95			adequately emptied of poison
						Physician attendance and supervision of hyperbaric
99183	165.42	90.27				oxygen therapy, per session
99185			38.93			Hypothermia; regional
99186			66.28			Hypothermia; total body
						Assembly and operation of pump with oxygenator
						or heat exchanger (with or without ECG and/or
99190			I.C.			pressure monitoring); each hour
						Assembly and operation of pump with oxygenator
						or heat exchanger (with or without ECG and/or
99191			I.C.			pressure monitoring); 45 minutes
						Assembly and operation of pump with oxygenator
						or heat exchanger (with or without ECG and/or
99192			I.C.			pressure monitoring); 30 minutes
99195			50.09			Phlebotomy, therapeutic (separate procedure)
99199			I.C.			Unlisted special service, procedure or report
						Office or other outpatient visit for the evaluation
						and management of a new patient, which requires
						these 3 key components: A problem focused history;
						A problem focused examination; Straightforward
						medical decision making. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the presenting problem(s) are self
1						limited or minor. Physicians typically spend 10
99201	30.42	18.17				minutes face-to-face with the patient and/or family.

114.3 CMR 17.00: MEDICINE

tion
uires
em
ed
on
are
l
and the
;
tes
tion
uires
A
ng of
tion of
vided
and the
ty.
o-face
J-1ace
tion
uires
istory;
sion
and/or
ure of
y's
e of
ly
nt
tion
uires
istory;
sion
or
ure of
ys e of
y's ly tie ui sis ou ui y's

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician. Usually, the presenting problem(s) are minimal. Typically, 5
99211	16.88	6.95				minutes are spent performing or supervising these services.
						Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the
99212	31.41	18.17				presenting problem(s) are self limited or minor. Physicians typically spend 10 minutes face-to-face with the patient and/or family.
99213	50.49	34.93				Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Physicians typically spend 15 minutes face-to-face with the patient and/or family.
99214	75.80	54.61				Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 25 minutes face-to-face with the patient and/or family.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Office or other outpatient visit for the evaluation
						and management of an established patient, which
						requires at least 2 of these 3 key components: A
						comprehensive history; A comprehensive
						examination; Medical decision making of high
						complexity. Counseling and/or coordination of care
						with other providers or agencies are provided
						consistent with the nature of the problem(s) and the
						patient's and/or family's needs. Usually, the
						presenting problem(s) are of moderate to high
						severity. Physicians typically spend 40 minutes
99215	102.24	78.40				face-to-face with the patient and/or family.
						Observation care discharge day management (This
						code is to be utilized by the physician to report all
						services provided to a patient on discharge from
						observation status if the discharge is on other than
						the initial date of observation status. To report
						services to a patient designated as observation status
						or inpatient status and discharged on the same date,
						use the codes for Observation or Inpatient Care
00217			52.00			Services [including Admission and Discharge
99217			53.90			Services, 99234-99236 as appropriate.])
						Initial observation care, per day, for the evaluation
						and management of a patient which requires these 3 key components: A detailed or comprehensive
						history; A detailed or comprehensive examination;
						and Medical decision making that is straightforward
						or of low complexity. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the problem(s) requiring admission
99218			50.59			to observation status are of low severity.
						Initial observation care, per day, for the evaluation
						and management of a patient, which requires these 3
						key components: A comprehensive history; A
						comprehensive examination; and Medical decision
						making of moderate complexity. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the problem(s) requiring admission
99219			83.40			to observation status are of moderate severity.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
JUL	1,1110					Initial observation care, per day, for the evaluation
						and management of a patient, which requires these 3
						key components: A comprehensive history; A
						comprehensive examination; and Medical decision
						making of high complexity. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the problem(s) requiring admission
99220			117.25			to observation status are of high severity.
99220			117.23			Initial hospital care, per day, for the evaluation and
						- · · · · · · · · · · · · · · · · · · ·
						management of a patient, which requires these 3 key
						components: A detailed or comprehensive history;
						A detailed or comprehensive examination; and
						Medical decision making that is straightforward or
						of low complexity. Counseling and/or coordination
						of care with other providers or agencies are
						provided consistent with the nature of the
						problem(s) and the patient's and/or family's needs.
						Usually, the problem(s) requiring admission are of
						low severity. Physicians typically spend 30 minutes
						at the bedside and on the patient's hospital floor or
99221			70.53			unit.
						Initial hospital care, per day, for the evaluation and
						management of a patient, which requires these 3 key
						components: A comprehensive history; A
						comprehensive examination; and Medical decision
						making of moderate complexity. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the problem(s) requiring admission
						are of moderate severity. Physicians typically spend
						50 minutes at the bedside and on the patient's
99222			97.44			hospital floor or unit.
						Initial hospital care, per day, for the evaluation and
1						management of a patient, which requires these 3 key
						components: A comprehensive history; A
						comprehensive examination; and Medical decision
						making of high complexity. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the problem(s) requiring admission
						are of high severity. Physicians typically spend 70
						minutes at the bedside and on the patient's hospital
99223			143.06			floor or unit.

114.3 CMR 17.00: MEDICINE

and management of a patient, which requires at la 2 of these 3 key components: A problem focused examination Medical decision making that is straightforward of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's need Usually, the patient is stable, recovering or improving. Physicians typically spend 15 minute the bedside and on the patient's hospital floor or unit. Subsequent hospital care, per day, for the evalual and management of a patient, which requires at la 2 of these 3 key components: An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 25 min at the bedside and on the patient's hospital floor of unit. Subsequent hospital care, per day, for the evalual and management of a patient, which requires at la 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a signific				GLOBAL	PC	TC	
and management of a patient, which requires at la 2 of these 3 key components: A problem focused interval history; A problem focused examination Medical decision making that is straightforward of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's need Usually, the patient is stable, recovering or improving. Physicians typically spend 15 minute the bedside and on the patient's hospital floor or unit. Subsequent hospital care, per day, for the evalual and management of a patient, which requires at la 2 of these 3 key components: An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 25 min at the bedside and on the patient's hospital floor of unit. Subsequent hospital care, per day, for the evalual and management of a patient, which requires at la 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a signific	CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
Subsequent hospital care, per day, for the evaluar and management of a patient, which requires at least of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 25 min at the bedside and on the patient's hospital floor of unit. Subsequent hospital care, per day, for the evaluar and management of a patient, which requires at least of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a signific							provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is stable, recovering or improving. Physicians typically spend 15 minutes at
and management of a patient, which requires at least of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 25 mins at the bedside and on the patient's hospital floor of unit. Subsequent hospital care, per day, for the evaluat and management of a patient, which requires at least of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant complication complication or a significant complication complication complicati	99231			29.47			
and management of a patient, which requires at least of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant complication or a significant complication.	99232			52.90			focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 25 minutes at the bedside and on the patient's hospital floor or unit.
							and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Observation or inpatient hospital care, for the
						evaluation and management of a patient including
						admission and discharge on the same date, which
						requires these 3 key components: A detailed or
						comprehensive history; A detailed or
						comprehensive examination; and Medical decision
						making that is straightforward or of low complexity.
						Counseling and/or coordination of care with other
						providers or agencies are provided consistent with
						the nature of the problem(s) and the patient's and/or
						family's needs. Usually the presenting problem(s)
99234			101.73			requiring admission are of low severity.
						Observation or inpatient hospital care, for the
						evaluation and management of a patient including
						admission and discharge on the same date, which
						requires these 3 key components: A comprehensive
						history; A comprehensive examination; and Medical
						decision making of moderate complexity.
						Counseling and/or coordination of care with other
						providers or agencies are provided consistent with
						the nature of the problem(s) and the patient's and/or
99235			134.04			family's needs. Usually the presenting problem(s)
99233			134.04			requiring admission are of moderate severity.
						Observation or inpatient hospital care, for the evaluation and management of a patient including
						admission and discharge on the same date, which
						requires these 3 key components: A comprehensive
						history; A comprehensive examination; and Medical
						decision making of high complexity. Counseling
						and/or coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually the presenting problem(s) requiring
99236			166.69			admission are of high severity.
						Hospital discharge day management; 30 minutes or
99238			54.02			less
						Hospital discharge day management; more than 30
99239			77.71			minutes

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Office consultation for a new or established patient,
						which requires these 3 key components: A problem
						focused history; A problem focused examination;
						and Straightforward medical decision making.
						Counseling and/or coordination of care with other
						providers or agencies are provided consistent with
						the nature of the problem(s) and the patient's and/or
						family's needs. Usually, the presenting problem(s)
						are self limited or minor. Physicians typically spend
00241	10.16	26.22				15 minutes face-to-face with the patient and/or
99241	40.46	26.22				family.
						Office consultation for a new or established patient, which requires these 3 key components: An
						expanded problem focused history; An expanded
						problem focused examination; and Straightforward
						medical decision making. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the presenting problem(s) are of low
						severity. Physicians typically spend 30 minutes
99242	74.64	55.11				face-to-face with the patient and/or family.
						Office consultation for a new or established patient,
						which requires these 3 key components: A detailed
						history; A detailed examination; and Medical
						decision making of low complexity. Counseling
						and/or coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of
						moderate severity. Physicians typically spend 40
99243	102.28	76.79				minutes face-to-face with the patient and/or family.
JJ243	102.20	70.75				Office consultation for a new or established patient,
						which requires these 3 key components: A
						comprehensive history; A comprehensive
						examination; and Medical decision making of
						moderate complexity. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the presenting problem(s) are of
						moderate to high severity. Physicians typically
0024	4.40.07	100.07				spend 60 minutes face-to-face with the patient
99244	149.97	120.84				and/or family.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Office consultation for a new or established patient,
						which requires these 3 key components: A
						comprehensive history; A comprehensive
						examination; and Medical decision making of high
						complexity. Counseling and/or coordination of care
						with other providers or agencies are provided
						consistent with the nature of the problem(s) and the
						patient's and/or family's needs. Usually, the
						presenting problem(s) are of moderate to high
						severity. Physicians typically spend 80 minutes
99245	184.89	151.78				face-to-face with the patient and/or family.
						Inpatient consultation for a new or established
						patient, which requires these 3 key components: A
						problem focused history; A problem focused
						examination; and Straightforward medical decision
						making. Counseling and/or coordination of care
						with other providers or agencies are provided
						consistent with the nature of the problem(s) and the
						patient's and/or family's needs. Usually, the
						presenting problem(s) are self limited or minor.
						Physicians typically spend 20 minutes at the bedside
99251			37.92			and on the patient's hospital floor or unit.
						Inpatient consultation for a new or established
						patient, which requires these 3 key components: An
						expanded problem focused history; An expanded
						problem focused examination; and Straightforward
						medical decision making. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the presenting problem(s) are of low
						severity. Physicians typically spend 40 minutes at
00252			60.25			the bedside and on the patient's hospital floor or
99252			60.35			unit. Inpatient consultation for a new or established
						*
						patient, which requires these 3 key components: A
						detailed history; A detailed examination; and
						Medical decision making of low complexity.
						Counseling and/or coordination of care with other
						providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or
						family's needs. Usually, the presenting problem(s)
						are of moderate severity. Physicians typically spend
						55 minutes at the bedside and on the patient's
99253			90.22			hospital floor or unit.
27433	l .		90.22			nospital nool of unit.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Inpatient consultation for a new or established patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 80 minutes at the bedside and on the patient's
99254			130.38			Inpatient consultation for a new or established patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 110 minutes at the bedside and on the patient's hospital floor or
99255			160.87 15.97			unit. Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor.
99282			30.39			Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Emergency department visit for the evaluation and
						management of a patient, which requires these 3 key
						components: An expanded problem focused history;
						An expanded problem focused examination; and
						Medical decision making of moderate complexity.
						Counseling and/or coordination of care with other
						providers or agencies are provided consistent with
						the nature of the problem(s) and the patient's and/or
						family's needs. Usually, the presenting problem(s)
99283			48.60			are of moderate severity.
						Emergency department visit for the evaluation and
						management of a patient, which requires these 3 key
						components: A detailed history; A detailed
						examination; and Medical decision making of
						moderate complexity. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's
						needs. Usually, the presenting problem(s) are of
						high severity, and require urgent evaluation by the
			00.05			physician but do not pose an immediate significant
99284			90.02			threat to life or physiologic function.
						Emergency department visit for the evaluation and
						management of a patient, which requires these 3 key
						components within the constraints imposed by the
						urgency of the patient's clinical condition and/or
						mental status: A comprehensive history; A
						comprehensive examination; and Medical decision
						making of high complexity. Counseling and/or
						coordination of care with other providers or
						agencies are provided consistent with the nature of
						the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of
						high severity and pose an immediate significant
99285			133.85			threat to life or physiologic function.
77203			133.03			Physician direction of emergency medical systems
99288			I.C.			(EMS) emergency care, advanced life support
						Critical care services delivered by a physician, face-
						to-face, during an interfacility transport of critically
						ill or critically injured pediatric patient, 24 months
						of age or less; first 30-74 minutes of hands on care
99289			180.57			during transport
						Critical care services delivered by a physician, face-
						to-face, during an interfacility transport of critically
						ill or critically injured pediatric patient, 24 months
						of age or less; each additional 30 minutes (List
99290			97.71			separately in addition to code for primary service)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
99291	210.23	169.51				Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes
99292	93.31	85.03				Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)
99293			611.45			Initial inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 29 days through 24 months of age
99294			299.89			Subsequent inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 29 days through 24 months of age
99295			704.71			Initial inpatient neonatal critical care, per day, for the evaluation and management of a critically ill neonate, 28 days of age or less
99296			306.04			Subsequent inpatient neonatal critical care, per day, for the evaluation and management of a critically ill neonate, 28 days of age or less
99298			106.89			Subsequent intensive care, per day, for the evaluation and management of the recovering very low birth weight infant (present body weight less than 1500 g)
99299			97.05			Subsequent intensive care, per day, for the evaluation and management of the recovering low birth weight infant (present body weight of 1500-2500 g)
99300			95.70			Subsequent intensive care, per day, for the evaluation and management of the recovering infant (present body weight of 2501-5000 g)
99304			63.56			Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of low severity. Physicians typically spend 25 minutes with the patient and/or family or caregiver.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
CODE	MAC	FAC	FEE	PEE	TEE	Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring
99305			88.21			admission are of moderate severity. Physicians typically spend 35 minutes with the patient and/or family or caregiver.
99306			113.15			Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Physicians typically spend 45 minutes with the patient and/or family or caregiver.
99307			31.46			Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is stable, recovering, or improving. Physicians typically spend 10 minutes with the patient and/or family or caregiver.
99308			48.47			Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 15 minutes with the patient and/or family or caregiver.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient has developed a significant complication or a significant new problem. Physicians typically spend 25 minutes
99309			64.75			with the patient and/or family or caregiver.
						Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A comprehensive interval history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Physicians typically spend 35 minutes with the
99310			94.46			patient and/or family or caregiver.
99315			46.85			Nursing facility discharge day management; 30 minutes or less
99316			61.37			Nursing facility discharge day management; more than 30 minutes
99318			66.35			Evaluation and management of a patient involving an annual nursing facility assessment, which requires these 3 key components: A detailed interval history; A comprehensive examination; and Medical decision making that is of low to moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is stable, recovering, or improving. Physicians typically spend 30 minutes with the patient and/or family or caregiver.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
99324			44.49			Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Physicians typically spend 20 minutes with the patient and/or family or caregiver.
00225			61.16			Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Physicians typically spend 30 minutes with the patient and/or family or
99325			64.46			caregiver.
99326			104.36			Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 45 minutes with the patient and/or family or caregiver.
99327			135.45			Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity. Physicians typically spend 60 minutes with the patient and/or family or caregiver.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other providers or
99328			160.31			agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant new problem requiring immediate physician attention. Physicians typically spend 75 minutes with the patient and/or family or caregiver.
						Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self-limited or minor. Physicians typically spend 15 minutes with the
99334			44.63 68.50			patient and/or family or caregiver. Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Physicians typically spend 25 minutes with the patient and/or family or caregiver.
99336			96.75			Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 40 minutes with the patient and/or family or caregiver.

114.3 CMR 17.00: MEDICINE

ODE NFAC FAC FEE FEE FEE DOMICITIARY OF THE PRESENCE OF THE PR				GLOBAL	PC	TC	
Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key of these 3 key of these 3 key of these 4 key of these 4 key of these 4 key of these 4 key of moderate to high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Physicians typically spend 60 minutes with the patient and/or family or caregiver. Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg. assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of subsequent reports of patient status, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg. legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 15-29 minutes Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg. assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other status, review of related laboratory and other status, review of related laboratory and other of the care of the status, review of related laboratory and other of the car	CODE	NFAC	FAC				DESCRIPTION
99337 138.80 Caregiver. Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg. assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg. legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical treatment plan and/or adjustment of medical treatment plan and/or adjustment of medical treatment plan and/or adjustment of medical treatment plan and/or adjustment of patient (patient not present) in home, domiciliary or rest home (eg. assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg. legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical	COBE	THE STATE OF THE S	The	TEL	THE	TEL	Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive interval history; A comprehensive examination; Medical decision making of moderate to high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Physicians typically
Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical treatment plan patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical	00337			138 80			
Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical							Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical
99340 therapy, within a calendar month; 30 minutes or more							Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
99341			44.16			Home visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Physicians typically spend 20 minutes face-to-face with the patient and/or family.
99342			64.46			Home visit for the evaluation and management of a new patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Physicians typically spend 30 minutes face-to-face with the patient and/or family.
99343			101.90			Home visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 45 minutes face-to-face with the patient and/or family.
99344			I.C.			Home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity. Physicians typically spend 60 minutes face-to-face with the patient and/or family.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's
99345			I.C.			needs. Usually, the patient is unstable or has developed a significant new problem requiring immediate physician attention. Physicians typically spend 75 minutes face-to-face with the patient and/or family.
99347			42.35			Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Physicians typically spend 15 minutes face-to-face with the patient and/or
99348			63.70			family. Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Physicians typically spend 25 minutes face-to-face with the patient and/or family.
99349			92.79			Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are moderate to high severity. Physicians typically spend 40 minutes face-to-face with the patient and/or family.

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Home visit for the evaluation and management of an
						established patient, which requires at least 2 of these
						3 key components: A comprehensive interval
						history; A comprehensive examination; Medical
						decision making of moderate to high complexity.
						Counseling and/or coordination of care with other
						providers or agencies are provided consistent with
						the nature of the problem(s) and the patient's and/or
						family's needs. Usually, the presenting problem(s)
						are of moderate to high severity. The patient may be
						unstable or may have developed a significant new
						problem requiring immediate physician attention.
						Physicians typically spend 60 minutes face-to-face
99350			I.C.			with the patient and/or family.
						Prolonged physician service in the office or other
						outpatient setting requiring direct (face-to-face)
						patient contact beyond the usual service (eg,
						prolonged care and treatment of an acute asthmatic
						patient in an outpatient setting); first hour (List
						separately in addition to code for office or other
99354	74.63	70.32				outpatient Evaluation and Management service)
						Prolonged physician service in the office or other
						outpatient setting requiring direct (face-to-face)
						patient contact beyond the usual service (eg,
						prolonged care and treatment of an acute asthmatic
						patient in an outpatient setting); each additional 30
						minutes (List separately in addition to code for
99355	73.42	68.79				prolonged physician service)
						Prolonged physician service in the inpatient setting,
						requiring direct (face-to-face) patient contact
						beyond the usual service (eg, maternal fetal
						monitoring for high risk delivery or other
						physiological monitoring, prolonged care of an
						acutely ill inpatient); first hour (List separately in
						addition to code for inpatient Evaluation and
99356			67.77			Management service)
						Prolonged physician service in the inpatient setting,
						requiring direct (face-to-face) patient contact
						beyond the usual service (eg, maternal fetal
						monitoring for high risk delivery or other
						physiological monitoring, prolonged care of an
						acutely ill inpatient); each additional 30 minutes
						(List separately in addition to code for prolonged
99357			67.99			physician service)

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	I
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
0022	1,2120	1110				Prolonged evaluation and management service
						before and/or after direct (face-to-face) patient care
						(eg, review of extensive records and tests,
						communication with other professionals and/or the
						patient/family); first hour (List separately in
						addition to code(s) for other physician service(s)
						and/or inpatient or outpatient Evaluation and
99358			77.43			Management service)
						Prolonged evaluation and management service
						before and/or after direct (face-to-face) patient care
						(eg, review of extensive records and tests,
						communication with other professionals and/or the
						patient/family); each additional 30 minutes (List
						separately in addition to code for prolonged
99359			37.38			physician service)
						Physician standby service, requiring prolonged
						physician attendance, each 30 minutes (eg,
2225			42.04			operative standby, standby for frozen section, for
99360			43.84			cesarean/high risk delivery, for monitoring EEG)
						Anticoagulant management for an outpatient taking
						warfarin, physician review and interpretation of
						International Normalized Ratio (INR) testing,
						patient instructions, dosage adjustment (as needed),
						and ordering of additional tests; initial 90 days of
99363	90.60	60.14				therapy (must include a minimum of 8 INR measurements)
99303	90.00	00.14				Anticoagulant management for an outpatient taking
						warfarin, physician review and interpretation of
						International Normalized Ratio (INR) testing,
						patient instructions, dosage adjustment (as needed),
						and ordering of additional tests; each subsequent 90
						days of therapy (must include a minimum of 3 INR
99364	31.02	23.08				measurements)
						Medical team conference with interdisciplinary
						team of health care professionals, face-to-face with
						patient and/or family, 30 minutes or more,
						participation by nonphysician qualified health care
99366	30.80	30.47				professional
						Medical team conference with interdisciplinary
						team of health care professionals, patient and/or
						family not present, 30 minutes or more;
99367			40.05			participation by physician
						Medical team conference with interdisciplinary
						team of health care professionals, patient and/or
						family not present, 30 minutes or more;
000.63			2621			participation by nonphysician qualified health care
99368			26.04			professional

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Physician supervision of a patient under care of
						home health agency (patient not present) in home,
						domiciliary or equivalent environment (eg,
						Alzheimer's facility) requiring complex and
						multidisciplinary care modalities involving regular
						physician development and/or revision of care
						plans, review of subsequent reports of patient status,
						review of related laboratory and other studies,
						communication (including telephone calls) for
						purposes of assessment or care decisions with health
						care professional(s), family member(s), surrogate
						decision maker(s) (eg, legal guardian) and/or key
						caregiver(s) involved in patient's care, integration of
						new information into the medical treatment plan
						and/or adjustment of medical therapy, within a
99374	52.30	43.03				calendar month; 15-29 minutes
						Physician supervision of a patient under care of
						home health agency (patient not present) in home,
						domiciliary or equivalent environment (eg,
						Alzheimer's facility) requiring complex and
						multidisciplinary care modalities involving regular
						physician development and/or revision of care
						plans, review of subsequent reports of patient status,
						review of related laboratory and other studies,
						communication (including telephone calls) for
						purposes of assessment or care decisions with health
						care professional(s), family member(s), surrogate
						decision maker(s) (eg, legal guardian) and/or key
						caregiver(s) involved in patient's care, integration of
						new information into the medical treatment plan
						and/or adjustment of medical therapy, within a
99375	87.86	81.91				calendar month; 30 minutes or more
						Physician supervision of a hospice patient (patient
						not present) requiring complex and
						multidisciplinary care modalities involving regular
						physician development and/or revision of care
						plans, review of subsequent reports of patient status,
						review of related laboratory and other studies,
						communication (including telephone calls) for
						purposes of assessment or care decisions with health
						care professional(s), family member(s), surrogate
						decision maker(s) (eg, legal guardian) and/or key
						caregiver(s) involved in patient's care, integration of
						new information into the medical treatment plan
						and/or adjustment of medical therapy, within a
99377	52.30	43.03				calendar month; 15-29 minutes

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Physician supervision of a hospice patient (patient
						not present) requiring complex and
						multidisciplinary care modalities involving regular
						physician development and/or revision of care
						plans, review of subsequent reports of patient status,
						review of related laboratory and other studies,
						communication (including telephone calls) for
						purposes of assessment or care decisions with health
						care professional(s), family member(s), surrogate
						decision maker(s) (eg, legal guardian) and/or key
						caregiver(s) involved in patient's care, integration of
						new information into the medical treatment plan
						and/or adjustment of medical therapy, within a
99378	94.49	88.53				calendar month; 30 minutes or more
						Physician supervision of a nursing facility patient
						(patient not present) requiring complex and
						multidisciplinary care modalities involving regular
						physician development and/or revision of care
						plans, review of subsequent reports of patient status,
						review of related laboratory and other studies,
						communication (including telephone calls) for
						purposes of assessment or care decisions with health
						care professional(s), family member(s), surrogate
						decision maker(s) (eg, legal guardian) and/or key
						caregiver(s) involved in patient's care, integration of
						new information into the medical treatment plan
						and/or adjustment of medical therapy, within a
99379	52.09	42.82				calendar month; 15-29 minutes
						Physician supervision of a nursing facility patient
						(patient not present) requiring complex and
						multidisciplinary care modalities involving regular
						physician development and/or revision of care
						plans, review of subsequent reports of patient status,
						review of related laboratory and other studies,
						communication (including telephone calls) for
						purposes of assessment or care decisions with health
						care professional(s), family member(s), surrogate
						decision maker(s) (eg, legal guardian) and/or key
						caregiver(s) involved in patient's care, integration of
						new information into the medical treatment plan
00202	70.22	67.12				and/or adjustment of medical therapy, within a
99380	78.38	67.12				calendar month; 30 minutes or more

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Initial comprehensive preventive medicine
						evaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
						procedures, new patient; infant (age younger than 1
99381	83.55	51.02				year)
						Initial comprehensive preventive medicine
						evaluation and management of an individual
						including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
						procedures, new patient; early childhood (age 1
99382	90.25	58.45				through 4 years)
						Initial comprehensive preventive medicine
						evaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
						procedures, new patient; late childhood (age 5
99383	88.79	58.45				through 11 years)
						Initial comprehensive preventive medicine
						evaluation and management of an individual including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
						procedures, new patient; adolescent (age 12 through
99384	96.46	65.75				17 years)
						Initial comprehensive preventive medicine
						evaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
99385	96.46	65.75				appropriate immunization(s), laboratory/diagnostic procedures, new patient; 18-39 years
99303	30.40	05.15				Initial comprehensive preventive medicine
						evaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
99386	112.60	80.80				procedures, new patient; 40-64 years

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Initial comprehensive preventive medicine
						evaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
99387	122.90	88.17				procedures, new patient; 65 years and older
						Periodic comprehensive preventive medicine
						reevaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
00204	66.71	42.54				procedures, established patient; infant (age younger
99391	66.74	43.71				than 1 year)
						Periodic comprehensive preventive medicine
						reevaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
00202	74.41	51.00				procedures, established patient; early childhood (age
99392	74.41	51.02				1 through 4 years) Periodic comprehensive preventive medicine
						reevaluation and management of an individual including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
						procedures, established patient; late childhood (age
99393	73.68	51.02				5 through 11 years)
77373	75.00	31.02				Periodic comprehensive preventive medicine
						reevaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
						procedures, established patient; adolescent (age 12
99394	80.75	58.45				through 17 years)
						Periodic comprehensive preventive medicine
						reevaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
99395	81.48	58.45				procedures, established patient; 18-39 years

114.3 CMR 17.00: MEDICINE

			CLOBAL	DC	TC	1
CODE	NFAC	FAC	GLOBAL FEE	PC FEE	TC FEE	DESCRIPTION
CODE	NIAC	TAC	FISIS	FISE	FEE	Periodic comprehensive preventive medicine
						reevaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
99396	89.15	65.75				procedures, established patient; 40-64 years
77270	07.13	03.73				Periodic comprehensive preventive medicine
						reevaluation and management of an individual
						including an age and gender appropriate history,
						examination, counseling/anticipatory guidance/risk
						factor reduction interventions, and the ordering of
						appropriate immunization(s), laboratory/diagnostic
99397	99.45	73.50				procedures, established patient; 65 years and older
77271	77113	75.50				Preventive medicine counseling and/or risk factor
						reduction intervention(s) provided to an individual
99401	29.84	18.58				(separate procedure); approximately 15 minutes
77401	27.04	10.50				Preventive medicine counseling and/or risk factor
						reduction intervention(s) provided to an individual
99402	49.97	37.72				(separate procedure); approximately 30 minutes
9940Z	47.71	31.12				Preventive medicine counseling and/or risk factor
						reduction intervention(s) provided to an individual
99403	69.42	56.51				(separate procedure); approximately 45 minutes
99403	09.42	50.51				Preventive medicine counseling and/or risk factor
						reduction intervention(s) provided to an individual
99404	88.94	75.37				(separate procedure); approximately 60 minutes
<i>33</i> 404	00.94	13.31				Smoking and tobacco use cessation counseling visit;
						intermediate, greater than 3 minutes up to 10
99406	10.22	9.56				minutes
99400	10.22	9.50				
99407	58.32	55.45				Smoking and tobacco use cessation counseling visit;
99407	30.32	33.43				intensive, greater than 10 minutes Alcohol and/or substance (other than tobacco) abuse
99408	24.65	23.32				structured screening (eg, AUDIT, DAST), and brief
99406	24.65	23.32				intervention (SBI) services; 15 to 30 minutes Alcohol and/or substance (other than tobacco) abuse
						· · · · · · · · · · · · · · · · · · ·
99409	48.19	46.86				structured screening (eg, AUDIT, DAST), and brief
99409	46.19	40.80				intervention (SBI) services; greater than 30 minutes
						Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in
						a group setting (separate procedure); approximately
00411	11.02	6.06				30 minutes
99411	11.02	0.00				
						Preventive medicine counseling and/or risk factor
						reduction intervention(s) provided to individuals in
00412	15 47	0.04				a group setting (separate procedure); approximately
99412	15.47	9.84				60 minutes
00420			7.50			Administration and interpretation of health risk
99420			7.50			assessment instrument (eg, health hazard appraisal)
99429			I.C.			Unlisted preventive medicine service

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						History and examination of the normal newborn
						infant, initiation of diagnostic and treatment
						programs and preparation of hospital records. (This
						code should also be used for birthing room
99431			64.21			deliveries.)
						Normal newborn care in other than hospital or
						birthing room setting, including physical
00400	60.50	45.00				examination of baby and conference(s) with
99432	68.79	47.93				parent(s)
00.422			24.04			Subsequent hospital care, for the evaluation and
99433			34.81			management of a normal newborn, per day
						History and examination of the normal newborn
						infant, including the preparation of medical records.
						(This code should only be used for newborns
00425			88.42			assessed and discharged from the hospital or
99435			88.42			birthing room on the same date.)
						Attendance at delivery (when requested by delivering physician) and initial stabilization of
99436			56.40			newborn
99430	1		30.40			Newborn resuscitation: provision of positive
						pressure ventilation and/or chest compressions in
						the presence of acute inadequate ventilation and/or
99440			160.58			cardiac output
33110			100.50			Telephone evaluation and management service
						provided by a physician to an established patient,
						parent, or guardian not originating from a related
						E/M service provided within the previous 7 days nor
						leading to an E/M service or procedure within the
						next 24 hours or soonest available appointment; 5-
99441	10.39	9.39				10 minutes of medical discussion
						Telephone evaluation and management service
						provided by a physician to an established patient,
						parent, or guardian not originating from a related
						E/M service provided within the previous 7 days nor
						leading to an E/M service or procedure within the
						next 24 hours or soonest available appointment; 11-
99442	19.02	18.03				20 minutes of medical discussion
						Telephone evaluation and management service
						provided by a physician to an established patient,
						parent, or guardian not originating from a related
						E/M service provided within the previous 7 days nor
						leading to an E/M service or procedure within the
						next 24 hours or soonest available appointment; 21-
99443	28.20	27.21				30 minutes of medical discussion

114.3 CMR 17.00: MEDICINE

			GLOBAL	PC	TC	
CODE	NFAC	FAC	FEE	FEE	FEE	DESCRIPTION
						Online evaluation and management service provided
						by a physician to an established patient, guardian, or
						health care provider not originating from a related
						E/M service provided within the previous 7 days,
						using the Internet or similar electronic
99444			I.C.			communications network
						Basic life and/or disability examination that
						includes: Measurement of height, weight, and blood
						pressure; Completion of a medical history following
						a life insurance pro forma; Collection of blood
						sample and/or urinalysis complying with chain of
						custody protocols; and Completion of necessary
99450			I.C.			documentation/certificates.
						Work related or medical disability examination by
						the treating physician that includes: Completion of a
						medical history commensurate with the patient's
						condition; Performance of an examination
						commensurate with the patient's condition;
						Formulation of a diagnosis, assessment of
						capabilities and stability, and calculation of
						impairment; Development of future medical
						treatment plan; and Completion of necessary
99455			I.C.			documentation/certificates and report.
						Work related or medical disability examination by
						other than the treating physician that includes:
						Completion of a medical history commensurate with
						the patient's condition; Performance of an
						examination commensurate with the patient's
						condition; Formulation of a diagnosis, assessment of
						capabilities and stability, and calculation of
						impairment; Development of future medical
						treatment plan; and Completion of necessary
99456			I.C.			documentation/certificates and report.
						Initial hospital care, per day, for the evaluation and
						management of the neonate, 28 days of age or less,
						who requires intensive observation, frequent
99477			267.81			interventions, and other intensive care services
99499			I.C.			Unlisted evaluation and management service
						Home visit for prenatal monitoring and assessment
						to include fetal heart rate, non-stress test, uterine
99500	1		I.C.			monitoring, and gestational diabetes monitoring
						Home visit for postnatal assessment and follow-up
99501			I.C.			care
99502			I.C.			Home visit for newborn care and assessment
						Home visit for respiratory therapy care (eg,
						bronchodilator, oxygen therapy, respiratory
99503			I.C.			assessment, apnea evaluation)
99504			I.C.			Home visit for mechanical ventilation care

114.3 CMR 17.00: MEDICINE

CODE	NFAC	FAC	GLOBAL FEE	PC FEE	TC FEE	DESCRIPTION
						Home visit for stoma care and maintenance
99505			I.C.			including colostomy and cystostomy
99506			I.C.			Home visit for intramuscular injections
						Home visit for care and maintenance of catheter(s)
99507			I.C.			(eg, urinary, drainage, and enteral)
						Home visit for assistance with activities of daily
99509			I.C.			living and personal care
						Home visit for individual, family, or marriage
99510			I.C.			counseling
						Home visit for fecal impaction management and
99511			I.C.			enema administration
99512			I.C.			Home visit for hemodialysis
99600			I.C.			Unlisted home visit service or procedure
1						Home infusion/specialty drug administration, per
99601			I.C.			visit (up to 2 hours);
						Home infusion/specialty drug administration, per
						visit (up to 2 hours); each additional hour (List
						separately in addition to code for primary
99602			I.C.			procedure)
						Medication therapy management service(s)
						provided by a pharmacist, individual, face-to-face
00.50.7						with patient, with assessment and intervention if
99605			I.C.			provided; initial 15 minutes, new patient
						Medication therapy management service(s)
						provided by a pharmacist, individual, face-to-face
00606			I.C.			with patient, with assessment and intervention if
99606	1		I.C.			provided; initial 15 minutes, established patient
						Medication therapy management service(s)
						provided by a pharmacist, individual, face-to-face with patient, with assessment and intervention if
						provided; each additional 15 minutes (List
99607			I.C.			separately in addition to code for primary service)
99001			1.C.			Diabetes outpatient self-management training
G0108			23.72			services, individual, per 30 minutes
30100			25.12		1	Diabetes outpatient self-management training
G0109			13.46			services, group session (2 or more), per 30 minutes
30107			13.70			Medical nutrition therapy; reassessment and
						subsequent intervention(s) following second referral
						in same year for change in diagnosis, medical
						condition or treatment regimen (including additional
						hours needed for renal disease), individual, face-to-
G0270	20.14	19.81				face with the patient, each 15 minutes
						Medical nutrition therapy, reassessment and
						subsequent intervention(s) following second referral
						in same year for change in diagnosis, medical
						condition, or treatment regimen (including
1						additional hours needed for renal disease), group (2
G0271	11.50	11.17				or more individuals), each 30 minutes

114.3 CMR 17.00: MEDICINE

TOBACCO CESSATION COUNSELING SERVICES

CODE	NFAC	FAC	DESCRIPTION
			Smoking and tobacco use cessation counseling visit; intensive, greater than 10
			minutes (at least 30 minutes). (Eligible providers are physician, independent nurse
99407	58.32	55.45	practitioner, and independent nurse midwife.)
			Smoking and tobacco use cessation counseling visit; intensive, greater than 10
			minutes (at least 30 minutes). (Eligible providers are nurse practitioners employed
99407 SA	49.58	47.13	by an eligible billing entity.)
			Smoking and tobacco use cessation counseling visit; intensive, greater than 10
00405 GB	40.50	45.10	minutes (at least 30 minutes). (Eligible providers are nurse midwives employed by
99407 SB	49.58	47.13	an eligible billing entity.)
			Smoking and tobacco use cessation counseling visit; intensive, greater than 10
99407 HN	49.58	47.12	minutes (at least 30 minutes). (Eligible providers are physician assistants employed
9940/ HN	49.38	47.13	by an eligible billing entity.) Smoking and tobacco use cessation counseling visit; intensive, greater than 10
			minutes (at least 30 minutes). (Eligible providers are registered nurses employed
99407 TD	49.58	47.13	by an eligible billing entity.)
77407 ID	77.50	77.13	Smoking and tobacco use cessation counseling visit; intensive, greater than 10
			minutes (at least 30 minutes). (Eligible providers are tobacco cessation counselors
99407 U1	49.58	47.13	employed by an eligible billing entity.)
			Smoking and tobacco use cessation counseling visit; intensive (intake assessment
			for an individual, at least 45 minutes). (Eligible providers are physician,
99407 TF	87.49	83.17	independent nurse practitioner, and independent nurse midwife.)
			Smoking and tobacco use cessation counseling visit; intensive (intake assessment
			for an individual, at least 45 minutes). (Eligible providers are nurse practitioner,
			nurse midwife, physician assistant, registered nurse, and tobacco cessation
99407 U2	74.36	70.69	counselor.)
			Smoking and tobacco use cessation counseling visit; intensive (for an individual in
			a group setting, 60-90 minutes). (Eligible providers are physician, independent
99407 HQ	34.99	33.27	nurse practitioner, and independent nurse midwife.)
			Smoking and tobacco use cessation counseling visit; intensive (for an individual in
00407 112	20.75	20.20	a group setting, 60-90 minutes). (Eligible providers are nurse practitioner, nurse
99407 U3	29.75	28.28	midwife, physician assistant, registered nurse, and tobacco cessation counselor.)

BEHAVIORAL HEALTH SCREENING SERVICES

CODE	RATE	DESCRIPTION
96110 U1	9.82	Developmental testing; limited (e.g. Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report. (Eligible providers are Physician, Independent Nurse Midwife, Independent Nurse Practitioner, Community Health Center (CHC), Outpatient Hospital Department (OPD), completed behavioral health screening with no behavioral health need identified.)
96110 U2	9.82	Developmental testing; limited (e.g. Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report. (Eligible providers are Physician, Independent Nurse Midwife, Independent Nurse Practitioner, Community Health Center (CHC), Outpatient Hospital Department (OPD), completed behavioral health screening and behavioral health need identified.)

114.3 CMR 17.00: MEDICINE

CODE	RATE	DESCRIPTION
96110 U3	9.82	Developmental testing; limited (e.g. Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report. (Eligible providers are Nurse Midwife employed by Physician or CHC, completed behavioral health screening with no behavioral health need identified.)
96110 U4	9.82	Developmental testing; limited (e.g. Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report. (Eligible providers are Nurse Midwife employed by Physician or CHC, completed behavioral health screening and behavioral health need identified.)
96110 U5	9.82	Developmental testing; limited (e.g. Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report. (Eligible providers are Nurse Practitioner employed by Physician or CHC, completed behavioral health screening with no behavioral health need identified.)
96110 U6	9.82	Developmental testing; limited (e.g. Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report. (Eligible providers are Nurse Practitioner employed by Physician or CHC, completed behavioral health screening and behavioral health need identified.)
96110 U7	9.82	Developmental testing; limited (e.g. Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report. (Eligible providers are Physician Assistant employed by Physician or CHC, completed behavioral health screening with no behavioral health need identified.)
96110 U8	9.82	Developmental testing; limited (e.g. Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report. (Eligible providers are Physician Assistant employed by Physician or CHC, completed behavioral health screening and behavioral health need identified.)

CODE	GLOBAL FEE	DESCRIPTION
H2011	21.28	Crisis intervention service, per 15 minutes
J0128	I.C.	Injection, abarelix, 10 mg
J0129	18.69	Injection, abatacept, 10 mg
J0135	330.68	Injection, adalimumab, 20 mg
J0170	1.04	Injection, adrenalin, epinephrine, up to 1 ml ampule
J0215	26.56	Injection, alefacept, 0.5 mg
J0256	3.38	Injection, alpha 1-proteinase inhibitor - human, 10 mg
		Injection, alprostadil, 1.25 mcg (code may be used for Medicare when drug
		administered under direct supervision of a physician, not for use when drug is self-
J0270	1.98	administered)
J0290	2.37	Injection, ampicillin sodium, 500 mg
J0295	4.66	Injection, ampicillin sodium/sulbactam sodium, per 1.5 g
J0348	1.86	Injection, anadulafungin, 1 mg
J0456	17.61	Injection, azithromycin, 500 mg
J0460	0.60	Injection, atropine sulfate, up to 0.3 mg
J0475	196.92	Injection, baclofen, 10 mg
J0476	70.96	Injection, baclofen, 50 mcg for intrathecal trial
J0530	14.75	Injection, penicillin G benzathine and penicillin G procaine, up to 600,000 units
J0540	33.00	Injection, penicillin G benzathine and penicillin G procaine, up to 1,200,000 units
J0550	33.00	Injection, penicillin G benzathine and penicillin G procaine, up to 2,400,000 units
J0560	23.77	Injection, penicillin G benzathine, up to 600,000 units
J0570	40.89	Injection, penicillin G benzathine, up to 1,200,000 units

114.3 CMR 17.00: MEDICINE

CODE	GLOBAL FEE	DESCRIPTION
J0580	46.53	Injection, penicillin G benzathine, up to 2,400,000 units
J0585	5.26	Botulinum toxin type A, per unit
J0587	8.71	Botulinum toxin type B, per 100 units
J0592	0.71	Injection, buprenorphine HCl, 0.1 mg
J0640	0.86	Injection, leucovorin calcium, per 50 mg
J0690	1.42	Injection, cefazolin sodium, 500 mg
J0694	8.28	Injection, cefoxitin sodium, 1 g
J0696	1.25	Injection, ceftriaxone sodium, per 250 mg
J0697	3.97	Injection, sterile cefuroxime sodium, per 750 mg
J0702	5.60	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
J0704	1.13	Injection, betamethasone sodium phosphate, per 4 mg
J0780	1.11	Injection, prochlorperazine, up to 10 mg
J0835	64.88	Injection, cosyntropin, per 0.25 mg
J0881	2.89	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882	2.89	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)
J0885	8.96	Injection, epoetin alfa, (for non-ESRD use), 1000 units
J0886	8.96	Injection, epoetin alfa, 1000 units (for ESRD on dialysis)
J0900	I.C.	Injection, testosterone enanthate and estradiol valerate, up to 1 cc
J1020	2.27	Injection, methylprednisolone acetate, 20 mg
J1030	4.63	Injection, methylprednisolone acetate, 40 mg
J1040	8.71	Injection, methylprednisolone acetate, 80 mg
J1055	I.C.	Injection, medroxyprogesterone acetate for contraceptive use, 150 mg
J1056	I.C.	Injection, medroxyprogesterone acetate/estradiol cypionate, 5 mg/25 mg
J1060	4.14	Injection, testosterone cypionate and estradiol cypionate, up to 1 ml
J1070	4.88	Injection, testosterone cypionate, up to 100 mg
J1080	12.44	Injection, testosterone cypionate, 1 cc, 200 mg
J1094	0.23	Injection, dexamethasone acetate, 1 mg
J1100	0.11	Injection, dexamethasone sodium phosphate, 1 mg
J1160	3.85	Injection, digoxin, up to 0.5 mg
J1170	2.02	Injection, hydromorphone, up to 4 mg
J1200	0.80	Injection, diphenhydramine HCl, up to 50 mg
J1260	4.80	Injection, dolasetron mesylate, 10 mg
J1320	I.C.	Injection, amitriptyline HCl, up to 20 mg
		Injection, etanercept, 25 mg (code may be used for Medicare when drug administered
		under the direct supervision of a physician, not for use when drug is self-
J1438	168.75	administered)
J1440	199.04	Injection, filgrastim (G-CSF), 300 mcg
J1441	305.39	Injection, filgrastim (G-CSF), 480 mcg
J1460	11.76	Injection, gamma globulin, intramuscular, 1 cc
J1470	23.52	Injection, gamma globulin, intramuscular, 2 cc
J1480	35.27	Injection, gamma globulin, intramuscular, 3 cc
J1490	47.04	Injection, gamma globulin, intramuscular, 4 cc
J1500	58.80	Injection, gamma globulin, intramuscular, 5 cc
J1510	70.58	Injection, gamma globulin, intramuscular, 6 cc
J1520	82.26	Injection, gamma globulin, intramuscular, 7 cc
J1530	94.07	Injection, gamma globulin, intramuscular, 8 cc
J1540	105.89	Injection, gamma globulin, intramuscular, 9 cc
J1550	117.59	Injection, gamma globulin, intramuscular, 10 cc
T1.5.61	22.00	Injection, immune globulin, (Gamunex), intravenous, nonlyophilized (e.g., liquid),
J1561	32.88	500 mg

114.3 CMR 17.00: MEDICINE

CODE	GLOBAL FEE	DESCRIPTION
J1562	7.08	Injection, immune globulin (Vivaglobin), 100 mg
		Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise
J1566	27.67	specified, 500 mg
		Injection, immune globulin, (Gammagard liquid), intravenous, nonlyophilized, (e.g.,
J1569	31.65	liquid), 500 mg
J1571	59.25	Injection, hepatitis B immune globulin (Hepagam B), intramuscular, 0.5 ml
J1580	1.33	Injection, garamycin, gentamicin, up to 80 mg
J1626	4.72	Injection, granisetron HCl, 100 mcg
J1630	1.79	Injection, haloperidol, up to 5 mg
J1644	0.22	Injection, Heparin sodium, per 1000 units
J1650	5.81	Injection, enoxaparin sodium, 10 mg
J1655	2.29	Injection, tinzaparin sodium, 1000 IU
J1670	101.19	Injection, tetanus immune globulin, human, up to 250 units
J1700	I.C.	Injection, hydrocortisone acetate, up to 25 mg
J1710	I.C.	Injection, hydrocortisone sodium phosphate, up to 50 mg
J1720	2.13	Injection, hydrocortisone sodium succinate, up to 100 mg
J1740	139.04	Injection, ibandronate sodium, 1 mg
J1745	55.21	Injection, infliximab, 10 mg
J1751	11.62	Injection, iron dextran 165, 50 mg
J1752	11.62	Injection, iron dextran 267, 50 mg
J1790	1.18	Injection, droperidol, up to 5 mg
J1800	3.27	Injection, propranolol HCl, up to 1 mg
J1815	0.28	Injection, insulin, per 5 units
J1885	0.41	Injection, ketorolac tromethamine, per 15 mg
J1890	I.C.	Injection, cephalothin sodium, up to 1 g
J1940	0.25	Injection, furosemide, up to 20 mg
J1950	453.31	Injection, leuprolide acetate (for depot suspension), per 3.75 mg
J1956	6.01	Injection, levofloxacin, 250 mg
J1990	21.05	Injection, chlordiazepoxide HCl, up to 100 mg
J2001	0.02	Injection, lidocaine HCl for intravenous infusion, 10 mg
J2060	0.95	Injection, lorazepam, 2 mg
J2150	0.88	Injection, mannitol, 25% in 50 ml
J2175	2.06	Injection, meperidine HCl, per 100 mg
J2248	1.36	Injection, micafungin sodium, 1 mg
J2250	0.24	Injection, midazolam HCl, per 1 mg
J2270	2.75	Injection, morphine sulfate, up to 10 mg
J2271	4.54	Injection, morphine sulfate, 100 mg
J2275	4.28	Injection, morphine sulfate (preservative-free sterile solution), per 10 mg
J2300	1.18	Injection, nalbuphine HCl, per 10 mg
J2310	3.06	Injection, naloxone HCl, per 1 mg
J2315	1.88	Injection, natrexone, depot form, 1 mg
J2323	7.51	Injection, natalizumab, 1 mg
J2355	249.02	Injection, oprelvekin, 5 mg
J2357	17.42	Injection, opicivekin, 5 mg
J2405	0.28	Injection, ondansetron HCl, per 1 mg
J2430	29.63	Injection, ondanseron rich, per ring Injection, pamidronate disodium, per 30 mg
J2440	0.45	Injection, panuaronate disodium, per 30 mg
J2440 J2469	16.64	Injection, papaverme rier, up to oo nig Injection, palonosetron HCl, 25 mcg
J2503	1045.48	Injection, patonoscuon rici, 23 meg Injection, pegaptanib sodium, 0.3 mg
J2505	2191.41	Injection, pegaptamo sodium, 0.3 mg Injection, pegfilgrastim, 6 mg
J23U3	∠171.41	mjection, pegingrasium, o mg

114.3 CMR 17.00: MEDICINE

CODE	GLOBAL FEE	DESCRIPTION
J2510	10.32	Injection, penicillin G procaine, aqueous, up to 600,000 units
J2515	7.69	Injection, pentobarbital sodium, per 50 mg
J2550	1.52	Injection, promethazine HCl, up to 50 mg
J2560	3.62	Injection, phenobarbital sodium, up to 120 mg
J2650	0.17	Injection, prednisolone acetate, up to 1 ml
J2675	1.58	Injection, progesterone, per 50 mg
J2680	2.11	Injection, fluphenazine decanoate, up to 25 mg
J2760	24.00	Injection, phentolamine mesylate, up to 5 mg
J2765	0.40	Injection, metoclopramide HCl, up to 10 mg
J2778	405.89	Injection, ranibizumab, 0.1 mg
J2780	0.61	Injection, ranitidine HCl, 25 mg
J2788	27.37	Injection, Rho D immune globulin, human, minidose, 50 mcg
J2790	81.03	Injection, Rho D immune globulin, human, full dose, 300 mcg
J2792	15.65	Injection, Rho D immune globulin, intravenous, human, solvent detergent, 100 IU
J2794	4.91	Injection, risperidone, long acting, 0.5 mg
J2820	24.57	Injection, rispertione, rong acting, v.5 mg Injection, sargramostim (GM-CSF), 50 mcg
J2910	I.C.	Injection, sargramostim (GM-CSF), 50 mg
J2916	4.85	Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg
J2910 J2920	1.98	Injection, methylprednisolone sodium succinate, up to 40 mg
J2920 J2930	3.49	Injection, methylprednisolone sodium succinate, up to 40 mg
J2940	I.C.	Injection, somatrem, 1 mg
J2940 J2941	49.24	Injection, somatropin, 1 mg
J3010	0.33	Injection, somatrophi, 1 mg Injection, fentanyl citrate, 0.1 mg
J3010	0.33	Injection, tentanyl children, 0.1 mg Injection, sumatriptan succinate, 6 mg (code may be used for Medicare when drug
		administered under the direct supervision of a physician, not for use when drug is self-
J3030	65.85	administered under the direct supervision of a physician, not for use when drug is sen-
J3110	I.C.	Injection, teriparatide, 10 mcg
J3110	5.29	Injection, temparatide, 10 mg
J3120 J3130	10.28	Injection, testosterone enanthate, up to 100 mg
J3230	3.33	Injection, testosterone enantiate, up to 200 mg
J3243	1.02	Injection, tigecycline, 1 mg
J3243 J3250	4.45	Injection, trimethobenzamide HCl, up to 200 mg
J3301	1.50	Injection, triamcinolone acetonide, per 10 mg
J3301 J3302	0.28	Injection, triamcinolone diacetate, per 10 mg
J3302 J3303	1.51	Injection, triamcinolone diacetate, per 5 mg
J3360	0.86	
J3396	9.12	Injection, diazepam, up to 5 mg Injection, verteporfin, 0.1 mg
J3390 J3410	0.18	Injection, verteportin, 0.1 mg Injection, hydroxyzine HCl, up to 25 mg
J3410 J3411	2.36	Injection, hydroxyzine HCl, up to 23 mg
J3411 J3420	0.55	Injection, thamine HCI, 100 mg Injection, vitamin B-12 cyanocobalamin, up to 1,000 mcg
J3420 J3430	3.62	Injection, vitamin B-12 cyanocoolalamin, up to 1,000 meg Injection, phytonadione (vitamin K), per 1 mg
J3430 J3475	0.13	Injection, magnesium sulfate, per 500 mg
J3487 J3490	208.76	Injection, zoledronic acid (Zometa), 1 mg
	I.C.	Unclassified drugs
J3590	I.C.	Unclassified biologics
J7030	1.20	Infusion, normal saline solution, 1,000 cc
J7040	0.60	Infusion, normal saline solution, sterile (500 ml = 1 unit)
J7042	0.45	5% dextrose/normal saline (500 ml = 1 unit)
J7050	0.30	Infusion, normal saline solution, 250 cc
J7060	1.46	5% dextrose/water (500 ml = 1 unit)

114.3 CMR 17.00: MEDICINE

17070 2.92	CODE	GLOBAL FEE	DESCRIPTION
17307 I.C. Etonogestrel (contraceptive) implant system, including implant and supplies 17321 102.06 Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose 17322 178.16 Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose 17323 110.87 Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose 17324 171.37 Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose Dermal and epidermal, (substitute) tissue of human origin, with or without of without bioengineered or processed elements, with metabolically active elements, per square centimeter Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, with metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, with metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements,			
J7321 102.06 Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose J7322 178.16 Hyaluronan or derivative, Synvisc, for intra-articular injection, per dose J7324 171.37 Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose J7324 171.37 Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose Dermal and epidermal, (substitute) tissue of human origin, with or without bioengineered or processed elements, with metabolically active elements, per square centimeter Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, with metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal and epidermal, (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter J7344 95.38 Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter J7346 770.02 Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements (Integra Matrix), per sq. cm. J7348 92.31 Dermal	J7307	I.C.	
17322 178.16			
17323 110.87			
17324 171.37			
Dermal and epidermal, (substitute) tissue of human origin, with or without bioengineered or processed elements, with metabolically active elements, per square centimeter			
bioengineered or processed elements, with metabolically active elements, per square centimeter Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, with metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, with metabolically active elements, per square centimeter Dermal and epidermal, (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, but without metabolically active elements, per square centimeter Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Integra Matrix), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Prisaueman), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Prisaueman), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Prisaueman), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Prisaueman), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered	0,02.	1/1.5/	
J7340 30.13 Centimeter			
Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, with metabolically active elements, per square centimeter	J7340	30 13	
J7341 2.03 processed elements, with metabolically active elements, per square centimeter	0,010	50.15	
Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, with metabolically active elements, per square centimeter bioengineered or processed elements, without metabolically active elements, per square centimeter	J7341	2.03	
J7342 36.73 processed elements, with metabolically active elements, per square centimeter	0,011	2.03	
Dermal and epidermal, (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, injectable, with or without other bioengineered or processed elements, without metabolically active elements, 1 cc Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, but without metabolically active elements, 1 cc Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Integra Matrix), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7549 40.86 Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7599 I.C. Immunosuppressive drug, NOC Acetyleysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg, fda-approved final product, noncompounded, administered through DME, unit dose form, up to 0.	J7342	36.73	
17343 19.97	0,0.2	50.75	
17343 19.97 Square centimeter Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter Dermal (substitute) tissue of human origin, injectable, with or without other bioengineered or processed elements, but without metabolically active elements, 1 cc Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Integra Matrix), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. Jr349			
Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, without metabolically active elements, per square centimeter	J7343	19.97	
J7344 95.38 processed elements, without metabolically active elements, per square centimeter	0,010		
Dermal (substitute) tissue of human origin, injectable, with or without other bioengineered or processed elements, but without metabolically active elements, 1 cc Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Integra Matrix), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7349 40.86 processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7599 I.C. Immunosuppressive drug, NOC Acetylcysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg	J7344	95.38	
J7346 770.02 bioengineered or processed elements, but without metabolically active elements, 1 cc Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Integra Matrix), per sq. cm.			
Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Integra Matrix), per sq. cm. J7348 92.31 Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7349 40.86 processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7599 I.C. Immunosuppressive drug, NOC Acetyleysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, noncompounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg	J7346	770.02	
J7347 32.77 cm. J7348			
J7347 32.77 cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7349 40.86 processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7599 I.C. Immunosuppressive drug, NOC Acetylcysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg			
Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7349 40.86 processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7599 I.C. Immunosuppressive drug, NOC Acetylcysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 1 mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg	J7347	32.77	
J7348 92.31 processed elements, without metabolically active elements (TissueMend), per sq. cm. Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7599 I.C. Immunosuppressive drug, NOC Acetylcysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME J7620 0.81 product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg		- '''	
Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7599 I.C. Immunosuppressive drug, NOC Acetylcysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg	J7348	92.31	
J7349 40.86 processed elements, without metabolically active elements (PriMatrix), per sq. cm. J7599 I.C. Immunosuppressive drug, NOC Acetylcysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,		- 15	
J7599 I.C. Immunosuppressive drug, NOC Acetylcysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,	J7349	40.86	
Acetylcysteine, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			
J7618 2.27 administered through DME, unit dose form, per g Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			
Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,	J7608	2.27	
J7611 0.07 administered through DME, concentrated form, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			
Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,	J7611	0.07	
J7612 0.12 administered through DME, condentrated form, 0.5mg Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			
Albuterol, inhalation solution, FDA-approved final product; noncompounded, administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,	J7612	0.12	
J7613 0.04 administered through DME, unit dose, 1 mg Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			
Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,	J7613	0.04	
J7614 0.28 administered through DME, unit dose, 0.5 mg Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			Levalbuterol, inhalation solution, FDA-approved final product, noncompounded,
J7620 0.81 product, non-compounded, administered through DME Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded, DORDA-approved fina	J7614	0.28	
Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final
Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,	J7620	0.81	product, non-compounded, administered through DME
J7626 5.09 administered through DME, unit dose form, up to 0.5 mg Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			Budesonide, inhalation solution, FDA-approved final product, noncompounded,
J7633 I.C. Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,	J7626	5.09	
J7633 I.C. administered through DME, concentrated form, per 0.25 mg Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,			
Dornase alpha, inhalation solution, FDA-approved final product, noncompounded,	J7633	I.C.	
J/639 20.85 administered through DME, unit dose form, per mg	J7639	20.85	administered through DME, unit dose form, per mg
Ipratropium bromide, inhalation solution, FDA-approved final product,			
J7644 0.21 noncompounded, administered through DME, unit dose form, per mg	J7644	0.21	
Metaproterenol sulfate, inhalation solution, FDA-approved final product,			
J7669 0.27 noncompounded, administered through DME, unit dose form, per 10 mg	J7669	0.27	

114.3 CMR 17.00: MEDICINE

CODE	GLOBAL FEE	DESCRIPTION
		Pentamidine isethionate, inhalation solution, compounded product, administered
J7676	I.C.	through DME, unit dose form, per 300 mg
		Tobramycin, inhalation solution, FDA-approved final product, noncompounded, unit
J7682	61.00	dose form, administered through DME, per 300 mg
J7699	I.C.	NOC drugs, inhalation solution administered through DME
J7799	I.C.	NOC drugs, other than inhalation drugs, administered through DME
J9000	6.83	Doxorubicin HCl, 10 mg
J9001	412.25	Doxorubicin HCl, all lipid formulations, 10 mg
J9025	4.39	Injection, azacitidine, 1 mg
J9031	117.34	BCG live (intravesical), per instillation
J9035	57.46	Injection, bevacizumab, 10 mg
J9040	35.88	Bleomycin sulfate, 15 units
J9041	34.44	Injection, bortezomib, 0.1 mg
J9045	7.05	Carboplatin, 50 mg
J9055	49.79	Injection, cetuximab, 10 mg
J9060	2.55	Cisplatin, powder or solution, per 10 mg
J9062	12.75	Cisplatin, 50 mg
J9070	1.89	Cyclophosphamide, 100 mg
J9080	3.78	Cyclophosphamide, 200 mg
J9090	17.06	Cyclophosphamide, 500 mg
J9091	18.90	Cyclophosphamide, 1 g
J9092	37.80	Cyclophosphamide, 2 g
J9093	1.93	Cyclophosphamide, lyophilized, 100 mg
J9094	3.85	Cyclophosphamide, lyophilized, 200 mg
J9095	9.63	Cyclophosphamide, lyophilized, 500 mg
J9096	19.27	Cyclophosphamide, lyophilized, 1 g
J9097	38.54	Cyclophosphamide, lyophilized, 2 g
J9130	5.58	Dacarbazine, 100 mg
J9140	11.16	Dacarbazine, 200 mg
J9170	319.42	Docetaxel, 20 mg
J9181	0.42	Etoposide, 10 mg
J9182	4.16	Etoposide, 100 mg
J9190	1.81	Fluorouracil, 500 mg
J9201	131.65	Gemcitabine HCl, 200 mg
J9202	191.86	Goserelin acetate implant, per 3.6 mg
J9206	126.31	Irinotecan, 20 mg
J9212	4.66	Injection, interferon alfacon-1, recombinant, 1 mcg
J9213	41.80	Interferon alfa-2a, recombinant, 3 million units
J9214	14.28	Interferon alfa-2B, recombinant, 1 million units
J9215	I.C.	Interferon alfa-N3, (human leukocyte derived), 250,000 IU
J9216	309.58	Interferon gamma-1B, 3 million units
J9217	242.79	Leuprolide acetate (for depot suspension), 7.5 mg
J9218	7.75	Leuprolide acetate, per 1 mg
J9219	1714.87	Leuprolide acetate implant, 65 mg
J9250	0.26	Methotrexate sodium, 5 mg
J9260	2.74	Methotrexate sodium, 50 mg
J9261	88.17	Injection, nelarabine, 50 mg
J9263	9.47	Injection, oxaliplatin, 0.5 mg
J9264	8.88	Injection, paclitaxel protein-bound particles, 1 mg
J9265	13.58	Paclitaxel, 30 mg
37200	15.50	1

114.3 CMR 17.00: MEDICINE

CODE	GLOBAL FEE	DESCRIPTION
J9293	105.14	Injection, mitoxantrone HCl, per 5 mg
J9300	2434.95	Gemtuzumab ozogamicin, 5 mg
J9305	46.08	Injection, pemetrexed, 10 mg
J9310	508.66	Rituximab, 100 mg
J9340	41.21	Thiotepa, 15 mg
J9350	875.46	Topotecan, 4 mg
J9355	59.02	Trastuzumab, 10 mg
J9360	1.07	Vinblastine sulfate, 1 mg
J9370	7.73	Vincristine sulfate, 1 mg
J9375	15.46	Vincristine sulfate, 2 mg
J9380	38.66	Vincristine sulfate, 5 mg
J9390	18.86	Vinorelbine tartrate, per 10 mg
J9395	81.37	Injection, fulvestrant, 25 mg
J9999	I.C.	NOC, antineoplastic drug
S0020	1.50	Injection, bupivicaine HCl, 30 ml
S0021	I.C.	Injection, cefoperazone sodium, 1 g
S0023	1.51	Injection, cimetidine HCl, 300 mg
S0028	0.78	Injection, famotidine, 20 mg
S0077	3.15	Injection, clindamycin phosphate, 300 mg
S0162	I.C.	Injection, efalizumab, 125 mg
		Completed early periodic screening diagnosis and treatment (EPSDT) service (or
		preventive pediatric healthcare screening and diagnosis (PPHSD)) (list in addition to
S0302	10.12	code for appropriate evaluation and management service)
		Screening to determine the appropriateness of consideration of an individual for
T1023	62.36	participation in a specified program, project or treatment protocol, per encounter

17.05: Severability

The provisions of 114.3 CMR 17.00 are severable and if any such provision or the application of such provisions to any person or circumstances shall be held to be invalid or unconstitutional, such invalidity shall not be construed to affect the validity or constitutionality of any remaining provisions to eligible providers or circumstances other than those held invalid.

REGULATORY AUTHORITY 114.3 CMR 17.00: M.G.L. c. 118G